2011 NATIONAL REPORT (2010 data) TO THE EMCDDA
by the REITOX National Focal Point

“GRAND DUCHY OF LUXEMBOURG”

New Developments, Trends and in-depth Information on Selected Issues

Alain Origer

REITOX
THE STATE OF THE DRUGS PROBLEM IN THE GRAND DUCHY OF LUXEMBOURG

EDITION 2011

AUTHOR: Alain ORIGER

CONTRIBUTORS: Sofia LOPES DA COSTA
              Céline DIEDERIC
              Simone SCHRAM
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST</td>
<td>Service d’Action Socio-Thérapeutique</td>
</tr>
<tr>
<td>CATF</td>
<td>Chemical Action Task Force</td>
</tr>
<tr>
<td>CePT</td>
<td>Centre de Prévention des Toxicomanies</td>
</tr>
<tr>
<td>CAS</td>
<td>Commission d’admission et de surveillance (CHDP)</td>
</tr>
<tr>
<td>CFSP</td>
<td>Common Foreign and Security Policy</td>
</tr>
<tr>
<td>CHNP</td>
<td>Centre Hospitalier Neuro-Psychiatrique</td>
</tr>
<tr>
<td>CICAD</td>
<td>Inter-American Drug Abuse Control Commission</td>
</tr>
<tr>
<td>CMO</td>
<td>Comprehensive Multidisciplinary Outline (UN)</td>
</tr>
<tr>
<td>CND</td>
<td>Commission on Narcotic Drug</td>
</tr>
<tr>
<td>CNDS</td>
<td>Comité National de Défense Sociale</td>
</tr>
<tr>
<td>CNER</td>
<td>Comité National d’Ethique de Recherche</td>
</tr>
<tr>
<td>CNPD</td>
<td>Commission Nationale de Protection des Données</td>
</tr>
<tr>
<td>CPG</td>
<td>Centre Pénitentiaire de Givenich</td>
</tr>
<tr>
<td>CPL</td>
<td>Centre Pénitentiaire de Luxembourg</td>
</tr>
<tr>
<td>CPOS</td>
<td>Centre de Psychologie et d’Orientation Scolaire</td>
</tr>
<tr>
<td>CRP-HT</td>
<td>Centre de Recherche Public - Henri Tudor</td>
</tr>
<tr>
<td>CRP-Santé</td>
<td>Centre de Recherche Public - Santé</td>
</tr>
<tr>
<td>CTM</td>
<td>Centre Thérapeutique de Manternach</td>
</tr>
<tr>
<td>DEA</td>
<td>Drug Enforcement Administration (United States)</td>
</tr>
<tr>
<td>EWS</td>
<td>Early Warning System on New Synthetic Drugs</td>
</tr>
<tr>
<td>GID</td>
<td>Groupe Interservices Drogue (de la Commission européenne)</td>
</tr>
<tr>
<td>EMCDDA/OEDT</td>
<td>European Monitoring Centre for Drugs and Drug Addiction</td>
</tr>
<tr>
<td>EMEA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>EUROPOL</td>
<td>European Police Office</td>
</tr>
<tr>
<td>FBI</td>
<td>Federal Bureau of Investigation (United States)</td>
</tr>
<tr>
<td>FED</td>
<td>Fond Européen de Développement</td>
</tr>
<tr>
<td>FATF</td>
<td>Financial Action Task Force on Money Laundering</td>
</tr>
<tr>
<td>FEDER</td>
<td>Fond Européen de Développement Régional</td>
</tr>
<tr>
<td>FLTS</td>
<td>Fonds de Lutte contre le Trafic des Stupéfiants</td>
</tr>
<tr>
<td>HAT</td>
<td>Heroin Assisted Treatment</td>
</tr>
<tr>
<td>HDG</td>
<td>Horizontal Working Party on Drugs</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Name</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Honlea</td>
<td>Heads of National Drug Law Enforcement Agencies</td>
</tr>
<tr>
<td>ICD</td>
<td>Interministerial Commission on Drugs</td>
</tr>
<tr>
<td>ICPO/Interpol</td>
<td>International Criminal Police Organization</td>
</tr>
<tr>
<td>ILO</td>
<td>International Labour Organization</td>
</tr>
<tr>
<td>INCB</td>
<td>International Narcotic Control Board</td>
</tr>
<tr>
<td>JDH</td>
<td>Fondation Jugend- an Drogenhelfef</td>
</tr>
<tr>
<td>LNS</td>
<td>Laboratoire National de Santé</td>
</tr>
<tr>
<td>MSF</td>
<td>Médecins Sans Frontières</td>
</tr>
<tr>
<td>NDLEA</td>
<td>National Drug Law Enforcement Administration (Nigeria)</td>
</tr>
<tr>
<td>NFP</td>
<td>National Focal Point of the EMCDDA</td>
</tr>
<tr>
<td>NIDA</td>
<td>National Institute on Drug Abuse (United States)</td>
</tr>
<tr>
<td>OAS</td>
<td>Organization of American States</td>
</tr>
<tr>
<td>OCDE</td>
<td>Organisation de Coopération et de Développement Economiques</td>
</tr>
<tr>
<td>OGD</td>
<td>Observatoire Géopolitique des Drogues</td>
</tr>
<tr>
<td>OLAF</td>
<td>European Anti-Fraud Office</td>
</tr>
<tr>
<td>ONDCP</td>
<td>Office of National Drug Control Policy of the White House (United States)</td>
</tr>
<tr>
<td>PECO</td>
<td>Pays d’Europe Centrale et Orientale</td>
</tr>
<tr>
<td>RELIS</td>
<td>Réseau Luxembourgeois d’Information sur les Stupéfiants</td>
</tr>
<tr>
<td>REITOX</td>
<td>European Information Network on Drugs and Drug Addiction</td>
</tr>
<tr>
<td>SADC</td>
<td>Southern African Development Community</td>
</tr>
<tr>
<td>SEPT</td>
<td>Semaine Européenne de Prévention des Toxicomanies</td>
</tr>
<tr>
<td>SID</td>
<td>Système d’Information Douanier</td>
</tr>
<tr>
<td>SIS</td>
<td>Système d’Information Schengen</td>
</tr>
<tr>
<td>SNJ</td>
<td>Service National de la Jeunesse</td>
</tr>
<tr>
<td>SPG</td>
<td>Système de Préférences Généralisées</td>
</tr>
<tr>
<td>SPJ</td>
<td>Service des Stupéfiants de la Police Judiciaire</td>
</tr>
<tr>
<td>TRANSRELIS</td>
<td>Réseau transfrontalier d’Information sur les Stupéfiants</td>
</tr>
<tr>
<td>UNDCP</td>
<td>United Nations International Drug Control Programme</td>
</tr>
<tr>
<td>UNDP</td>
<td>United Nations Development Programme</td>
</tr>
<tr>
<td>UNGASS</td>
<td>United Nations General Assembly Special Session on Drugs</td>
</tr>
<tr>
<td>UNODC</td>
<td>United Nations Office on Drugs and Crime</td>
</tr>
<tr>
<td>WCO</td>
<td>World Customs Organization</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>ZePF</td>
<td>Zentrum für Empirische Pädagogische Forschung – Universität Landau</td>
</tr>
</tbody>
</table>
Foreword

The 2011 edition of the national report on the state of the drugs problem in the Grand Duchy of Luxembourg aims to describe the framework in which drug use and drug trafficking evolve at the national level by providing a comprehensive overview of historical developments and recent trends.

Thanks are due to the following experts consulted in the framework of the 2011 edition of the report: Dr Arno Bache (Directorate of Health), Andrée Colas and Sophie Hoffmann (Ministry of Justice), Auguste Dicken (Customs Administration), J.-P. Juchem (CNS), Dr Ferdy Kasel (CHNP-BU-V), Dr Mühe (CHL), Marc Bamberg (Special Drug Department of the Judicial Police), J.-M. Schanck and Guy Reinart (Ministry of Health), Steve Schmitz (Judicial Police), Simone Schram and Linda Weis (Directorate of Health), Robert Welter (Public Prosecutor’s Office), Dr S. Schneider and Dr M. Yegles (National Laboratory of Health LNS) as well as heads of all national specialised NGOs.

Summary

Drug policy: legislation, strategies and economic analysis

In 1999 the government entrusted the Ministry of Health with the overall coordination of drug-related demand and risk reduction actions. This led to the creation of the national drug coordinator’s office in 2000.

The 2009 governmental programme has set the framework for the elaboration of the third national strategy and action plan (2010-2014) for the fight against drugs and addictions. The national strategy and action plan 2010-2014 relies upon the priorities of the Ministry of Health and a sustained collaboration with field actors and civil society. In order to optimize its impact, the new action plan has taken into account relevant issues from EU and EC treaties, the EU anti drugs strategy 2005-2012 and the EU drugs action plan 2009-2012. The general aim of the national strategy and action plan is to contribute to a high level of protection in terms of public health, public security and social cohesion.

The national drug strategy relies on two pillars, namely on demand reduction and supply reduction and on four transversal axes: 1. Risk, damage, nuisance reduction, 2. Research and information, 3. International relations and 4. Coordination mechanisms. The national drug coordinator, jointly with the Interministerial Committee on Drugs (ICD), follows up and steers the implementation process of the national drugs action plan.

The global budget of the Ministry of Health granted to drug demand reduction related services and programs went up from 1,270,169 EUR in 1999 to 8,635,867.- EUR in 2010, thus witnessing a progression rate of 580%. Overall public expenditures in the field of drug demand and drug supply reduction per year are currently estimated at 38,500,000.- EUR (Origer, 2010). Expenditures exclusively allocated to drug related treatment reached 16,320,606.- EUR in 2010.

Epidemiological Indicators

Globally, UNODC\(^1\) estimates that, in 2009, between 149 and 272 million people (3.3 to 6.1% of the population aged 15-64) used illicit substances at least once in 2008. Globally, cannabis users comprise the largest number of illicit drug users (125 - 203 million people). Based on global estimates of the number of cannabis, opiate, cocaine and ATS users, it is estimated that there were between 15 and 39 million problem drug users in the world in 2009.

Cannabis remains the most widely consumed drug worldwide. Global annual cannabis use prevalence is estimated between 2.8% and 4.5% of the population aged 15-64.

\(^1\) Extracts from the World Drug Report 2011 (UNODC, 2011)
There are an estimated 14.2 – 20.5 million annual cocaine users (annual prevalence of 0.3% to 0.5%) in the world. Between 12 and 21 million people used opiates in 2009. UNODC further estimates that between 14 and 57 million people aged 15 to 64 had used an amphetamine-type substance (ATS) in the past year (0.3% to 1.3% of the population), including 11 to 28 million ecstasy users (0.2% to 0.6% of the population).

**National drug prevalence in the general population**

*Drug prevalence in school population and in general population*

Comparable data from national school surveys conducted between 1992 and 2000 have been showing increasing lifetime prevalence in young people (16-20 years) for all common illicit substances. Use of opiates in school populations is consistently very low.

Data from the serial HBSC study (2005/2006) show a decrease of last 12 months prevalence of all retained psychoactive substances use in youngsters aged 13 to 17 years, except cocaine and psychotropic pharmaceuticals, compared to the situation in 2002. Last 12 months heroin use have been showing a fair overall stagnation between 2002 and 2006, whereas cannabis, ATS, LSD and magic mushrooms consumption in youngsters has sensibly decreased over the same period. A detailed analysis reveals that the age category of 15 years old youngsters is the only to show increasing use specifically for XTC and cocaine. Also, a higher proportion of 15 years old students report repeated lifetime drunkenness, compared to the data from 2002 (HBSC, 2002).

**National prevalence of problem drug use (PDU)**

*Data on institutional contacts and drug treatment demands*

The annual number of PDU contacts indexed by national institutions figured 5,415² in 2010 (2002: 4,701)

2,383 users have been indexed by national specialised drug demand reduction agencies and 2,318 drug law offenders by supply reduction agencies in 2002. In 2010 the same agencies have indexed 2,653 and 2,762 persons respectively. Overall the number of persons showing drug-related contacts with DR or SR agencies has reached a plateau between 2002 and 2008 and showed signs of increase in 2009 and 2010. During the referred period, however, the number of drug treatment demands constantly increased in contrast to the number of contacts with law enforcement agencies, with the notable exception of 2010. Referred to the general population aged 15-64, the proportion of persons in contact with DR or SR agencies for drug related matters, likewise PDU prevalence rates, has been generally decreasing between 2002 (15,8/1000 inhabitants) and 2009 (14,7/1000 inhabitants). In 2010, however, this rate shows a sensible increase exclusively due to an marginally high number of drug law offenders indexed by law enforcement agencies.

**Socio-demographic profile of PDU**

The male/female ratio of the PDU population currently sets at 4:1. Over the last decade the proportion of indexed non-native PDU has been showing strong variations but a clearly increasing trend since 2003 and has shown signs of stabilisation over the last 3 years (+/-51%). The population of non-native drug users largely consists of Portuguese nationals (39% of total number of non-native PDU), representing a proportion that is

---

² In this figure double counting is included meaning that a given person could have been indexed twice and more by different institutions. It is thus not representing the actual prevalence, which has to be assessed by other methods.
higher than the one observed in general population (37%). Citizens of French and German origins occupy the second (23%) and third (10%) rank respectively. Italian citizens, who occupied the third place in non-natives drug law offenders over the last 9-years, only represented 2% in 2010 (rank 7).

The mean age of indexed PDU has been evolving from 28 years and 4 months in 1995 to 31 years and 7 months in 2010. Mean age of male PDU has been increasing faster than for females. The gap between youngest and oldest PDU has been stabilised in recent years, after years of increase as one observed a long-term increase of the population of PDU aged 40 years and more and a sensitive decrease in PDU aged less than 30 years. The mean age of native PDU is consistently lower than the one observed for non-natives. Worth mentioning is also the significant increase of the average age of overdose victims until 2008 (slight increase in 2010 compared to 2009 data) and an increasing proportion of minors among drug law offenders in 2010 (2010: 9%; 2009: 6%).

Problem drug use prevalence and consume trends

National data are provided by serial prevalence studies on PDU aged between 15 and 64 years performed in 1997, 1999, 2000 and 2007 data (Origer, 2009). The estimation performed on 2007 data provides an absolute prevalence of problem drug users (PDU) of 2,470 persons (C.I. (95%): 2,089 to 3,199). In terms of prevalence rates estimates for the same age categories, 7.67 out of 1,000 habitants aged between 15 and 64 years show problem drug use. According to available serial data for the years 1997 to 2007, absolute prevalence and prevalence rates of PDU have been showing an increasing trend until 2000. After a brief plateau, a decrease has been observed from 2003 onwards. A similar evolution occurred also for problem heroin use (2007: 1,900 PDU: 5.90/1000). Absolute prevalence of intravenous drug use (IDU) has slightly increased compared with the situation observed at the end of the 20th century and so did the IDU prevalence rate in the national population aged 15 to 64 years. New data from the 2010 serial prevalence study will be available in 2012.

Injecting heroin use associated to poly-drug use has been reported being the most common consume pattern in PDU. The ratio of injecting opiates use to the inhalation mode has reached 2:1 in 2010. The prevalence of the use of cocaine as primary drug increased until 2006 and from there on discontinuously decreased. In 2010, the prevalence of problem cocaine use did not significantly increase compared to 2009.

The number of persons in contact with the national specialised network for (preferential) cannabis use currently represents 8% (sensitive decrease). Amphetamine type substances and ecstasy related treatment demands are only weakly represented, which, however, does not inform on their prevalence in general population as RELIS data refer to PDU and not to the overall population of recreational drug users. The proportion of poly-drug use (76% in 2010) has stabilised at high level.

3 Downloadable at [http://www.relis.lu](http://www.relis.lu)
4 IDU prevalence rates have been processed on basis of proportion of IDU in PDU by means of representative RELIS data sets for respective years
Drug-related treatment

The number of adult out- and in-patient clients tends to decrease, while out-patient minor treatment demanders have been continually increasing. The most remarkable increases between 2008 and 2010 have been observed in substitution treatment demanders and in the number of contacts in low threshold facilities (2010: 140,093 contacts). 4.7% of respondents are first treatment demanders, all treatment centres included. A confirmed trend has to be seen in the decrease of the proportion of substitution patients aged less than 25 years and the increase of the proportion of patients aged 40 years and more.

Health correlates and responses to consequences

The HIV/AIDS prevalence in PDU has been slightly increasing in 2010 while the infection of HCV (hepatitis C) has been showing a clear decrease since 2009. Data from the National Laboratory of Retrovirology suggest a long term and discontinuous decreasing tendency of the average proportion of IDU in newly diagnosed HIV cases. From 2004 to 2008 this proportion has been varying between 7 and 14 % and fell down to 3.1% in 2009, to increase in 2010 to 6.4%. HIV infection rates in IDU situate around 8 percent, which stands for an increase, after years of stability.

The implementation of the 2005-2009 and 2010-2014 action plans has been accompanied by a significant yet discontinuous, overall decrease of overdose cases in the Grand-Duchy of Luxembourg (2010: 12 cases).

In terms of number of overdose cases in the general population of the Grand-Duchy of Luxembourg, this proportion figured 1.76 overdose deaths per 100,000 inhabitants aged 15 to 64 years in 2005 (2000: 5.9 cases per 100,000 inhabitants). In 2010, 3.5 (2007: 5.67) acute OD cases per 100,000 inhabitants were registered, which stands for a decreasing tendency. Forensic data from 1992 to 2010 show that the most frequently involved substance in drug-related death is heroin, followed by methadone and cocaine consumed in a polyuse context. All victims were male (100%) in 2010 and their mean age at the moment of death shows a discontinued increase over the past 16 years (in 1992: 28.4 years and in 2010: 31 years). Although the mean age of drug overdose victims has been increasing, the number of victims aged less than 20 years has remained relatively unchanged. No underage victims were reported in 2010.

As regards nationality of overdose victims, 83% (57%) were natives, representing a considerable increase compared to previous years.

Social correlates and social reintegration

Social correlates of problem drug use are manifold and touch upon family, professional, financial and legal areas.

The educational levels of PDU are low and mostly incomplete. The residential status of the latter has improved over the last years. In 1995, 31% of the users reported stable accommodation; currently the same proportion situates 62%. This improvement is partly due to various accommodation and housing offers for addicted people set up in the framework of the drug action plan. Recent figures tend to confirm that although
specialised accommodation offers have been further developed, the current economic situation has created an even higher demand for this type of housing.

The unemployment rate (69%) tends to plateau. However, the proportion of active respondents reporting a stable job situation (e.g. long term contract) has sensibly decreased over the 3 last years, which should also be put in the context of the current economic parameters.

| Harm reduction activities |

The number of contacts indexed by national low threshold agencies has increased dramatically over the last ten years (2010: 140,093 / 2005: 47,739), and so has the number of syringes distributed by the same agencies. The proportion of new clients within low threshold settings is on the increase. Approximately 50% of clients are aged between 25 and 34 years, and 40% of clients aged 35 and more is observed. 56% (56%) of clients are natives.

The number of syringes distributed in the framework of the national needle exchange programme (2010: 308,350 / 1996: 76,259), stabilised and has been decreasing from 2006 onwards. A new upward trend was observed in 2009/2010. Return rates of used syringes have been increasing during the referred period and reached 96% in 2010. An increasing majority of injectors (46%) procure their syringes in specialised agencies followed by pharmacies and automatic dispensers.

| Law enforcement indicators5 |

Seizures of illicit substances at the national level

Great variations have been observed as to the quantity of illicit substances seized since the beginning of the nineties. A longitudinal data analysis from 2000 onwards indicates a general decreasing tendency of heroin and cocaine seizures, whereas cannabis resin seizures6 are showing a discontinuous increase. Quantities of herbal cannabis seized have increased compared to the situation observed in year 2000. Cocaine seizures (quantity) are highly variable since the beginning of the nineties.

The number of seizures did not show significant variations during the same period, with the exception of cannabis (resin and herbal products) going up significantly. Markedly, the number of cannabis seizures has risen from 167 to 947 between 1994 and 2010. Also, the number of offenders involved in seizures has been showing an overall decreasing trend. The total number of persons involved in traffic has followed a constant upward trend (2000: 1758 (2010: 2,530) persons). A confirmed majority of offenders involved in cannabis traffic are natives.

Crack (cocaine-base) seizures have not been reported to date by national authorities. The first national seizures of ecstasy type substances (MDMA, MDA, etc.) were recorded in 1994. The availability of ecstasy has been stable since 1996 but seized quantities increased remarkably in 2009 followed by a decrease in 2010.

---

5 If not specified, data refer to 2010. Figures in brackets refer to 2009 if not otherwise specified.
6 Non–transit drugs destined to the national market
Drug law offenders and prison sentences

The number of police records for presumed offences against the modified drug law of 1973 went from 764 in 1995 to 2,546 in 2010. A similar evolution has been observed with regard to the number of drug law offenders. In 2010, 229 arrests (225 in 2006) for presumed drug offences have been reported.

The population of drug law offenders is composed of 85% males; a proportion that has been varying between 79% and 89% during the past decade. 808 first drug law offenders were reported in 2003 and 949 in 2010. Also the percentage of minors (< 18 years) among drug law offenders, having increased between 1994 (4.9%) to 2000 (8.7%), shows a clear decrease confirmed by 2009 data (6.3%). In 2010 however, the percentage of minors among drug law offenders increased again (9.2%). Heroin and cocaine are the main drugs involved in registered first drug offences.

Since 1998, non-natives (53% in 2010) have been representing the majority of drug law offenders (52-68%). 38% (34%) of the registered cases were first drug law offenders. National prison data of 2010 refer to 927 (892) new admissions of which 232 (25.02%) were related to drug law offences; a proportion that represented 42.6% in 1996.

Profile of the national drug market

The national production and culture of illicit drugs appears to be irrelevant in terms of quantities and quality. In 2010 no clandestine drug-manufacturing laboratory has been dismantled at the national level. According to observational data provided by the Judicial Police and all decentralised national police units, a majority of illicit drugs consumed in the G.-D. of Luxembourg originate from the Netherlands (cannabis production and transit of other drugs), followed by Belgium (ecstasy and ATS production) and Morocco (cannabis production). Cocaine found on the national market is originating from Latin America and mostly transits South of Europe (Spain, Portugal) to reach the Netherlands via France, Switzerland, Austria and Germany. Heroin follows the main Balkan route and its derivate (Poland, Turkey, Belorussia).

In recent years more organised distribution networks have been developing nationally. The expansion of these structured distribution networks by criminal associations thus contributed to a significant increase in drug availability, and particular in the supply of cocaine and cannabis. More recently different ethnic groups have created synergies in drug distribution and traffic, whereas previously these groups have been operating separately. Moreover, it has been noted that traffickers tend to delocalize their selling points to locations or settings less visible for police as for instance private flats, bars or motorway rest areas in order to meet their clients halfway and sell gross quantities. The proportion of non-natives involved in drug trafficking has been increasing until 2005 and has since then been decreasing quite sensibly although non-native drug traffickers represent 62.7% (60% in 2007).

Over the last 6 years, purity of heroin has remained fairly stable whereas average potency of cocaine is on the decrease for the last 4 years, with a slight increase for 2010. Attention has to be paid to the striking differences in maximum and minimum purities as well as to a historically high maximum concentration of THC (35-40%) in cannabis resin products seized in Luxembourg in recent years. Prices show broad ranges for heroin and cocaine. Cannabis and derivates however have known certain stability during the last 6 years as far as street retail prices are concerned.
Most Relevant Trends

All indicators included, a decrease in PDU prevalence rates has been observed over recent years although results from latest prevalence studies suggest that IDU prevalence has slightly increased. Over the last decade an increasing number of PDU entered treatment or use low threshold offers and fewer come in contact with law enforcement agencies.

Injecting opiate use, combined with polyuse, is the predominant PDU pattern. However, overall quality of street drugs decreased, which resulted in an overall increase of polydrug use. The number of acute drug deaths went down to 12 cases in 2010 (27 cases in 2007).

Although current PDU prevalence shows a decreasing trend, new phenomena such as early drunkenness, binge drinking in youngsters and use of new synthetic drugs and products containing the latter must be monitored closely since they may have a relevant impact of PDU incidence in the future.

There is also great concern about infectious diseases in drug users and in particularly IDU. HIV rates in PDU are low and stable from 2000 to 2008, but show an increasing tendency for 2009 and 2010; however, hepatitis C has been increasing continuously from 2000 to 2008, to decrease again in 2009 and 2010. Latest research results based on serological testing (Origer & Removille, 2009) suggested HCV infection rates over 70% and even higher prevalence rates in prison populations in 2007.

The national drug market is led by more aggressive selling techniques and distribution strategies due to improved collaboration between criminal groups of different ethnic origins previously operating independently. A tendency to move selling points to locations or settings less visible for police as for instance private flats or bars is also observed in this context. Attention has finally to be paid to the striking differences in maximum and minimum purities of street drugs as well as to a historically high maximum concentration of THC (over 40%) in cannabis samples seized over the last years. Heroin purity has remained fairly stable, but cocaine purity and MDMA purity in XTC-like products has been decreasing over the last 10 years. In 2010 however, MDMA purity peaked since its first seizure.

The most relevant developments at the response side result from the implementation of the national drug strategy and its associated action plans. Over the last years counselling and specialized care networks have been developed, which had as a positive and documented consequence that PDU start treatment at an early stage of their drug career. Drug action plans have allowed disposing of financial means that have known an important increase compared to the time preceding drug action plans. If primary prevention is considered most important, there have been visible improvements in early intervention measures. Major efforts have also been made in the diversification of care offers and finally harm reduction measures have been significantly developed. Housing offers and reintegration programmes have obviously contributed to improve socio-professional situations as documented by latest RELIS data. Substitution treatment and low threshold offers have been decentralised and continue to be so.

Coordination mechanisms have been reinforced between NGOs and national authorities and evaluation mechanisms are in place. A first external evaluation of the national drugs action plan has been performed and outcomes have been integrated together with recommendations from a series of national expert groups and outcomes of user/clients surveys in the elaboration of the new drugs strategy and action plan 2010-2014.
Consistency between Indicators

Demand reduction indicators are consistent with supply reduction data (see fig. 4.4). Indirect PDU prevalence indicators reflect trends documented by in-depth PDU studies except for admission statistics in low threshold drug agencies from 2000 onwards and the number of fatal overdoses between 2005 and 2007. These trends are respectively to be linked to an increase in capacities of low threshold offers and better access to harm reduction measures at the national level and significant changes in supply and consume patterns.

Both indicators thus appear to be influenced by external factors not directly linked to a presumed increase of PDU prevalence and thus not in contradiction with a general stabilisation of the latter.

The number of drug law offenders has also stabilised between 1999 and 2009 but shows a peak in 2010. This recent evolution might be partly explained by the fact that law enforcement agencies increased their presence and interventions, notably in the vicinity of the supervised drug injection and low threshold facilities in order to fight increased drug deal activities. Next years trends of this particular indicator have to be interpreted in the light of further contextual data.

The number of fatal drug-related overdoses has peaked in 2007 but has been witnessing an obvious decrease since then.

Selected Issue 1: Drug-related health policies and services in prison

In 2009 and 2010 the national prison administration reported an average of 700 detainees of whom nearly 70% were non-natives and around 5% females. In 2010, 25% (232) of new prison entries (927) were due to offences against the national drug law.

From 2000 to 2005 a global drug care offer in prison was launched in the two national state prisons CPL and CPG. The now-called TOX PROGRAMME provides drug prevention, harm reduction and specialised care to drug dependant inmates. To date more than 50 health care professionals are providing care inside prison.

In 2010, 24.5% of prisoners in the CPL and 10.5% of prisoners in the CPG underwent intra-muros substitution treatment. A syringe exchange programme started in 2005 within national prisons. In 2010, 328 syringes have been exchanged in the framework of the referred programme.

A reform on governmental policy concerning the penitentiary institutions was presented in March 2010 to the national Parliament. The new concept is based on the improvement of prisoners care, accommodation, administrative reorganisation, further recruitment of guardsmen and continuous training. Since 2010, an external supervisor of all facilities of deprivation of liberty, controls detention settings and safeguards the rights of imprisoned persons.
Due to a diversification of, and a better access to treatment offers, the life expectancy of drug dependant persons has risen during the last years and so did the number of births among this population.

In 2003, a specialized service called “service parentalité” (parenthood service) was implemented by the Youth and Drug-help foundation “Jugend and Drogenhëllef” (JDH). In 2010, 16 births have been registered and a total of 1,035 counselling sessions have been held.

The “service parentalité” jointly with the National Drug Addiction Prevention Centre (CePT) started a pilot project for pregnant women and drug addicted mothers with children. Continuous training sessions on child development, attachment, emotions, educative models and values are provided by specialized agencies.

The national drug action plan (2010-2014) refers explicitly in its section “demand reduction” to the further improvement of offers dedicated to children and drug using parents.
Part A: New Developments and Trends

1. Drug policy: legislation, strategies and economic analysis

Introduction

Given the complex nature of drug use and its correlates, national drug policies are based on shared political competencies and responsibilities. Furthermore, in terms of intervention strategies, the more holistic concept of addictive behaviour has gained in importance and influences increasingly policy debates. This tendency is reflected by the enlargement of ICD (Interministerial Committee on Drugs) competences and its increased external visibility as well as the general framework set by the new national drugs strategy 2010-2014 on addictions (and not exclusively on illicit substances’ related problems).

The governmental programme 2009, foresees to further develop the national drugs action plan and specifically refers to the decentralisation of care and harm reduction structures, to further improve surveillance mechanisms in drug substitution treatment, to the creation of a heroin assisted treatment programme and to the extension of post-therapeutic offers. Further efforts are to be invested in effectiveness and efficiency evaluations of drug treatment offers and services.

The 2010 – 2014 national action plan on drugs and addictions built upon the outcome of the external evaluation of the national drug strategy and action plan 2005-2009 performed by the Trimbos Instituut (NL) in 2009.

- GENERAL LEGAL FRAMEWORK

Drug legislation and recent drug-related laws

The basic national drug law, namely: ‘Loi concernant la vente de substances médicamentueuses et la lutte contre la toxicomanie’ regulates both, the selling of controlled medicaments and the fight against drug addiction and dates back to the 19 February 1973. It has been last amended by the law of 27 April 2001. Besides the decriminalisation of cannabis use, alleviation of penalties for simple drug use, and an enhanced overall differentiation of penalties according to the type of drug offences and the nature of controlled substances involved, the law of 27 April 2001 foresees a legal framework for a series of treatment and harm reduction measures, namely, drug substitution treatment, needle exchange and shooting galleries (state accredited and, in addition to article 13 of the Grand ducal decree of 30 January 2002 (see below), Heroin Assisted Treatment (HAT).

No new law related to drugs or precursors have been voted in 2010.

---

9 Legal texts prevail on selectively produced summaries. The integral national legislation on drugs and drug addiction is available under: http://www.emcdda.europa.eu/eld
10 Official gazette A 1973, p.319
Grand Ducal Decrees

As regards regulation mechanisms on the control of substances and precursors, the national drug legislation mainly relies on the following Grand ducal decrees, amended (text or annexes) according to decisions on new substances’ inscription into national law:

- Grand ducal decree of 4 March 1974 regarding certain toxic substances
- Grand ducal decree of 20 March 1974 regarding certain psychotropic substances
- Grand ducal decree of 26 March 1974 establishing the list of controlled narcotics
- Grand ducal decree of 8 May 1993 regarding commerce of narcotics and psychotropic substances
- Grand ducal decree of 2 February 1995 regarding the production and distribution of certain substances used in the illicit production of narcotics and psychotropic substances
- Grand ducal decree of 30 January 2004 modifying the grand ducal decree of 2 February 1995\[12\]
- Grand ducal decree of 13 February 2007 on the surveillance and commerce of drug precursors\[13\]

The full text of the current basic national drug law as well as recent decrees can be accessed through the following web sites: http://www.legilux.public.lu or http://eldd.emcdda.europa.eu.

CHANGES IN 2010: The grand ducal decree of September 30, 2010\[14\] modifies the annex of the grand ducal decree of 20 March 1974 on certain psychotropic substances by putting MEPHEDRONE (4-MMC or 4-méthylmethcathinone) under national control.

Laws implementation

Legally speaking, police has no discretional power: each offence, once disclosed, must be reported. However, depending on the case, (e.g. first offence for cannabis use) it may occur that no further action is taken. Once a drug law offence case has been reported to the Public Prosecutor, the latter decides on the opportunity to prosecute or not. The legal concept of ‘prosecution opportunity’ may be applied, which implies a case-by-case decision.

Narcotic-related offences are covered by the law (concerning the sale of medicinal substances and the fight against drug addiction) of 19 February 1973 (hereinafter referred to as ‘the 1973 law’) that was modified by the law of 27 April 2001.

The modified 1973 law essentially remains a repressive law, towards drug consumers as well as dealers. Even though the 1973 law does not specifically provide for alternative measures to prison for drug-addicted law offenders, the following options exist.

In accordance with article 23 of the 1973 law, cases involving personal use of drugs (individually or in a group) and/or cases involving offences against Article 8 of the 1973 law are dropped if the offender, before the illegal use was disclosed, undertook treatment for drug addiction. Moreover, the public prosecutor can offer the offender the option of voluntary treatment of his/her addiction.

According to the terms of Article 24 of the 1973 law, when preliminary charges are brought for personal use of drugs and when it is established that the offender is the

---

\[12\] Official gazette A 2004 (Adoption: 13/02/2004, Entry in force: 22/02/2004). See also ELDD.
\[13\] Official gazette A 2007 (Adoption: 30/01/2004, Entry in force: 13/02/2004). See also ELDD.
subject of medical treatment, the investigative judge may order treatment for drug addiction at the request of the prosecutor or the accused person.

Article 25 of the 1973 law makes provision for the juvenile court to refer an addicted minor to treatment.

Article 26 of the 1973 law provides for the courts to order a drug addict to undergo treatment, in which case the verdict can be postponed. If the accused person meets all conditions imposed by the courts, the charges for illegal use may be dropped.

The above measures are only available to drug users and no other categories of offenders.

In addition to the special measures set forth in the 1973 law, the courts can still avail of the reformed sentencing measures or of any of the extenuating circumstances which are an option for all offences, as outlined in the Code of Criminal Law and the Code of Criminal Investigation. The extenuating circumstances outlined in Articles 73 to 79 of the Code of Criminal Law allow the judge the option of ordering community service or a fine, or even to forgo sentencing in favour of a police fine (between EUR 25 and 248).

Articles 619 to 634 (1) of the Code of Criminal Investigation allow the judge the option of either postponing the verdict, with/without a trial period, or suspending the sentence, with/without probation and with a trial period.

The law of 27 April 2001 modifying the basic drug law of 19 February 1973 by decriminalising cannabis use, and enhancing the differentiation of penalties according to the type of drug offences and the nature of controlled substances involved and the grand ducal decree of 30 January 2002 on substitution treatment, have largely contributed to increase the congruity between drug legislations and prosecution routines. Also, current drug legislation and prosecution policies put higher priority on drug dealing and trafficking than on drug consumption and promote harm and risk reduction measures. The creation of a national supervised drug consumption room is a sound example of this holistic approach.

As a legal principal, the reaction to an offence committed by a drug user must be proportional to the harm it aims to prevent. In fact, as long as the drug addict remains a simple user, any damage caused is to himself/herself and the legal response remains minimal as long as public order is not greatly disturbed. However, if the drug addict causes harm to others, the response will become firmer according to the seriousness of the offence.

- NATIONAL ACTION PLAN, STRATEGY, EVALUATION AND COORDINATION

Coordination mechanisms
The coordination of drug demand reduction, risk reduction and related research is a competence of the Ministry of Health. Since 2000 a National Drug Coordinator, appointed by the Minister of Health, has been mandated with the overall coordination (including interministerial coordination) in the domains of drug-related demand and harm reduction and represents Luxembourg at the international level. Supply reduction and

---

international cooperation aspects remain a competence of the Ministry of Justice and the Ministry of Foreign Affairs respectively.

At the national level, the coordination among the competent ministries takes place in the Inter-ministerial Commission on Drugs (ICD), chaired by the national drugs coordinator. The ICD is composed of official delegates from involved governmental departments and constitutes the top decision level with respect to coordination and orientation of actions. Both, the ICD and the Ministry of Health are responsible for the implementation of national drugs strategies and action plans. The ICD, has an advisory role and addresses issues ranging from illicit drug use to alcohol use and prescription drugs under the general heading of addictive behaviour and its consequences.

The National Drug Coordinator is also the head of the national delegation within the Horizontal Drugs Group and the national permanent correspondent within the Pompidou Group. Furthermore, he has been nominated chair of the national substitution treatment surveillance commission in 2010 and is member of the national AIDS surveillance commission.

**National plan and strategy**

Having taken into consideration the EU drugs strategy 2005-2012, the EU drugs action plan 2009-2012, the national strategy and drugs action plan are meant to contribute to a high level of health protection, public security and social cohesion and rely on two policy pillars, namely supply reduction and demand reduction. More precisely, it is designed to contribute to reduce initiation of drug use, to develop and maintain diversity and quality in care and treatment offers, to tangibly reduce drug use prevalence in the general population as well as health and social damage generated by illicit drug use and drug trafficking.

Furthermore the 2010-2014 national action plan\(^\text{17}\) includes, in addition to international cooperation and research, information, evaluation (retained by the EU action plan), two more cross-cutting themes: coordination and harm, risk and nuisance reduction. Luxembourg considers the latter two activity fields to be essential and of transversal nature.

The new governmental drugs strategy builds upon a more holistic approach than the previous ones. It addresses addictive behaviour as a whole and not only illicit drugs and drug addiction. Thus alcohol, tobacco and psychotropic pharmaceutics dependence as well as addictive behaviour not associated with substance use are now an integral part of an unique strategy. Specific action plans have been conceived or are currently under preparation in order to integrate the framework of a global national policy on addictions.

**Operational objectives are as follows:**

1. To contribute to the maintenance of individual and collective well-being.
2. To increase means for action and to improve coordination mechanisms and synergies between available resources in order to guarantee their best possible use.
3. Reduce the burden for the community by promoting a rational culture of investments, allowing to generating sustainable achievements.
4. To adequately update drug-related legislation and other regulatory instruments according to emerging evidence on drugs and drug use pattern as well as on commercial strategies that are building upon new opportunities created by new consumer trends.

---

5. To increase the knowledge base on drugs and addictive behaviour by promoting research and the broadest possible diffusion of objective information to the general public and specific target groups.

6. To consolidate mechanisms that allow to critically analyse actions and achievements, and by doing so, improve drug policy making, action planning and implementation.

The national plan lists **60 separate actions** associated to a clear definition of tasks, involved management actors, financial requirements, deadlines and performance indicators. Some of the referred actions are submitted to a series of conditions to fulfil by the action manager in order to be proposed for financing. The action plan reflects priorities set by the government: primary prevention (4 projects), treatment and care (7), socio-professional reintegration (5), reduction of risks and damages (9), research, evaluation and information (8), supply reduction (18), coordination and international relations (9). Special focus is placed on primary prevention, offers of accommodation and housing, socio-professional reinsertion measures, diversification and access to therapeutic offers and quality management.

The selection of specific actions, projects or programmes has occurred on basis of a 6 criteria matrix including: pertinence, opportunity, feasibility, cost–benefice/quality factors, quality assurance mechanisms and measurability of results or impact.

**Implementation of policies and strategies**

The outcome of a national drugs action plan highly relies on the way it has been elaborated. The successive action plans reflect the general strategy of the Ministry of Health in order to optimize the overall interventions in the fight against drugs and drug addiction in the light of stated priorities, assessed needs and available resources. It constitutes an open framework meaning that complementary projects can be included if required.

In 2009, in order to best meet current needs in the elaboration of the 2010-2014 action plan, the national drug coordinator has launched a third multilateral consultation process involving ministerial departments, specialised NGOs and civil society. A special working group, chaired by the Ministry of Health, performed a needs assessment and elaborated national recommendations focusing on specialised drug care and rehabilitation offers. A more restricted group composed of representatives of the Ministry of Health and the National Addiction Prevention Centre drafted the action plan in the framework of primary prevention strategies. The priorities set by the Ministry of Health were discussed and, if necessary, complementary measures were added. A consensus on priority rankings of listed actions has been reached among involved parties. Finally, all retained actions were structured in an output oriented way as follows: ‘1. Description/objective of action – 2. Responsibilities – 3. Budget – 4. Outcome – 5. Deadlines for outcome and evaluation’.

The active involvement of specialised NGOs / civil society from the very start of the conceptualisation work and consensus making prior to the implementation phase have shown to be a major criterion to guarantee an effective implementation process. Summarily, one should stress that the multilateral involvement of competent actors and the fact that most agencies involved in the implementation process are financed and controlled by the centrally coordinating Ministry of Health highly promote the effectiveness of the national strategic model.
Evaluation of policies and strategies

The implementation progress of the drugs action plan has been on the political agenda since its start in 2000 and consequently the visibility of achievements was continuously high. Media also contributed to this enhanced awareness and activity boosting, especially since they have been able to identify a central personalised key actor in the person of the national drug coordinator. Another positive side effect of consecutive drugs action plans is an increased commitment of NGOs / civil society in the drug policies as they have been involved since the very beginning of the process. The general public has equally welcomed drug action plans since it enables them to follow up public efforts to fight a problem of great concern and to compare announced objectives with achieved actions.

Beside efforts made by all involved actors and networks, the positive outcome has also to be related to the considerable increase of the budgetary means allocated to the fight against drug addiction. An increase of almost 300% of the budget invested by the Ministry of Health in drug demand reduction occurred between 2000 and 2010.

Budgetary means invested allowed to increase resources in terms of primary prevention, to extend admission capacities of low threshold services, to increase the number of post-therapeutic offers, to further regionalize ambulatory treatment offers, to improve technical control measures related to substitution treatment, to reduce risks and damages, especially related to synthetic drugs and the transmission of certain infectious diseases, endemic to the population of PDU, to reduce the rate of drug overdoses and finally to promote research activities in the field.

Over the last 10 years the concept of implementation follow-up, evaluation and external evaluation strategies have gained in importance in the field of drugs and drug addiction. In the beginning of 2010, the Minister of Health jointly with the National Drug Coordinator has presented the new drug strategy and action plan 2010 – 2014. The referred action plan is based on the evaluation outcome of previous action plans and the assessment of current and future needs. In this context and for the first time nationally, a final external output and progress evaluation of the national drug strategy and action plan 2005-2009 has been performed (Trimbos Instituut)\(^\text{18}\) in 2009.

The contractual scope of the evaluation was a critical analysis of the implementation of the National Drug Action Plan 2005-2009. It built upon the above mentioned mid-term evaluation of the Drug Action Plan. The aim was to serve policy relevant information to the stakeholders involved in making and implementing drug policy in Luxembourg. The following questions were addressed:

- **Priorities:** Does the Action Plan address in an appropriate way the priorities put forward by the different stakeholders, e.g. by clear problem definitions and clearly defined actions?
- **Conditions:** Were conditions given to realise the actions formulated in the Action Plan, e.g. by serving the necessary instruments and resources, and by dividing and defining the responsibilities and by facilitating cooperation between the different stakeholders? Has the existing coordination structure proved to be appropriate and efficient?
- **Results:** Did the implementation of the National Drug Action Plan result in the realisation of the envisaged actions?

- **Process:** Did the process of policy formulation and implementation go well (managed appropriately, allowing and taking-up input from all stakeholders, etc.)?

In implementing the evaluation the following guiding principles were applied:

- The evaluation is based on reliable and verifiable facts/results;
- The evaluation process is transparent to all stakeholders;
- All relevant parties are invited to participate in the evaluation process;
- All these parties must feel free to express their opinions;
- The evaluation is meant to formulate concrete recommendations that could lead to improvement of the quality, efficacy and efficiency of the Luxembourg drug policy;
- The evaluation does not take a stand in the political debate in Luxembourg.

The evaluation report also lists a set of recommendations regarding the new National Drug Action Plan, the coordination structure and the policy-making process. Main results and recommendations were presented in the 2010 edition of the national drugs report. In addition to the recommendations of previously referred to working groups, the final output of the external evaluation exercise has been serving the National Drug Coordinator and the Interministerial Commission on Drugs to elaborate the new national drugs action plan 2010-2014.

**Other drug policy developments: Initiatives in Parliament and civil society**

Drug-related parliamentary questions submitted during the reporting period mainly addressed the use and availability of mephedrone and the use of cannabis in research.

No projects or propositions of law in relation with drugs or drug addiction were introduced in 2010 and no specific Parliamentary debates or initiatives in the field of illicit drugs are to be reported.

Special topics addressed by the GIT in 2010 were:
- regulatory means to prohibit the selling and use of substances able to reduce levels of drug concentration in urine or blood of drug users and thus to distort test results;
- the spread of shisha smoking;
- substitution treatment and diacetylmorphine assisted treatment;
- the phenomenon of research or designer drugs and their diversion. Creation of new legal instruments to fight the phenomenon of “legal highs”. Regulation of selling and confiscation of psychoactive substances not yet controlled.

- **ECONOMIC ANALYSIS**

**Public expenditures**

The fight against drugs is multidisciplinary. Thus, in Luxembourg: 11 ministries and 13 departments are involved to a different extent in the enforcement of national drug policies. As in most EU Member states, the structure of the national state budget does not allow for a drug budget allocation analysis exclusively based on labelled expenditures. Following are some of the preliminary problems one typically is confronted with in a public expenditure study:

- Budget lines may be generic (legal & illegal drugs), aggregated (addiction prevention), over inclusive (social solidarity) or unidentifiable (others),

---

19 See related chapter in Part B
- Apportionment of budgets may not be provided,
- Difference between provisional budget, voted budget and final expenditure (provisional budget often more detailed than voted budget),
- Expenditures may be annual, multiannual, unique, ordinary, extraordinary, etc. If they occur during the study reference year, they should be included even though they might give a biased picture of average or routine expenditures, especially when they are important (e.g. investments in real estate)\textsuperscript{20},
- In terms of follow-up: budget lines may be restructured, integrated or divided over time,
- In the field of public health, expenditures may result from direct state financing or social security reimbursement,
- Lack of clarity due to national mixed (Multi-ministries) financing (e.g. Public research Centres – multi projects’ financing) or national & EU & International shared financing,
- Eligibility of cooperation projects vs. variability of yearly contributions,
- Assessment of impact of general education and educational interventions (e.g.) on DDR impossible.

This list is not exhaustive. Nevertheless drug-related public expenditure studies are feasible although they demand a considerable amount of analytical work for labelled or dedicated budget lines as they require a certain degree of creativity as far as non-labelled expenditures are concerned. Researchers may be forced to take decisions whether to include or not a series of expenditures. It is important that those decisions are taken according to reproducible standards and, even better so, according to harmonized and ultimately widely recognized methodological benchmarks.

In order to tailor and fine tune a methodology that fits the national context and in line with the work plan of the EMCDDA, a national study on direct economic costs of drug policies and interventions has been performed from 1999 to 2002 and refers to data from 1999 (Origer 2002\textsuperscript{b}). \textit{(Etude du coût économique direct des interventions et de la politique publique en matière de drogues et de toxicomanies)}. The original research report can be accessed under: \url{http://www.relis.lu}. In the framework of 2006 EMCDDA contractual requirements, an update of the Origer 2002 study has been performed. A detailed description of the methodology applied in 2002 can be consulted in the original study. The same methodology has been applied for the present and other yearly updates.

\textbf{Methodology}

In the 2010 edition of the present report an overall estimation of direct public expenditures in 2009 compared to 1999 has been presented. Main results of these comparative studies are summarised in table 1.4. As overall estimations of public expenditures are not feasible on a yearly basis, the objective of the present analysis is to assess exclusively direct public health expenditures for the fight against drugs and drug

\textsuperscript{20} In order to highlight the different status/nature of budget lines, the following abbreviations have been used in the expenditure tables: \$ : Standard budget (annual expenditure / budget line) \$: Investments (unique year dependant expenditure)
addiction (drug-related prevention and treatment costs). The constituent concepts are defined as follows:

**DIRECT**: Excluding ‘costs of indirect consequences’ (e.g. loss of income, taxes) and ‘non quantifiable costs’ (e.g. loss of welfare) as well as expenditures related to the acquisition of illicit drugs by the consumer him- or herself.

**ECONOMIC**: Monetary impact and not social impact (costs) or loss of life quality e.g. costs.

**COSTS**: Expenditures and not revenues created by illegal drug market.

**NATIONAL DRUG POLICIES**: Public finances and not private expenditures or investments.

**DRUG-RELATED TREATMENT**: ‘... any activity that directly targets individuals who have problems with their drug use and which aims to improve the psychological, medical or social state of those who seek help for their drug problems. This activity often takes place at specialised facilities for drug users, but may also occur in the context of general services offering medical and/or psychological help to people with drug problems’ (EMCDDA, 2000). The harm reduction approach directly targets drug addicted persons and aims to improve their psychological, health and social state or situation. In the national understanding, drug-related treatment therefore also includes harm reduction interventions.

The applied methodology refers to the concepts of the ‘Cost of Illness’ (C.O.I.) theory in opposition to “Cost-Benefit” approach. **COFOG and REUTERS** classifications were applied as recommended by the EMCDDA. The following techniques have been applied and combined according to existing contexts:

- Analysis of state budget and provisional state budget
- Clarification meeting with involved financial authorities
- Qualitative interviews
- Analysis of activity reports of ministerial departments and NGOs
- Analysis of state conventions and financial statements of specialized NGOs
- Detailed financial breakdown and budget apportionment provided on demand by a series of institutions (NGOs, Social Security, Hospitals)

**Main data sources:**

- Laws and projects of law regarding the budget of revenues and expenditures of state
- Annual ministerial activity reports
- Activity reports of specialised agencies
- State conventions with NGOs
- Annual financial statements of specialised NGOs
- Statistical outputs and financial breakdowns of the CNS

**Main reference documents:**


**National estimates of labelled and non-labelled public drug demand reduction expenditures**

Table 1.1 provides an exhaustive overview of labelled and non labelled drug-related public expenditures in the field of drug prevention, treatment and harm reduction. In case an attributable proportion key was required, a detailed description of the calculation procedures is provided in the last column.

**Tab. 1.1.** National estimates of labelled and non-labelled public drug demand reduction expenditures (Data year: 2010)

<table>
<thead>
<tr>
<th>Ministry of Justice</th>
<th>S 7.2/12.370 0.30 TOX PROGRAMME: Care and treatment programme for drug addicts in prison</th>
<th>820,000.-</th>
<th>Extracted from the national state budget 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-11 Ministry of Education [...]</td>
<td>S 11.4 12.301 08.30 Drugs prevention campaigns in schools</td>
<td>2,000.-</td>
<td>Extracted from the national state budget 2010</td>
</tr>
<tr>
<td>Ministry of Health</td>
<td>S 14.0 12.000.05.00 Fees for National Drug Substitution treatment commission</td>
<td>0.-</td>
<td>Extracted from the national state budget 2010</td>
</tr>
<tr>
<td></td>
<td>S 14.1/33.013 05.23 – 33.015 05.23 Staff and operational costs of specialised drug agencies conventionned by state (25/40% non specialised)</td>
<td>7,548,226.-</td>
<td>Idem</td>
</tr>
<tr>
<td></td>
<td>S 14.1 12.311 05.10 Provision of drug injection material in the framework of the national NEP</td>
<td>537,000.-</td>
<td>Idem</td>
</tr>
<tr>
<td></td>
<td>S 14.2 12.301 05.20/12.801 05.20 Toxicological surveillance of drug addicts</td>
<td>150,000.-</td>
<td>Idem</td>
</tr>
<tr>
<td>Directorate of Health</td>
<td>S 14.1/33.014 05.23 Staff and operational costs of drug related activities of the National Aids counselling Centre</td>
<td>201,449.-</td>
<td>25% of total budget of the centre: average proportion of PLWHIV/AIDS infected via IDU in clients</td>
</tr>
<tr>
<td>Ministry of Social Security*</td>
<td>S 17.2 Staff, operational and mission costs for agents in charge of drug treatment referral abroad</td>
<td>80,000.-</td>
<td>Estimation by MSS based on analysis of work/mission/career</td>
</tr>
<tr>
<td>Ministry of Public Works</td>
<td>Maintenance work on/in buildings occupied by specialised NGOs (not covered by other budgets)</td>
<td>25,000.-</td>
<td>Extracted from the national state budget 2010</td>
</tr>
</tbody>
</table>
## NON LABELLED EXPENSES

### Health/Social Insurance

<table>
<thead>
<tr>
<th>A. Substitution treatment</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Reimbursement of prescription substitution drugs (methadone, buprenorphin, etc.) (net, patient’s contribution excluded)</td>
<td>327,451.-</td>
<td>Detailed breakdown by the National Health Insurance Funds (NHSF) and Union of Sickness Fund.</td>
</tr>
<tr>
<td>Reimbursement of pharmacies fees generated by substitution medication preparation /delivery</td>
<td>48,835.-</td>
<td>Detailed breakdown by the National Health Insurance Funds (NHSF) and Union of Sickness Fund.</td>
</tr>
<tr>
<td>Reimbursement of medical counselling costs related to substitution prescriptions</td>
<td>234,796.-</td>
<td>Number of substitution prescriptions (- free prescription JDH) X prescription fees (50% counselling &amp; 50% prescription renewal) X % reimbursed by health insurance (95%).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B. Inpatient hospital drug treatment</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Reimbursement of inpatient hospital drug treatment costs (e.g. detoxification)</td>
<td>3,001,734.-</td>
<td>2010 data.  ICD-10, F11, F12, F14, F15, F16, F18, and F19 hospital episodes X average cost per episode (adjusted CNS data).</td>
</tr>
<tr>
<td>Medical counselling costs associated to hospital treatment episodes</td>
<td>201,855.-</td>
<td>Number of medical consultations X reimbursed fees according to duration of stay.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C. Drug treatment abroad</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Reimbursement of drug treatment costs abroad/ e.g. residential therapy or therapeutic offer unavailable in Luxembourg</td>
<td>1,428,800.-</td>
<td>Year-adjusted breakdown provided by CNS.</td>
</tr>
</tbody>
</table>
D. Inpatient therapeutic treatment extra-hospital

797.705.-

Institution specific budget of 2001 adjusted for salary costs and inflation

D. Drug treatment costs subsidised by Min. Health

105,755.-

Budgetary section 14.0.34.011: Breakdown of real costs generated by drug treatment not covered by the CNS

E. Cost of HIV/AIDS treatment provided to patients infected via IDU

576,000.-

Number of HIV/AIDS patients infected via IDU x yearly average cost of HIV/AIDS treatment x reimbursable proportion

F. Estimation of state revenue loss from low renting prices for real estates provided to specialised NGOs

234,000.-

Yearly sum of differences between paid rent and market value rent.

* Ministry of Social Security (Health expenditures)

HIV/AIDS treatment (IDU related infections and health costs)

For HIV/AIDS treatment rates the following calculation formula has been applied:

- A: Total number of registered PLW HIV/AIDS infected via IDU (diagnosis reporting) (status: alive)
  - (if available: Total number of PLWHIV/AIDS infected via IDU X mortality rate of target population)
  - (higher precision (if available): Total number of PLW HIV/AIDS in treatment during year X that might be provided directly by central social security department)
- B: Average cost of HIV/AIDS treatment/ year
- Total cost of PLW HIV/AIDS IDU Treatment = A X B

Tab. 1.2 National estimates of non labelled drug related expenditures (attributable proportions)

<table>
<thead>
<tr>
<th>Ministry / Department</th>
<th>Budget / Expense (EUR)</th>
<th>COFOG 1</th>
<th>COFOG 2</th>
<th>SECTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>01 Ministry of Foreign Affairs and Immigration</strong></td>
<td>21,400.-</td>
<td>Gf01</td>
<td>Gf0101</td>
<td>S1312</td>
</tr>
<tr>
<td><strong>07 Ministry of Justice</strong></td>
<td>17,057,430.-</td>
<td>Gf03</td>
<td>Gf0306</td>
<td>S1312</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gf03</td>
<td>Gf0303</td>
<td>S1312</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gf03</td>
<td>Gf0304</td>
<td>S1312</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gf03</td>
<td>Gf0301</td>
<td>S1312</td>
</tr>
<tr>
<td><strong>12/13 Ministry of Family, Social Solidarity and Youth</strong></td>
<td>37,700.-</td>
<td>Gf10</td>
<td>Gf1010</td>
<td>S1312</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gf10</td>
<td>Gf1004</td>
<td>S1312</td>
</tr>
<tr>
<td><strong>14 Ministry of Health</strong></td>
<td>491,341.-</td>
<td>Gf07</td>
<td>Gf0704</td>
<td>S1312</td>
</tr>
<tr>
<td><strong>14.1 Directorate of Health</strong></td>
<td></td>
<td>Gf07</td>
<td>Gf0702</td>
<td>S1312</td>
</tr>
</tbody>
</table>

28
### 14.2 Public Health Laboratory

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>17 Ministry of Social Security</strong></td>
<td><strong>Health / Social insurance</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Substitution treatment</td>
<td>7,258,805.-</td>
</tr>
<tr>
<td></td>
<td>B. Inpatient hospital drug treatment</td>
<td>Gf07</td>
</tr>
<tr>
<td></td>
<td>C. Drug treatment abroad</td>
<td>Gf07</td>
</tr>
<tr>
<td></td>
<td>D. Drug treatment costs (Min. Health)</td>
<td>Gf07</td>
</tr>
<tr>
<td></td>
<td>E. Cost of HIV/AIDS treatment provided to patients infected via IDU</td>
<td>Gf07</td>
</tr>
<tr>
<td></td>
<td>F. Estimation of state revenue loss from low renting prices for real estates provided to specialised NGOs</td>
<td>S1314</td>
</tr>
</tbody>
</table>

**TOTAL B**<br>24,866,676

**TOTAL A+B**<br>38,438,483

### Table 1.3: Comparative analysis of drug demand reduction costs in Luxembourg 1999 vs. 2009 /2010 (EUR)

<table>
<thead>
<tr>
<th>Year</th>
<th>1999</th>
<th>2009</th>
<th>2010</th>
<th>Progression rate 1999-2010</th>
<th>Progression rate 2009-2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total expenditure</td>
<td>6,903,203.-</td>
<td>15,458,853.-</td>
<td>16,320,606.-</td>
<td>136 %</td>
<td>6%</td>
</tr>
<tr>
<td>Expenditure per inhabitant</td>
<td>16.-</td>
<td>31.-</td>
<td>32.-</td>
<td>100 %</td>
<td>0.3%</td>
</tr>
<tr>
<td>Expenditure per PDU</td>
<td>2,937.-</td>
<td>6,209.-</td>
<td>6,607.-</td>
<td>125 %</td>
<td>6.4%</td>
</tr>
<tr>
<td>Percentage of GNP</td>
<td>0.03</td>
<td>0.04</td>
<td>0.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percentage of state budget</td>
<td>0.15</td>
<td>0.17</td>
<td>0.19</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Source:** Origer 2002, PF OEDT, REITOX report 2009

### Table 1.4: Comparative analysis of overall direct drug-related public expenditures in Luxembourg 1999-2009 according to various indicators (EUR) (Origer 2002, 2010)

<table>
<thead>
<tr>
<th></th>
<th>2009</th>
<th>1999*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total expenditure</td>
<td>38,438,483.-</td>
<td>23,345,000.-</td>
</tr>
<tr>
<td>Expenditure per inhabitant</td>
<td>77.-</td>
<td>54.-</td>
</tr>
<tr>
<td>Expenditure per PDU</td>
<td>15,562.-</td>
<td>9,934.-</td>
</tr>
<tr>
<td>Percentage of GNP</td>
<td>0.1</td>
<td>0.13</td>
</tr>
<tr>
<td>Percentage of state budget</td>
<td>0.4</td>
<td>0.5</td>
</tr>
</tbody>
</table>


Budget

The NFP follows up the annual budgetary evolution by means of the most accessible and specific indicator, which is the annual budget of the Ministry of Health allocated to drug-related activities. Figure 1.1 shows the budgetary progression since the implementation of the first drugs action plan in 2000 and figure 1.2 summarises the annual progression of budget of the Ministry of Health and human resources allocated to drug-related activities.

**Fig. 1.1** Annual budget of the Ministry of Health allocated to drug demand reduction activities 2000 - 2011

<table>
<thead>
<tr>
<th>Year</th>
<th>2000</th>
<th>2005</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Budget (EUR)</td>
<td>2,066,000.-</td>
<td>6,196,000.-</td>
<td>8,321,620.-</td>
</tr>
<tr>
<td>Progression rate</td>
<td>Reference year</td>
<td>200%</td>
<td>303%</td>
</tr>
</tbody>
</table>


**Fig. 1.2** Annual progression of the budget of the Ministry of Health and human resources allocated to drug-related activities 2004 - 2011

<table>
<thead>
<tr>
<th>Budget Year</th>
<th>2004</th>
<th>2006</th>
<th>2009</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Budget (EUR)</td>
<td>5,771,000.-</td>
<td>6,584,000.-</td>
<td>7,991,583.-</td>
<td>8,321,620-</td>
</tr>
<tr>
<td>Annual progression rate</td>
<td>Reference year</td>
<td>6.27%</td>
<td>9.65%</td>
<td>4.13%</td>
</tr>
<tr>
<td>Annual cumulative progression rate</td>
<td>Reference year</td>
<td>14.09%</td>
<td>38.48%</td>
<td>44.20%</td>
</tr>
<tr>
<td>Dedicated human resources</td>
<td>Reference year</td>
<td>59.5</td>
<td>69.25</td>
<td>83.75</td>
</tr>
<tr>
<td>Full Time Equivalent (FTE)</td>
<td>Reference year</td>
<td>59.5</td>
<td>69.25</td>
<td>83.75</td>
</tr>
<tr>
<td>Annual progression rate</td>
<td>Reference year</td>
<td>9.06%</td>
<td>6.70%</td>
<td>1.7%</td>
</tr>
<tr>
<td>Annual cumulative progression rate</td>
<td>Reference year</td>
<td>16.39%</td>
<td>40.76%</td>
<td>49.16%</td>
</tr>
</tbody>
</table>


- Funding arrangements

Funding of drug-related interventions is centralised at state level. There exist no specific regional or local funding mechanisms. Few drug prevention activities are subsidised by council districts on an ad hoc basis. Respective ministries or governmental departments, according to their attributions, are co-ordinating the creation, the implementation and the funding of required infrastructures. Governmental departments directly rely on the state budget while NGOs involved in drug treatment or research activities have either signed a so-called ‘convention de collaboration’ with concerned ministries or are financed or co-financed on basis of regular subventions. A governmental delegate follows-up activities and functioning of a given NGO by attending a mandatory ‘coordination platform’.

The funding of drug action plan is subject to an annual budgetary decisions process. Specific local projects designed by non-governmental actors requiring external financial support are generally submitted to respective ministries or to other national funding sources (Fund Against Drug Trafficking, Foundations, private funds, etc.) or international bodies (EU, EMCDDA, etc.).

Social costs

Origer (2002) assessed the direct economic costs of policies and interventions in the field of illicit drug use referred to year 1999 (see www.relis.lu). An update of the Origer 2002 study has been performed according to data requirements for 2007 selected issues and results have been presented in the 2008 edition of the national report.

In July 2006, the STATEC (Central service of statistics and economical studies) published a study estimating the economic impact of the illegal drugs related activities in Luxembourg over the period 1999 to 2004 (Statec, 2006). The study was
carried out within the framework of a European project intended to improve the comparability and the coverage of national accounting. Results were presented in the 2009 edition of the national report.

**National media coverage of drug-related issues**

Relation with the media is an indispensable tool in communications strategies aiming at informing a broad public by providing up-to-date and reliable data on the numerous topics related to drugs and drug use. In 2010 the NFP performed an in-depth analysis of national written media base on an exhaustive press review and focusing on thematic areas touched upon and frequency of appearance. Of 454 articles on drug related matters, 90% were published by the most read national daily newspaper. Most represented topics in order of importance are: national short news, international short news and doping in sports. Table 1.3 summarizes main results and covers the period from August 2009 to July 2010.

![Fig. 1.3 National coverage of written media regarding drug-related topics from August 2009 to July 2010](image)

<table>
<thead>
<tr>
<th>Paper/magazine</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>TOT</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SR, law enforcement</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>111</td>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National short news item (arrests, seizures)</td>
<td>66</td>
<td>2</td>
<td>9</td>
<td>77</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Court news (convictions, sentences)</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National drug scene (perquisitions, etc)</td>
<td>15</td>
<td>4</td>
<td>19</td>
<td>19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prison related topics</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Road safety</td>
<td>2</td>
<td></td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Research</strong></td>
<td>4</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statec, Ceps/Instead</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Substances and addiction</strong></td>
<td>48</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Addictions in general</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannabis</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicaments</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doping</td>
<td>40</td>
<td>2</td>
<td>42</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mephedrone</td>
<td>2</td>
<td></td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Campaigns, prevention, laws</strong></td>
<td>45</td>
<td>9.91</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drugs in general</td>
<td>6</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>4</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tobacco</td>
<td>12</td>
<td>4</td>
<td>16</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious diseases</td>
<td>7</td>
<td></td>
<td>7</td>
<td></td>
<td>12</td>
<td></td>
<td></td>
<td>12</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>1</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Specialised drug agencies</strong></td>
<td>49</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NGOs</td>
<td>5</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOXIN / Drug injection room</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>7</td>
<td>2</td>
<td>11</td>
<td>2</td>
<td>11</td>
<td>41</td>
<td>41</td>
<td>41</td>
<td>41</td>
<td>1.41</td>
<td></td>
</tr>
<tr>
<td><strong>EMCDDA National Focal point</strong></td>
<td>7</td>
<td>1.54</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
<td>1.54</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activities and publications</td>
<td>3</td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td>2</td>
<td></td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ministry of Health, Government, Parliament</strong></td>
<td>28</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EU drugs strategy and action plans</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Health Commission, Questions to government, Interministerial Groups on Drugs</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Heroin Assisted Treatment</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methadone</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>External relations</strong></td>
<td>159</td>
<td>35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

Organised crime/trans-border cooperation | 5 | 4 | 9
International Organisations | 1 | 1 | 1
Afghanistan | 2 | 1 | 3
Mexico | 23 | 5 | 28
HIV | 14 | 14 | 14
International short news | 54 | 50 | 104
Miscellaneous | 3 | 0.66 |
Readers letters | 3 | 3 |
TOTAL | 298 | 6 | 3 | 5 | 12 | 10 | 13 | 1 | 2 | 1 | 2 | 3 | 98 | 454 | 100
PERCENTAGE | 56 | 1.32 | 0.66 | 1 | 2.64 | 2.2 | 2.86 | 0.22 | 0.44 | 0.44 | 0.66 | 21.59 | 100

Source: NFP 2010

2. Drug use in the general population and specific targeted groups

Introduction

Drugs referred to in the present report include narcotic drugs and psychotropic substances covered by the international drug control conventions (the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, the Convention on Psychotropic Substances of 1971 and the Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988). Drugs not listed in the latter UN conventions are addressed by the present strategy only in the context of their associated use to listed drugs.

‘Drug use’ is hereinafter defined as the self-administration of a psychoactive substance, that, when ingested, affects mental processes. Psychoactive substances may be of licit or illicit production, sale, or use and associated risks may be considered more or less important.

Prevalence estimations on drug use in the general population are based on data collected in more (e.g. schools) or less (general population: age group 15-64 years) targeted and representative samples of the national overall population. According to the most recent surveys, cannabis and derivates are by far the most common illicitly used psychoactive substances in the national population followed by Amphetamine Type Stimulants (ATS). Cannabis use in youngsters has been stabilizing over recent years but still shows the highest prevalence regardless considered age categories, whereas the prevalence of other psychoactive drugs varies according to age and data collection setting factors.

- DRUG USE IN THE GENERAL POPULATION

To date, no national, large-scale (representative) general population survey on drug use has been conducted. Several community or targeted population surveys however allow estimating current prevalence.

A primary prevention pilot project at community level was launched by the CePT in 1995. In 2000, 13 council districts participated in this project. In the framework of this project a non-representative survey on drug use in the general population (reference 1: “Fischer 1999 study”) was conducted.
A second survey organized by the CePT was published in 2000 ("Fischer 2000 study"). Even though cannabis consumption was the main subject of the study, several other substances have been taken into account. The samples have been drawn on the one hand from a cinema visitor's population in Luxembourg City (ref.:2.1) and on the other hand from a population of 6 council districts (ref.:2.2).
Regarding **lifetime prevalence**, the Fischer 1999 study revealed that youngsters from the age group 17 to 25 (18.9 %) are most vulnerable to cannabis consumption. The Fischer 2000 study reported 40.1% of lifetime prevalence concerning cannabis use (cinema sample). Discussions are currently held with the Ministry of Health to collaborate in a general study on health behaviour in general population in order to include items on drug use. This study may be conducted given required financial means are granted.

- **Drug use in the school and youth population**

National school surveys may be divided in **two categories**. A first category refers exclusively to drug prevalence surveys in schools; the second refers to cross-sectional surveys combining data collection in school settings and other youth environments.
## Surveys: category 1

### Reference 1:
**EN.** Students and Drugs

<table>
<thead>
<tr>
<th>Year of data collection</th>
<th>1992</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single/repeated study</td>
<td>Repeated study 1983 – 92</td>
</tr>
<tr>
<td>Context</td>
<td>Public Health</td>
</tr>
<tr>
<td>Area covered</td>
<td>Nation wide</td>
</tr>
<tr>
<td>Type of school</td>
<td>5th years of all types of secondary school classes at the national level</td>
</tr>
<tr>
<td>Age range</td>
<td>16-20 years (AGE ENTERING 5th CLASS)</td>
</tr>
<tr>
<td>Data coll. Procedure</td>
<td>Anonymous self-administrated questionnaires in school classes</td>
</tr>
<tr>
<td>Sample size</td>
<td>1,341</td>
</tr>
</tbody>
</table>

#### Fig. 2.4 Lifetime prevalence of drug use according to age (valid %) (Matheis, Prussen 1995)

<table>
<thead>
<tr>
<th>Substance</th>
<th>Lifetime prevalence (13-16 years)</th>
<th>Current use prevalence (13–16 years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannabis</td>
<td>4.5%</td>
<td>2.9%</td>
</tr>
<tr>
<td>Solvents</td>
<td>3.7%</td>
<td>2.9%</td>
</tr>
<tr>
<td>Heroin</td>
<td>5.2%</td>
<td>0.8%</td>
</tr>
<tr>
<td>Cocaine</td>
<td>1.4%</td>
<td>1.2%</td>
</tr>
<tr>
<td>LSD</td>
<td>1.8%</td>
<td>1.4%</td>
</tr>
</tbody>
</table>

**Source:** Dickes 1996

### Reference 2:
Dickes P. et al. (1996), La consommation de drogues légales et illégales des élèves des 6ème de l’enseignement secondaire et des 8ème de l’enseignement secondaire technique, CEPS/INSTEAD, Luxembourg.
**EN.** The use of licit and illicit drugs by students in 6th and 8th classes of national secondary schools.

<table>
<thead>
<tr>
<th>Year of data collection</th>
<th>1994</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single/repeated study</td>
<td>Single study</td>
</tr>
<tr>
<td>Context</td>
<td>Drug prevention. Commissioned by the National Drug Prevention Centre (CePT)</td>
</tr>
<tr>
<td>Area covered</td>
<td>City of Luxembourg</td>
</tr>
<tr>
<td>Type of school</td>
<td>6th secondary school level and 8th secondary technical school level</td>
</tr>
<tr>
<td>Age range</td>
<td>13-16 years</td>
</tr>
<tr>
<td>Data coll. Procedure</td>
<td>Anonymous self-administrated questionnaires in school classes</td>
</tr>
<tr>
<td>Sample size</td>
<td>650</td>
</tr>
<tr>
<td>Response rate (M, F, T)</td>
<td>100%</td>
</tr>
</tbody>
</table>

**Substance** | **Lifetime prevalence (13-16 years)** | **Current use prevalence (13–16 years)** |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannabis</td>
<td>4.5%</td>
<td>2.9%</td>
</tr>
<tr>
<td>Solvents</td>
<td>3.7%</td>
<td>2.9%</td>
</tr>
<tr>
<td>Heroin</td>
<td>5.2%</td>
<td>0.8%</td>
</tr>
<tr>
<td>Cocaine</td>
<td>1.4%</td>
<td>1.2%</td>
</tr>
<tr>
<td>LSD</td>
<td>1.8%</td>
<td>1.4%</td>
</tr>
</tbody>
</table>

**Source:** Dickes 1996
A comparison of the Matheis 1992 study and the HBSC 2000 study revealed that in 1992, 18.1% of secondary school students of 5th class in secondary school (16-20 years) declared having had contact with illegal drugs. In 2000, this proportion increased to 41.1%. The HBSC 2000 study reported a proportion of nearly 50% of youngsters aged 18 having consumed at least once in their life an illegal drug. However, the consumption of “hard” drugs is not widespread among youngsters. Approximately 4 to 5% of youngsters reported consumption of “hard” drugs, mostly due to experimenting, while a lower proportion effectively develops a related dependency.

It should be stressed that a new HBSC study referring to 2005/2006 data has been presented in 2008 (Ministry of Health, in press). The section on drug use in youngsters thus allows to updating a series of former data. A further HBSC wave has been performed in 2010. Respective data will be presented in the 2012 edition of the present report.
### Tab. 2.1 Comparative results from the serial HBSC 2002 and HBSC 2005/2006 surveys

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>age 11</td>
<td>age 13</td>
<td>age 15</td>
<td>age 11</td>
<td>age 13</td>
<td>age 15</td>
<td>age 11</td>
<td>age 13</td>
<td>age 15</td>
<td>age 11</td>
<td>age 13</td>
<td>age 15</td>
</tr>
<tr>
<td><strong>Tobacco</strong></td>
<td>boy</td>
<td>girl</td>
<td>boy</td>
<td>girl</td>
<td>boy</td>
<td>girl</td>
<td>boy</td>
<td>girl</td>
<td>boy</td>
<td>girl</td>
<td>boy</td>
<td>girl</td>
</tr>
<tr>
<td>ever smoked tobacco</td>
<td>-</td>
<td>-</td>
<td>39.4%</td>
<td>38.8%</td>
<td>59.6%</td>
<td>57.9%</td>
<td>13%</td>
<td>8%</td>
<td>34%</td>
<td>29%</td>
<td>57%</td>
<td>60%</td>
</tr>
<tr>
<td>at least once a week</td>
<td>0.5%</td>
<td>0%</td>
<td>9.2%</td>
<td>8%</td>
<td>24.7%</td>
<td>26.1%</td>
<td>2%</td>
<td>1%</td>
<td>6%</td>
<td>6%</td>
<td>17%*</td>
<td>21%*</td>
</tr>
<tr>
<td>daily smoking</td>
<td>0.5%</td>
<td>0%</td>
<td>5%</td>
<td>5.5%</td>
<td>20%</td>
<td>21%</td>
<td>1%</td>
<td>0%</td>
<td>4%</td>
<td>5%</td>
<td>13%</td>
<td>16%</td>
</tr>
<tr>
<td><strong>Alcohol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drunkenness</td>
<td>2.3% (11 and 12 years)</td>
<td>1.4% (11 and 12 years)</td>
<td>6% (HBSC 2006: 5.5%)</td>
<td>21.9% (HBSC 2006: 23.5%)</td>
<td>2%</td>
<td>1%</td>
<td>6%</td>
<td>5%</td>
<td>27%*</td>
<td>20%*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>weekly drinking</td>
<td>-</td>
<td>-</td>
<td>17.1%</td>
<td>13.4%</td>
<td>37.7%</td>
<td>22.9%</td>
<td>4%*</td>
<td>2%*</td>
<td>9%</td>
<td>6%</td>
<td>30%*</td>
<td>19%*</td>
</tr>
<tr>
<td>Cannabin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lifetime use</td>
<td>3.9%</td>
<td>0.2%</td>
<td>3.5%</td>
<td>21.8% (HBSC 2006: 23%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recent use – last 30 days – at least once</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannabis use in the last 12 months</td>
<td>3.8% (11 and 12 years)</td>
<td>0.6% (11 and 12 years)</td>
<td>3.5%</td>
<td>21.8% (HBSC 2006: 18%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* indicates a significant gender difference (p <0.05)
Surveys: category 2

### Reference 4:

<table>
<thead>
<tr>
<th>Year of data collection</th>
<th>1997</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single/repeated study</td>
<td>Single</td>
</tr>
<tr>
<td>Context</td>
<td>Public Health – primary drug prevention</td>
</tr>
<tr>
<td>Area covered</td>
<td>Nation wide</td>
</tr>
<tr>
<td>Type of school</td>
<td>2nd and 6th years of classical (N: 311) and technical (N: 355) secondary schools</td>
</tr>
<tr>
<td>Age range</td>
<td>13-22 years (13-14: N347; 15-17: N193; 18-22: N118)</td>
</tr>
<tr>
<td>Data coll. Procedure</td>
<td>Self-administrated questionnaires</td>
</tr>
<tr>
<td>Sample size</td>
<td>666</td>
</tr>
<tr>
<td>Sampling frame</td>
<td>Schools participating in the &quot;European 'Health-Schools' network&quot;</td>
</tr>
<tr>
<td>Response rate (M, F, T)</td>
<td>100%</td>
</tr>
</tbody>
</table>

#### Fig 2.6
Lifetime prevalence of drug use according to age groups (valid %) (Meisch 1998)

<table>
<thead>
<tr>
<th>Drug</th>
<th>13-14</th>
<th>15-17</th>
<th>18-22</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannabis</td>
<td>7.2</td>
<td>18.6</td>
<td>22.9</td>
<td>13.5</td>
</tr>
<tr>
<td>Solvents</td>
<td>4.3</td>
<td>2.0</td>
<td>2.5</td>
<td>3.3</td>
</tr>
<tr>
<td>Cocaine</td>
<td>0.3</td>
<td>1.0</td>
<td>0.9</td>
<td>0.6</td>
</tr>
<tr>
<td>Ecstasy</td>
<td>1.5</td>
<td>1.6</td>
<td>4.2</td>
<td>2.1</td>
</tr>
<tr>
<td>Heroin</td>
<td>0.6</td>
<td>0.5</td>
<td>0</td>
<td>0.5</td>
</tr>
</tbody>
</table>

### Reference 5:

<table>
<thead>
<tr>
<th>Year of data collection</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single/repeated study</td>
<td>Single</td>
</tr>
<tr>
<td>Context</td>
<td>Cannabis prevalence</td>
</tr>
<tr>
<td>Area covered</td>
<td>Nation wide</td>
</tr>
<tr>
<td>Type of school</td>
<td>2nd and 6th years of secondary schools</td>
</tr>
<tr>
<td>Age range</td>
<td>13-20 years</td>
</tr>
<tr>
<td>Data coll. Procedure</td>
<td>Self-administrated questionnaires</td>
</tr>
<tr>
<td>Sample size</td>
<td>562</td>
</tr>
<tr>
<td>Sampling frame</td>
<td>Schools selected on basis of their geographical situation (national representativity), exhaustive student sampling within the selected schools.</td>
</tr>
<tr>
<td>Response rate (M, F, T)</td>
<td>100%</td>
</tr>
</tbody>
</table>

#### Fig 2.7
Current and lifetime prevalence of cannabis use according to school levels (valid %) (Fischer 2000)

<table>
<thead>
<tr>
<th>Level</th>
<th>8th class (13 - 15 years)</th>
<th>12th class (16 - 20 years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannabis - lifetime prevalence</td>
<td>14.5</td>
<td>43.4</td>
</tr>
<tr>
<td>Cannabis - current use prevalence</td>
<td>4.64</td>
<td>13.45</td>
</tr>
</tbody>
</table>
SYNOPSIS OF MAIN COMPARABLE RESULTS AND OBSERVED TRENDS

LIFETIME PREVALENCE: SCHOOL POPULATION:

Prevalence figures for age group 12-20, provided by HBSC (2000) and Fischer (1999) varied between narrow limits and stressed increasing lifetime prevalence rates for cannabis, psilocybin and amphetamines/ecstasy, in accordance to results of previous surveys. The most relevant differences according to gender are lower prevalence figures for females with regard to cannabis, amphetamines and magic mushrooms use but a higher prevalence of medicament use.

The HBSC study (2000), the Fischer study (2000) and the serial surveys by Matheis (1985/95) provide trends in lifetime prevalence between 1983 and 1999 applied to age group 16-20. Cannabis use has shown the most significant increase during the referred period. Also on the increase in order of importance are magic mushrooms, ecstasy, cocaine and heroin. LSD and solvents use show stable figures since 1992.

Regarding age group 13-14, one should emphasise the increase of cannabis (9.7 - 10.5%) and cocaine (1.6 - 2%) lifetime prevalence. In age group 15-16 years, all prevalence rates show increasing figures since 1992 (cannabis: 27.7%, psilocybin: 4.1%). Compared with the latter group, age group 17-18 (HBSC) shows doubled lifetime prevalence rates except for cannabis, medicaments and solvents.
LAST 12 MONTHS PREVALENCE: SCHOOL POPULATION

The HBSC surveys (2000, 2006) provide last 12 months national prevalence figures in 12 to 20 years aged schoolchildren. Results mirror respective proportions of lifetime prevalence rates with particular emphasis on high cannabis (22.5%), psilocybin (3.3%) and amphetamines (2.2%) prevalence. Gender differences reflect the results of the lifetime prevalence surveys except for amphetamines use that is proportionally higher in females during the last 12 months. Medicaments use in females is more prevalent than in males.

Latest data available from the serial HBSC studies (2002 and 2005/2006) show a recent decrease of last 12 months prevalence (tab.2.2) of cannabis use in youngsters aged 13 to 17 years. This observation is particularly obvious in youngsters aged 14, 16 and 17. Last 12 months heroin and cocaine use have been showing a certain overall stagnation between 2002 and 2006 whereas XTC, amphetamines, LSD and magic mushrooms consumption in youngsters has sensibly decreased over the same period. After a more detailed analysis, one notices that the age category of 15 years is the only to show increasing use specifically for XTC and cocaine. This age group should be monitored with greater attention in coming years.

Tab. 2.2 HBSC 2002 and 2005/2006: Analysis according to age (last 12 months prevalence)
LAST 30 DAYS PREVALENCE: SCHOOL POPULATION

Fischer (1999) provides last 30 days prevalence figures for 13 to 20 year old school children. Cannabis and ecstasy prevalence figure 13.8% and 1.1%, respectively. Heroin, cocaine and LSD prevalence rates are close to last 12 months prevalence rates. Gender breakdowns are currently not available.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannabis</td>
<td>13.8%</td>
</tr>
<tr>
<td>Heroin</td>
<td>0.6%</td>
</tr>
<tr>
<td>Cocaine</td>
<td>1.3%</td>
</tr>
<tr>
<td>Ecstasy</td>
<td>1.1%</td>
</tr>
<tr>
<td>LSD</td>
<td>1%</td>
</tr>
<tr>
<td>Psilocybin</td>
<td>1.8%</td>
</tr>
</tbody>
</table>

Drugs among targeted groups

In 2007, the National EMCDDA focal point published the results of action research on HIV and hepatitis infections in drug users (Origer and Removille, 2007).

REFERENCE c.1


EN: Prevalence study on HIV, HCV, HBV and HAV in PDU in Luxembourg

Year: 2007
Single/repeated study: Single
Context: HIV, HCV and injecting drug use prevalence national PDU population
Area covered: In- and outpatient drug agencies and national prisons
Age range: > 17
Data coll. Procedure: ANONYMOUS SELF-ADMINISTRATED QUESTIONNAIRES AND SEROLOGICAL TESTING
Sample size: 366
Sampling frame: Random sampling
Response rate (M, F, T): 33.96%

MAIN RESULTS:
- 67.21% of PDU reported at least 1 prison stay during the last 10 years
- of which 56.1% report drug use in prison
- of which 54.3% report IDU in prison

Furthermore, a study on “Drug addiction in the working environment: Prevalence of use of psychoactive substances use and its relationship to high-risk occupation and stress” (S. Krippler and F. Kittel, 2011)22 has been published in April 2011. The aim of the study was to explore the prevalence of licit and illicit psychoactive substances use among employees aged between 18–39 years in the private sector in the G.D. of Luxembourg as well as its relationship to high risk occupations and other potential risk factors in occupational settings, (e.g. high-stress tasks). For this purpose, a self-administered questionnaire containing validated tools from the EMCDDA concerning street drugs, the AUDIT-C for alcohol use and the Siegrist Effort-Reward-Imbalance questionnaire on stress were distributed during occupational medical check-ups during June and July 2008. Alcohol, cigarettes, amphetamines, cocaine, heroine, ecstasy, LSD and psychotropic drugs use were investigated together with socio-demographic and professional factors. Among the 1358 respondents, 8.4% consumed illicit substances, cannabis accounting for 8.2%. High-risk occupations are significantly related to illegal

substance use. Age (young), gender (men), smoking and family situation (bachelor living alone) show the same relationship. No effect was found for stress on illicit drug use while there was a significant effect on alcohol and prescription drug use in bivariate analysis only.

A new Flash Eurobarometer N°330 (for more details see chapter 3) was carried out in May 2011 on the request of the European Commission among young people aged 15-24. Among others, one item referred to self-reported use of cannabis and another to the experience with legal substances that imitate the effects of illicit drugs (“legal highs”).

<table>
<thead>
<tr>
<th></th>
<th>LU</th>
<th>EU 27</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes – in past year</td>
<td>11</td>
<td>14</td>
</tr>
<tr>
<td>Yes – but more than one year ago</td>
<td>10</td>
<td>12</td>
</tr>
<tr>
<td>No, I have never used</td>
<td>77</td>
<td>72</td>
</tr>
<tr>
<td>Don’t want to answer</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

Concerning self-reported use of cannabis, more young people in Luxembourg (77%) declared not having used cannabis compared to the European average (72%). All in all, however, there was no significant variation with regard to self-reported cannabis use among Luxembourg youngsters and the EU average.

Concerning “legal highs”, in most EU countries not more than 1 in 20 young people reported having used legal substances imitating the effects of illicit drugs. In Luxembourg self-reported use was 7% and higher than the EU average (5%).

### 3. Prevention

#### Introduction

Capacity building, awareness raising and mobilization of individual resources and promoting protective factors are the main benchmarks as far as national prevention strategies are concerned. Measures may target the general public or selective, specific or risk populations or communities.

The present chapter provides a summary of recent universal and selective prevention measures undertaken at the national level. More detailed information and examples of good practice can be found in the EDDRA / Best practice database of the EMCDDA under: [http://www.emcdda.europa.eu/themes/best-practice/examples](http://www.emcdda.europa.eu/themes/best-practice/examples).

The national drugs action plan 2010-2014 addresses primary prevention as a main intervention area.

The priorities of the drug prevention action plan and the GIT as approved in 2010 are as follows:

- Multidisciplinary training programmes and training of multipliers
- Interventions in school and youth environments, peer education;
- Prevention in homes for youngsters and socio-educative facilities;
- Intervention in recreational and festive venues;
- Cannabis, alcohol, shisha and designer drugs use in youngsters;
- Mass media campaigns;
- Documentation strategies.

The National Prevention Centre on Drug Addiction (CePT), which has started its activities in 1996, covers illicit drug use prevention as well as other types of addictive behaviour. Legally speaking the CePT is a foundation co-financed by the Ministry of Health.

A second important player in the field of primary drug prevention is the Division of Preventive Medicine of the Directorate of Health. Although the latter coordinates activities in the larger field of public health promotion and prevention, it plays a major role, jointly with the CePT in the definition of the overall framework of addiction prevention.

The overall coordination of counselling, treatment and low threshold interventions is within the competence of the AST (Department of Directorate of Health, future division of Drug Addiction and Social Medicine) and the national drug coordinator’s office. The AST has coordination and financial control missions (supervision of financial contract implementation of subsidised NGOs) in the field of drug addiction and psychiatry. Furthermore, the national drug coordinator is responsible for the conceptualisation and the implementation of activities included in the drugs action plan 2010 - 2014 (see 1.1).

Direct drug prevention expenditures reached 672,000.- EUR in 2000 and 985,000.- EUR in 2010. These figures include staff and operating costs of agencies and ministerial department specialised in drug prevention.

Training interventions in drug demand reduction are increasingly developed at the national level. The CePT publishes an annual training directory including training activities ranging from evaluation methodologies to demand reduction action-research strategies targeted at drug prevention and public health actors, educators, youth animators and teachers. The ‘Recherche et Innovation Pédagogiques et Technologiques (SCRIPT)’ department is actively involved in the referred training activities. The Department for Scientific and Applied Research may finance training activities following request.

A special department named ‘Trampolin’ has been set up within the CePT, to ensure the development of training activities and instruments covering national needs. Target groups are professionals from the educative, social, psychological and medical fields as well as parents and other interested stakeholders.

As regards ad-hoc continuous training of national field actors, most of the involved structures are conventioned by the government and, as such, rely on the Ministry of Health’s regulation on continuous training.

---

23 The exact estimation of prevention related costs is speculative since multiple factors influence the development of a youngster. Education, leisure activities, sport, etc may have a positive impact on resources building; they however cannot be quantified in terms of exclusive input.
• UNIVERSAL PREVENTION

School
Drug prevention programmes in schools are not mandatory. National drug prevention activities integrated within national school programmes have mainly resulted from corporate actions of different governmental and non-governmental actors: Ministry of Family and Integration – National Youth Service (SNJ), Ministry of Health - Division of Social and Preventive Medicine, Ministry of National Education – Psychological Care and Educational Orientation Department (CPOS) and since 1996, the National Addiction Prevention Centre (CePT).

The CPOS is permanently represented in all secondary schools by at least one trained psychologist and several ad hoc teachers. In major schools there are supplementary trained social workers. Among other tasks, they are supposed to detect, at the very early stage, problems or behaviours in relation to substance abuse. Drug and addiction topics are included in more general courses as for instance, hygiene or ethics, which might not be mandatory. However, on the school director’s demand, trained staff from the CePT does intervene. Furthermore, the Grand-Ducal Police organises school courses for the 6th classes of primary school and 7th classes of secondary schools provided by specialized police teams out of regional police units and from the drug department of the Judicial Police.

In 2000, the CePT in collaboration with the SCRIPT started a pilot project called ‘d’Schoul op der Sich’ (School on quest) (see EDDRA) running for two years and having been evaluated in 2003. The aim of this participative project consisted in creating so-called prevention groups among all participating secondary schools in order to initiate a process of reflection on drug related themes. In 2004, the CePT managed to set up a primary prevention tool adjustable to the needs of the different secondary schools. Prevention groups are now operating routinely in several secondary schools in order to find solutions that fit each particular context.

In this context a further development stage has been reached in 2009 by the launch of the CePT Toolbox. This ‘box’ includes the necessary tools to understand and promote life competences of children from 3 to 15 years and accompany them on their way to autonomy. The referred instruments are primarily meant to serve educators, pedagogues, psychologists and teachers to assist them in their professional activities. The CePT toolbox can be downloaded at: http://cept.lu/fr/projets/548-ceptoolbox

As far as training activities are concerned, around 1,000 persons have participated in training sessions and conferences organized by the National Prevention Centre on Drug Addiction (CePT) during 2010, namely in the framework of the collaboration with the Service of Coordination of Research and of Pedagogical and Technological Innovations (SCRIPT) and the Luxembourg University, the City of Luxembourg, the national federation of School children’ parents, the Police academy and specialised agencies.

Various schools have also been involved directly in the elaboration of prevention programmes. Thus, a group of students from private schools have conceived, jointly with the prevention service of the local police, a project called ‘Clean is cool’ to draw attention on the dangers of cannabis abuse. The main objective was to incite youngsters to actively and autonomously seek for information and knowledge in order to promote self-motivated preventive attitudes.
A mobile interactive and prevention instrument called the ‘Extra-Tour Sucht’ and aiming to reach students aged 15 to 18 years in secondary school settings was further developed and adapted for instance to new trends such as shisha smoking. It was specifically designed for the Luxembourgish school settings by the German company KomPass. Interactive intervention modules are applied alternatively and allow for a participation of 60 pupils. Currently the following thematic sessions are proposed:

- Tobacco – Lust for life
- Dependence and pleasure
- Life skills – Fit for life
- Norms – New world
- Alcohol – To win and to loose

In 2009 the CePT jointly with the Ministry of Education published a brochure on cannabis specifically designed for teachers and other professionals from the educational sector called ‘School and cannabis – Recommendations for Education professionals’. It includes epidemiological data, recommendations on early recognition, prevention and intervention means and information on existing networks: http://cept.lu/fr/projets/456-schule-a-cannabis-ein-leitfaden-fuer-das-schulpersonal.

The project ‘Nach ëmmer allcool’ was developed jointly by the CePT, the National Theatre of Luxembourg (TNL) and SCRIPT. The outcome was a theatre play, addressing prevention of alcoholism presented in secondary schools from January to March 2009 reaching approximately an audience of 1,300 persons. A new edition of the project is planned for 2011.

Finally, trained police staff periodically visits various schools of the country, to inform students on drugs and their risks.

Family

Even though interventions aiming at the promotion of positive life experiences within the family and the kindergarten are not expressively addressed in the national drug prevention action plan, there are local or regional initiatives focusing on information and advice providing to teachers and the organisation of parents’ evenings during which educational and health topics are discussed.

Active collaboration between the CePT and parent’s association at each education level does exist. In 2001 CePT has released the so called ‘prevention boxes’ including didactic material destined to potential multipliers as for instance teachers, parents and youth animators. The first prevention box, targeting 3 to 6 years old children has been released in September 2001. Due to its success, the 3-6 years prevention box will be reedited and a second one for children aged 11 to 15 years has been released in 2002. In 2004, seminars on the ‘prevention boxes’ took place in different communities participating in the project of addiction prevention in local communities. Also, the CePT collaborates with the Kannerschlass Foundation, in the framework of the project ‘Parents’ School’.

To date, there exists no outreach prevention programme specifically aiming at parents, pregnant women, childbirth or young parents.
Community
As most of drug-related interventions and strategies for prevention in community settings are organised centrally and nation wide, projects are rarely initiated by the local community level without close collaboration of national authorities.

Generally speaking, local and regional communities do rarely dispose of a comprehensive drug prevention strategy. Commonly, a given national agency initiates projects, defines the general intervention framework and seeks active collaboration with community authorities in order to meet local needs. The observed situation is mainly due to geographical parameters of the Grand Duchy. At present only one agency focuses on interventions in recreational settings, namely the CePT (community project24).

The CePT is continuously developing the project ‘adventure circuit’, an instrument for interactive and tangible drug prevention targeting general population. This itinerant exhibition has been prepared in 2004 by more than 40 volunteers who since then have fine-tuned and further developed the concept for national prevention tours. In 2008/2009 a performance tour was organised in Mondorf Group regions entitled ‘The Quest of happiness’.

- SELECTIVE PREVENTION IN AT-RISK GROUPS AND SETTINGS

At-risk groups
In 2006, MDs without frontiers - Youth Solidarity (currently Jongenheem asbl) in collaboration with the Public Prosecutor's Department of Youth Protection and the Judicial Police- Drugs Unit launched a new project called CHOICE, which is based upon a pilot project of ‘early intervention of first drug offenders’ (FreD) initiated by the Federal Ministry of Health and social security of Germany. The target group consists of youngsters aged 12 to 17 who entered in conflict with drug law. The overall aim of CHOICE is to offer youngsters an early and short-term intervention in order to prevent further development of drug abuse and drug addiction. An ‘in-take’ interview allows assessing whether a participation in the CHOICE project or an individual psychological follow up is indicated. A CHOICE group consists of four interactive sessions (6 to 8 participants) which provide information on drugs, legislation and treatment services, promote auto-reflexion, reinforcement of personnel skills and motivation to change attitudes towards drugs. In a first phase, the project is regionally limited to the judicial district of Luxembourg City. Police officers hand out CHOICE flyers to youngsters in breach with drug law including all information on the intervention and inform the Public Prosecutor's department of Youth Protection. The youngsters and eventually their parents contact the CHOICE team within two weeks and the latter inform the Public Prosecutor on the participation level. A certificate testifies the participation of the youngster.

24 In the beginning of 1995, a pilot project on community-based drug prevention has been launched by CePT (see EDDR). The main idea was to focus prevention activities on the very environment and daily life experiences of young people. Various demand reduction activities have been undertaken, either developed by CePT, SNJ and several youth centres, or initiated by the respective District Councils. 13 district councils and 150 volunteers are currently involved in the project. The funding of this community project is jointly ensured by the involved district councils, the EU (Drug Prevention Programme DG-V) and CePT.

The primary aim of the project is to improve communication skills on drugs, to increase participants’ abilities in handling conflicts, stress and frustration (age range: 12 to 65 years) and to set up autonomous groups to continue implementing local prevention measures. In each participating municipality, prevention groups were composed of local volunteers who were asked to organise local drug-prevention activities related to their specific needs. Cornerstone concepts of the project are as follows: - Multidisciplinary drug prevention, - Tailor-made community solutions, - Health promotion with regard to risk and protective factors, - Holistic and systemic approach, - Target groups oriented, - Routine evaluation.

The community-based prevention network is an ongoing project, which is expected to develop its proper dynamic over the time. The idea was to switch from a centrally coordinated pilot project to routine and autonomous local programmes.
In 2009 Aidsberodung Croix-Rouge in collaboration with the Ministry of Health and the CHL launched a project called ‘DIMPS’ (Intervention mobile for sexual health) in the framework of the national action plan on Aids 2006-2010. DIMPS is meant to inform on risk behaviour and provide free infectious disease testing in difficult-to-access populations, such as immigrants. Combined rapid tests for HIV and HCV are proposed and the new drugs action plan foresees to broaden the mobile offer to vaccination of hepatitis A and B in case of medical indication. Currently the DIMPS van visits low threshold drug agencies, gay meeting places and immigration centres. The referred offer shows high acceptance and interest in the target groups. From 2009 to 2010, the DIMPS van registered 58 drives of 2 to 3 hours. At all, contact with 184 individuals has been made during this time and 212 counselling sessions have been held of an average time of 30 minutes. The clients are aged between 17 and 65 years with an average age of 32.7 years. Of 184 clients seen between 2009 and 2010, 66.8% were male and 33.2% were female.

Fig. 3.1: Nationality of DIMPS clients 2009-2010

34.6% of DIMPS clients are drug users and 29.4% of all the clients are injecting their drugs. 44% of this population reported that they never made an HIV test at an earlier stage and 61% never submitted to a HVC test before.

Moreover, the CePT introduced an EU project in the framework of the Grundtvig-Programme called ‘Promotion of social and personal competences in socially unprivileged persons’ – PROSKILLS. Its objective is to elaborate didactic material for multipliers working in the field of the promotion of social and personal competences. Germany, Finland, Greece, Italy, Slovenia and Hungary collaborate in the project.

Finally, a targeted survey ‘Youth attitudes to drugs’ (Eurobarometer, no 330) was conducted for the European Commission, from the 9th to 13th of May 2011. Telephone interviews were conducted in each of the 27 EU countries. Each national sample was representative of the general population between 15 and 24 years. Sample size varied between 250 and 500 respondents. The main results are briefly presented hereinafter:

- Information on illicit drugs and drug use - Potential sources of information
Likewise results from the previous 2008 Flash Eurobarometer study, the internet was the most popular source of information, with 64% (EU) (LU: 59%) of 15-24 year-olds, who said they would use the Internet when looking for general information about illicit drugs and drug use. The second preferred source were friends (EU: 37%; LU: 48%) and on third position, parents or relatives (EU: 28%; LU: 35%) as well as doctors or nurses (EU: 28%; LU: 35%). The same order has been observed in the Luxembourgish sample.

Fig. 3.2: Potential sources of information about illicit drugs and drug use

Potential sources of information

Source. Eurobarometer 330

Information channels reaching youngsters in the past year

When asked through which information channels young people had been informed on the effects and risks of illicit drug use during the past year, 39% of respondents referred to the internet (LU: 42%), compared to 46% who reported media campaigns (LU: 43%) and 41% who mentioned school prevention programmes (LU: 57%).

Twenty-six percent said they had discussed these issues with friends (LU: 41%) in the past year, and roughly a sixth (17%) of respondents had been informed by their parents or other relatives (LU: 24%). A minority of respondents said they have been informed on effects and risks of drug use by police (EU: 8%; LU: 22%) or via drug and/or alcohol helpline (EU: 2%; LU: 2%). Finally, 10% of respondents reported not to have been informed at all (LU: 7%) about the effects and risks of illicit drug use in the 12 months prior to the survey.

In both surveys, conducted in 2008 and 2011, the most frequently mentioned information channel was media campaigns, followed by school prevention programmes and the internet. Compared to 2008, the gap between the proportion of young people who mentioned school prevention programmes and those who referred to the internet has decreased – this suggests that the internet has become somewhat more important as a source for drug-related information. Most popular information channels for the youngsters in Luxembourg are: school prevention programmes, followed by media campaigns and the internet.
How should drug problems be tackled?

As in the 2008 Flash Eurobarometer, the largest proportion of respondents considered that public authorities should tackle problems on the supply side: 64% mentioned **tough measures against drug dealers and traffickers** (LU: 69%) as one of the most effective ways to reduce drug problems.

As far as drug demand reduction is concerned, young people thought that other measures, such as prevention or treatment and rehabilitation of drug users, would be more effective than repressive measures. Nearly half of respondents (49%) referred to **information and prevention campaigns** (LU: 57%) as one of the most effective ways of reducing drug problems; the **treatment and rehabilitation of drug users** followed, with 37% (LU: 43%) of respondents choosing this as an effective measure. By comparison, **tough measures against drug users** were considered to be a valuable way of dealing with drug problems by a third of respondents (EU: 33%; LU: 34%).

Reducing one of the possible primary causes of drug abuse – i.e. **poverty and unemployment** – was mentioned by 24% (LU: 29%) of interviewees. A similar proportion (EU: 23%; LU: 22%) thought that offering **more leisure opportunities** would be an effective way of dealing with drug problems. As in 2008, **legalisation of drugs** was thought of to be the least effective way of fighting drug problems: 13% (LU: 19%) of young people, however, put forward this measure as one of the most effective ones.
Fig. 3.4: How should society’s drug problems be tackled?

<table>
<thead>
<tr>
<th>Most effective ways for public authorities to reduce drug problems</th>
</tr>
</thead>
<tbody>
<tr>
<td>Making drugs legal</td>
</tr>
<tr>
<td>More leisure opportunities</td>
</tr>
<tr>
<td>Reduction of poverty and unemployment</td>
</tr>
<tr>
<td>Tough measures against drug users</td>
</tr>
<tr>
<td>Treatment and rehabilitation of drug users</td>
</tr>
<tr>
<td>Information and prevention campaigns</td>
</tr>
<tr>
<td>Tough measures against drug dealers and traffickers</td>
</tr>
</tbody>
</table>

Source. Eurobarometer 330

At-risk families

Since 2003, the Youth-and Drughelp foundation (JDH) is running a parental project with the aim to provide psycho-social aid to drug-dependant parents and their children. The primary objective of the project is to ensure security and well-being to children and to strengthen parents’ educative capacities. This long term project is based upon contractual commitments, co-intervention, home visits and functions in close collaboration with involved services. In 2010, the interventions concerned 96 parents as well as 50 children living with their parent(s) and 47 children, who don’t live with their parent(s). An essential part of the project constitutes the outreach work. Meetings and interviews are held within the natural environment of the family (at home).

Moreover the CePT, in collaboration with JDH offers training courses for at risk mothers in order to build up their capacities as parent and improve mother-child relationship. (Project: O Mamm O Kanner, which was renamed “1-2-3 lass” “1-2-3 go!” in 2009.)

Recreational settings

Youngster do spend an important share of their time in leisure, recreational or social activities and numerous programmes in recreational settings take place at the community level, church and youth organisations or sport-oriented clubs. The latter are not necessarily drug specific and as such difficult to list exhaustively.

Since its creation in 1995, the CePT, has initiated projects in the field of active leisure organisation: anti-drug discos, art performances, theatre, media supports (films, cartoons, etc.), seminars, ambulatory exhibitions, travel experiences, etc. The CePT increasingly ensures the national coordination of such activities. A broad offer of activities for youngsters integrating the drug prevention topic as one of the various components of Health education is developing. The latter approach is believed to have more impact on youngsters (users and non users) than a drug-centred approach. Indeed, human interactions in daily life situations as for instance adventure or sports activities are most adequate as a conceptual framework for the progressive integration of drug-related prevention initiatives.
In this respect, the demand reduction activities organised by the ‘Mondorf Group’ (joint initiatives of border regions of France, Germany, Belgium and Luxembourg) jointly with the CePT and SNJ combine a non drug-centred approach with intercultural components in organising corporate leisure activities for youngsters from border countries based on the concept of ‘adventure pedagogy’. The annual ‘adventure weeks’ do fit in a broader programme named ‘Adventure pedagogy and primary addiction prevention’. Those activities primarily aim to provide the opportunity to youngsters to experience group dynamics, conflict management, limit and risk assessment as well as the feeling of solidarity within a group of socially and culturally different people. The programme further aims at the reduction of risk factors and the enhancement of protection factors, by focussing on youngsters and their environment, rather than on drugs and addiction. Regional teams specialised in drug prevention meet in autonomous working and training groups and report activities to the Mondorf Group.

The CePT continued its close collaboration with the National School for Physical Education and Sports (ENEPS) in the framework of a project called ‘Give strength to children’. Sportive activities are used as a framework and a tool for preventive action. More information is available under: http://cept.lu/fr/projets/376-kanner-staark-maachen-am-sport.

Currently there exists no legal framework regulating prevention and harm reduction interventions in recreational settings such as on site information providing or pill testing. Discussions and a related parliamentary motion during the amendment process of the national drug legislation (amended in 2001) did not bring up a final decision on the matter. Prevention material and info flyers on synthetic drugs and multiple drug use are provided to bars and nightlife establishments by the initiative of CePT or on demand. There remains however an obvious lack of interventions in the referred settings.

Since May 2008, the National Prevention Centre on Drug Addiction (CePT) is an active member of the working group on health promotion in festive environment and this especially for the project ‘Democracy, Cities and Drugs II’, a project derived from a collaboration with the European Forum for the Urban Security. CePT has participated as associated partner in the elaboration of the project called ‘Club Health- Healthy and Safer Nightlife of Youth’ (www.democitydrug.org/safernightlife).

In the framework of the INTERREG IV Programme: Grande Région 2007-2013 Project 52 GR 3 3 100 the CePT participates in the project MAG-Net: http://cept.lu/fr/projets/442-mag-net - Promotion of well being and prevention of addictive behavior in school and recreational settings by youngsters and risk groups. The referred project includes the creation of a network of experts from Germany, France, Belgium and Luxembourg aiming to develop preventive measures for school, recreational and social settings. The duration of the project covers June 2009 to May 2012.

The governmental programme of 2009 puts emphasis on the phenomenon of binge drinking and its increasing prevalence in youngsters. The government also intends to promote the selling of non alcoholic drinks at a lower price than alcoholic drinks in recreational setting and overall. A special working group chaired by the Ministry of Health has received a mandate to continue its work. Measures implemented according to recommendations from the referred group included a significant raise of taxes imposed on alcopops, 16 years minimum age for the purchase of alcoholic beverages and zero tolerance for young drivers. The group currently elaborates an action plan on alcohol to be integrated in the general framework of the national strategy to fight addictive behaviour.

25 See EDDRA
Occupational settings
In cooperation with the human resources department of the City of Luxembourg, the CePT runs a pilot project to prevent addiction behaviour and its consequences in City employees based on a preliminary situation and needs assessment.

- **INDICATED PREVENTION**

Children at risk with individually attributable risk factors
Three basic mechanisms are in place in order to prevent the onset of problem drug use related to behavioural problems including for instance ADHD. Outpatient psychiatric care by trained psychiatrist or by specialist consultation centres is a first option. In more severe cases the national juvenile psychiatric service may provide in-patient care. More specifically targeting drug use the parentality service of JDH is aiming to assist drug dependant parents to take care of their children and to build up capacities helping them to deal with potential related problems.

A special CD-Rom has been developed by the Ministry of Education providing information on ADHD in school settings and to parents. Teachers are also trained to recognise ADHD symptoms and to react adequately.

- **NATIONAL AND LOCAL MEDIA CAMPAIGNS**

Since September 2007, CePT has enlarged its offer of existing information (library, leaflets, brochures and homepage) by adding a telephone line, which is accessible every day from 9 am to 1 pm, as well as an electronic help-line (FRO NO). The redesign of the CePT homepage: [www.cep.lu](http://www.cep.lu) guarantees better access to information related to drugs and addictions.

Furthermore, leaflets on alcohol and cannabis and the latest one on psychotropic medications, informing the general public on effects of referred substances, their legal status, related risks, were diffused to a very broad national public. All these leaflets are available at [http://cept.lu/fr/publications/cat_view/203-publications/30-substances-psychotropes-a-comportements-addictifs?limit=10&order=date&dir=ASC&start=10](http://cept.lu/fr/publications/cat_view/203-publications/30-substances-psychotropes-a-comportements-addictifs?limit=10&order=date&dir=ASC&start=10)

A flyer on solvent abuse was exclusively addressed to adults taking care of children and adolescents. A rapid assessment survey within different professional groups conducted by a newly created department of CePT (2009) ([MeSH](http://cept.lu/fr/projets/342-mesh-un-nouveau-service-du-cept)) provided a better insight in this phenomenon in Luxembourg. 2,700 short questionnaires were sent out to MDs, teachers in primary schools, counselling services in secondary school and Police district offices. The return rate only reached 5 % and the non published results are therefore to be considered with caution.

The survey report concluded: ‘In contrast to the alarming scene depicted by the media, our results show very localised and isolated occurrences of inhalant abuse in the Grand Duchy of Luxembourg. Furthermore, very few reports concern primary school pupils. Well intentioned dissemination of information and hazard warnings can easily backfire and, instead of preventing inhalant abuse, turn into a publicity stunt for these products. On the basis of our results of this poll we refrained from launching a widespread information campaign and decided to publish instead a fact sheet for professionals working with children and teenagers.’
In June 2009, CePT launched a new awareness raising campaign on what dependency actually is about. Without further explanation, yo-yos with the inscription ‘I make dependent’, the phone number and the e-mail address of the national prevention centre were distributed next to the central railway station and in the pedestrian area of Luxembourg City. Additionally, newspaper articles with provocative questions on different consumption behaviours were published: Chocolate makes dependent? Cannabis makes dependent? Mobile phones make dependent? Alcohol makes dependent? Yo-yos make dependent? The main objective of this campaign was to tackle interest of the general public, to motivate them to ask questions and to realise the versatility of the concept of addiction.

4. Problem Drug Use

Introduction

At the national level ‘problem drug use’ (PDU) or ‘harmful use’ is defined according to the WHO Lexicon of Alcohol and Drug terms (Geneva, 1994): ‘A pattern of psychoactive substance use that is causing damage to health, physical or mental. Harmful use commonly, but not invariably, has adverse social consequences […]’. In contrast to the EMCDDA definition, the mode of administration (injection) is not a selective criterion in the national definition although types of substances involved are identical. Regular / long duration use of heroin via inhalation is thus included. According to the national definition, problem drug use is associated to a high probability of intervention or the need of involvement of a third party from the law enforcement or the care sector. This approach is consistent with the fact that PDU surveillance systems in Luxembourg are based on the institutional contact indicator and not exclusively on the treatment demand indicator.

Data on PDU in this chapter originate from the national drug monitoring system RELIS developed and maintained by the national EMCDDA focal point. The RELIS network includes specialised drug agencies (100% coverage), law enforcement agencies, national prisons and since 2009, psychiatric departments of general hospitals nationwide.

According to the latest serial and multi-methods prevalence study (Origer, 2010) performed in 2009, national prevalence of PDU situates at 2,470 persons (C.I. (95%): 2,089 to 3,199). A decreasing trend in PDU prevalence has been observed from 2003 onwards. A similar evolution occurred also for problem heroin use (2007: 1,900 PDU: 5.90/1000). Although absolute prevalence of intravenous drug use (IDU) has slightly increased compared to the situation observed at the end of the 20th century, IDUs prevalence rate in the national population aged 15 to 64 years shows an obvious decreasing trend over the referred period. Almost all indirect PDU prevalence indicators reflect trends documented by in-depth PDU studies.

Intravenous heroin use associated to poly-drug use has been reported as the most common consume pattern in PDU. Low quality cocaine use in combination with heroin continues to be observed. Ecstasy-like substances and ATS are still popular even though seizure figures did suggest an inverse trend until 2010. Methamphetamine use in Luxembourg is very limited. The use of most ‘new synthetic substances’ recently detected in other EU Member States has not been reported thus far with the exception of

26 Substances such as MBDB, 4-MTA, Ketamin, PMMA 2C-I, 2C-T-2, 2C-T-7, 2C-D, 2C-E, TMA-2, BZP, TFMPP, 5-MeO-DIPT, 5-MeO-DMT, AMT, ALEPH 7, DXM, DPT.
mephedrone seized in May 2010 in a secondary school. All indicators on cannabis use (problematic and recreational) have been on the increase for several years but tend to stabilise more recently. Cannabis showing high THC concentrations (in 2008 max: +/-22% - in 2009 max: +/-40% - in 2010 max: +/-21%) is increasingly found on the national market.

- PREVALENCE AND INCIDENCE ESTIMATES OF PDU

NATIONAL PREVALENCE DATA

Data presented in the present chapter have been provided by serial drug prevalence study on PDU aged between 15 and 64 years performed on 1997, 1999, 2000 and most recently on 2003 and 2007 data (Origer, 2001, 2010)\(^{27}\). The latest, yet unpublished study, was performed in 2009 in the framework of the evaluation of the 2005-2009 national drug action plan. With this latest study based on robust 2007 data, it became possible to assess the evolution of PDU prevalence over the last decade knowing that applied methodologies and data sources referred to, during the same period, are highly comparable.

The research strategy relied on the methodological framework of the Luxembourghish Information System on Drugs and Drug Addiction (RELIS), set up in 1995 by the national focal point of the EMCDDA. RELIS stands for a nationwide multisectorial information network, including specialised drug treatment institutions, general hospitals, counselling centres and competent law enforcement agencies. As such, it provides for the most comprehensive and reliable data on problem drug users indexed by national institutions. In compliance with RELIS case definitions, the present study specifically aims at the prevalence estimation of problem use of illicitly acquired high risk drugs (HRC) in the national population aged 15 to 65 years.

The following methods have been applied: Case finding (CF), capture-recapture on 2, 3 and 4 sources (CR 2,3,4), truncated Poisson model associated to Zelterman’s and Chao’s estimators (tPm), and four different multiplier methods using data from law enforcement sources, drug mortality registers (D1,2,3) and treatment agencies (T).

**Fig 4.1.** Absolute prevalence estimation of problem HRC drug use (2007)\(^{28}\) and confidence intervals

\(^{27}\) Downloadable at [http://www.relis.lu](http://www.relis.lu)

\(^{28}\) CR2 / CR3: Method « capture-recapture » 2 and 3 sources
CR4 DIC: Capture-recapture 4 sources (weighted mean of Bayes)
D1: Benchmark multiplier based upon police and overdose registers.
D2: Benchmark multiplier based upon number of drug law offenders and law enforcement contact rates of PDU
D3: Benchmark multiplier based upon mortality rates (DRD standard)
T: Treatment multiplier
**Tab. 4.1.** Prevalence and prevalence rates according to selected sub-groups (1997 – 2007)

<table>
<thead>
<tr>
<th>Year</th>
<th>General Population</th>
<th>HRC Users in Contact with the National Institutional Network</th>
<th>Problem Use: HRC Drugs</th>
<th>Problem Use: Main Drug - Heroin</th>
<th>Intravenous Drug Use (IDU)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>National population on 1st January</td>
<td>National population aged between 15 and 64 years on 1st January</td>
<td>Average prevalence</td>
<td>Prevalence heroin</td>
<td>Prevalence IDU</td>
</tr>
<tr>
<td>1997</td>
<td>418,300</td>
<td>281,100</td>
<td>2.100</td>
<td>1.680</td>
<td>1.000</td>
</tr>
<tr>
<td>1999</td>
<td>429,200</td>
<td>287,100</td>
<td>2.350</td>
<td>1.975</td>
<td>1.380</td>
</tr>
<tr>
<td>2000</td>
<td>435,700</td>
<td>291,000</td>
<td>2.450</td>
<td>2.010</td>
<td>1.447</td>
</tr>
<tr>
<td>2003</td>
<td>448,300</td>
<td>300,800</td>
<td>2.530</td>
<td>2.010</td>
<td>1.270</td>
</tr>
<tr>
<td>2007</td>
<td>476,200</td>
<td>322,000</td>
<td>2.470</td>
<td>1.900</td>
<td>1.482</td>
</tr>
</tbody>
</table>

**Source:** Origer, in press
The average of estimations performed on 2007 data provides an absolute prevalence of problem HRC drug users (PDU-HRC) of 2,470 persons (C.I. (95%): 2,089 to 3,199). In terms of prevalence rates estimates for the same age categories, 7.67 out of 1,000 inhabitants aged between 15 and 64 years show problem drug use.

According to serial data available for the period 1997 to 2007, absolute prevalence and prevalence rates of PDU-HRC have been showing an increasing trend until 2000. After a short stabilisation phase, a decreasing trend has been observed from 2003 onwards. A similar evolution occurred also for problem heroin use (2007: 1,900 PDU: 5.90/1000). Although absolute prevalence of intravenous drug use (IDU) has slightly increased compared to the situation observed at the end of the 20th century, IDUs prevalence rate in the national population aged 15 to 64 years shows an obvious decreasing trend over the referred period.

The stabilization and subsequent decrease of national PDU prevalence occurred within the implementation phase of the first and second national drug action plans, having started in 1999. The observed trends are also confirmed by most of pertinent indirect indicators related to demand and supply reduction.

A further serial PDU prevalence study on 2009 data and based on the same methodology than previous ones is currently performed and results will be available by the beginning of 2012.

**INDIRECT INDICATORS OF PDU PREVALENCE TRENDS**

In order to validate PDU estimates and follow up prevalence trends between two successive prevalence studies a set of indirect indicators have been compiled and analysed.

---

29 IDU prevalence rates have been processed on basis of proportion of IDU in PDU indexed by the highly representative RELIS data sets for respective years.
Indirect PDU prevalence indicators reflect trends documented by in-depth PDU studies except for admission statistics in low threshold drug agencies from 2000 onwards and the number of drug law offenders since 2008.

As for the first contradictory indirect indicator (low threshold contacts), its inversed evolution might be explained by the fact that since 2000 major efforts have been invested to increase capacities of low threshold offers and to facilitate access to harm reduction measures at the national level. This positive evolution, in terms of public health, had as a result that those users never in touch with drug agencies got into contact with the national care system. This said, the increasing use of low threshold offers resulted primarily in an increase of the visibility of previously hidden users and does not allow to conclude that the absolute prevalence of PDU user has increased since the beginning of the 21st century.

The number of drug law offenders has also stabilised between 1999 and 2009 but shows a peak in 2010. This recent evolution might be partly explained by the fact that law enforcement agencies increased their presence and interventions notably in the vicinity of the supervised drug injection and low threshold facilities in order to fight increased drug deal activities. Next years trends of this particular indicator have to be interpreted in the light of this supplementary data.

The number of fatal drug-related overdoses has peaked in 2007 but has been witnessing an obvious decrease since then. Likewise other EU Member States, the evolution of the referred indicator is known to show fairly important variations due to factors such as quality of available drugs, consume patterns, availability of harm reduction services, etc. A national expert group studied these variations and came to the conclusion that high variability in substances’ purities, increased polyuse and especially the combination of street drugs, substitution drugs and prescription drugs in general in out- and in-patient settings and gaps in the follow-up of patients after institutional release (detoxification, therapy, prison, etc.) are major risk factors at stake if it comes to drug-related mortality and morbidity but do not support the assumption of a significant increase of the PDU prevalence in general.
Moreover, although annual variations are observed, the trend line of recent years clearly shows a decrease in acute overdose death rates which is in concordance with national prevalence figures.

A new research project has been launched in 2009 on the consolidation and validation of PDU estimates by indirect indicators. A correlation matrix including 18 indirect trend indicators has been conceived to follow-up trends and strength of association between these indicators and between PDU/IDU prevalence figures and the latter. First results will be available in the course of 2012.

LOCAL OR REGIONAL PREVALENCE STUDIES (NNIA)

Due to the specificity of the national drug scene and the geographical dimension of the country, local prevalence studies are not considered being a priority.

CHARACTERISTICS OF INDEXED PDU

Relying on a multi-sectorial data network including specialised in- and outpatient treatment centres and low threshold facilities, general hospitals as well as law enforcement agencies and national prisons, RELIS enables the assessment of new trends in the *problem drug users* population in general as well as in drug treatment demanders in particular. NFP has opted for a holistic monitoring of the drug population. The following data are provided by RELIS thus referring to all HRC drug users indexed by the national specialised treatment and law enforcement network and, as such, defined as problem drug users.

The **number of problem PDU** indexed by national institutions in 2010 figured 5,142 (2002: 4,701) (in this figure double counting is included meaning that a given person could have been indexed twice and more by different institutions. It is thus not representing the actual prevalence, which has to be assessed by other methods).

More precisely, 2,383 users have been indexed by national specialised drug demand reduction agencies and 2,318 drug law offenders by supply reduction agencies in 2002. In 2010 the same agencies have indexed 2,653 and 2,762 persons respectively.

| Tab. 4.2. Main characteristics of PDU indexed by the national drug monitoring system, RELIS (valid percentage) |
|---|---|---|---|---|---|---|
| Gender | 2000 | 2004 | 2008 | 2009 | 2010 | TREND |
| Male | 77% | 78% | 77% | 83% | 80% | ↓ |
| Female | 23% | 22% | 23% | 17% | 20% | ↑ |
| Nationality | 54% | 54% | 48% | 48% | 49% | ↓ |
| Natives | 46% | 46% | 52% | 52% | 51% | ↓ |
| Non-natives | 51% | 58% | 38% | 49% | 39% | ↓ |
| - of which | 17% | 11% | 28% | 16% | 23% | ↓ |
| Portuguese | 32% | 31% | 34% | 35% | 38% | ↓ |
| French | 32% | 31% | 34% | 35% | 38% | ↓ |
| Others | 28% | 30% | 27% | 31% | 32% | ↓ |
| Mean age | 28Y4M | 31Y2M | 31Y8M | 31Y9M | 32Y4M | ↓ |
| Male | 26Y10M | 28Y4M | 28Y5M | 28Y3M | 28Y9M | ↑ |
| Female | 28Y9M | 30Y6M | 30Y11M | 31Y2M | 31Y7M | ↑ |
| Total | 28Y9M | 30Y6M | 30Y11M | 31Y2M | 31Y7M | ↑ |
| Primary drug | 84% | 76% | 72% | 78% | 81.6% | ↓ |
| Opiates | 7% | 16% | 17% | 9% | 9.5% | ↓ |
| Cocaine | 9% | 8% | 11% | 13% | 8.9% | ↓ |
| Others | 87% | 93% | 89% | 74% | 76% | ↑ |
| Polydrug use |
The male/female ratio of the PDU population is stable at 4:1. During the last ten years the proportion of indexed non-native PDU has shown strong variations but a clearly increasing tendency since 2003. The population of non-native drug users largely consists of Portuguese nationals, whose proportion is consistently higher than the one observed in general population. The remarkable and continuous increase of PDU of French origin over the last 8 years has been interrupted in 2009, but continues in 2010.

The mean age of indexed PDU evolved from 28 years and 4 months in 1995 to 31 years and 7 months in 2010. Mean age of male PDU has been increasing faster than for females. In general, the proportion of PDU aged more than 40 years has increased and the rate of users less than 30 years has been decreasing. In reference to years 2004 to 2010 a discontinuous decrease of minors in the overall PDU population has been observed in police data.

The mean age of native and non-native problem drug users tends to balance. One observes an average aging of the population of long-term drug injectors and a sensitive decrease in age referred to “new” PDU.

Worth mentioning is also the overall, yet discontinuous increase of the average age of overdose victims during the last eleven years. PDU tend to contact drug treatment facilities at an earlier stage, which may be due to a more diversified offer currently available.

Intravenous heroin use associated to poly-drug use has been reported as the most common consume pattern in PDU. The proportion of poly drug use 76% has reached stabilisation after a record level in 2004 (93%). In contrast to 1995 data, the switch to intravenous drug use occurs earlier in 2010. The ratio of intravenous opiates consume to the inhalation mode is 2:1 in 2010. Provision of ‘blowing paraphernalia’ (e.g. aluminium foils) by specialised drug agencies may have influenced consume patterns. The prevalence of the use of cocaine as primary drug shows an increasing trend since 2000, but tends to stabilise in 2009 and 2010. Ecstasy-like substances and ATS use appears to be stable which however does not inform on prevalence in general population as RELIS data refer to PDU and not to the overall population of recreational drug users.

All indicators on cannabis use (problematic and recreational) have been showing a discontinuous increase for several years. The number of persons in contact with the national specialised network for (preferential) cannabis use shows, however, a sensitive decrease in 2010 (8%).

PDU show fairly stable infection rates of HIV (6%) between 2000 and 2010, whereas the HCV prevalence rate (52%) is high, although on the decrease for the last two years.

The residential status of indexed respondents has improved over the last years. In 1995, 31% of the users reported stable accommodation; currently the same proportion situates 62%. This improvement is partly due to various accommodation and housing offers for addicted people set up in the framework of the drug action plan.
The unemployment rate (69%) tends to plateau. However, the proportion of professionally active respondents reporting a stable job situation (e.g. long term contract) has sensibly decreased over the 3 last years, which should also be put in the context of the current economic crisis.

- DATA ON PDU FROM NON-TREATMENT SOURCES

Data on PDU from non-treatment sources are mainly provided by the national specialized drug unit of Judicial Police. The profile of these users is similar to PDU from treatment settings knowing that the national drug monitoring system indexes both sources.

The ratio of male and female PDU is almost identical to PDU from treatment sources (80.9% male, 19.1% female offenders). Their mean age is 30.9 years, women being slightly younger than men (31.7 years for male 27.6 years and for female offenders).

46.1% of the offenders are natives and 53.9% are foreigners. Likewise 2009, most non-natives were Portuguese citizens (40.5%) followed by French native offenders (23%).

83.8% are recidivists (had more than one police record during their lifetime), 20.4% were arrested for dealing drugs, 44.1% are charged with illegal drug possession and 35.4% for other crimes related to drugs. Drug-law offenders (who are also problematic drug users) are mostly arrested for heroin and cocaine. A vast majority are reported polydrug users.

### 5. Drug-related treatment: treatment demand and treatment availability

**Introduction**

Drug treatment is the ‘use of specific medical and/or psychosocial techniques with the goal of reducing or abstaining from illegal drug use and thereby improving the general health of the client’.

Specialised drug treatment infrastructures are relying on state financing and on ministerial control and quality insurance mechanisms. Treatment offers are decentralised and most commonly provided by state accredited NGOs.

For the purpose of the present chapter, drug treatment is divided in the following categories:

- **Outpatient treatment:** the patient receives drug treatment without staying overnight, pharmaceutically assisted or not;
- **Inpatient treatment:** the patient is staying overnight, pharmaceutically assisted or not (including detoxification);
- **Substitution treatment:** a type of medical treatment provided to opiate addicts primarily based on the delivery of a similar or identical substance to the drug normally used. Substitution treatment may be accompanied by psycho-social care;

---

30 SOURCE: Classification of drug treatment in EU member states and Norway, Expert meeting, 8-9 February 2002
31 ‘Drug free treatment focus on psycho-social and therapeutic techniques and is not primarily based on the routine prescription of a substance or medicament with the goal of reducing or abstaining from illegal drug use thereby improving the general health of the client’.
Drug treatment is monitored and quality assurance occurs via a series of mechanisms that are described under the treatment system section. The external evaluation of the 2005-2009 national drugs action plan recommends to draw an inventory of current quality assurance mechanisms regarding drug treatment. Outcomes of this inventory, will allow to further harmonise existing routines.

- **DRUG TREATMENT STRATEGIES AND POLICY**

In the mid seventies the cooperation between state and NGOs working in the social field has progressively gained structure. The first (financing) convention between the Ministry of Family and a series of NGOs, signed in 1975, was the starting point of what is known today as the “Conventionned sector”. Over the years the collaboration schemes between State and NGOs evolved and were extended to the Public Health sector. In 1998 the so-called ASFT law\(^{32}\) entered in force, regulating the relationship between State and private organisations working in the social, family and therapeutic fields.

Treatment needs' assessment as well as quality control largely rely on the ASFT legal framework and the existing network of conventionned service providers who have to meet a series of quality standards and be granted a special accreditation from the Ministry of Health. The elaboration of the demand reduction section of the national drugs strategies and action plans builds upon the expertise and involvement of the referred network. A detailed description of collaboration and control mechanisms in place is provided below.

The first specialised drug agency (JDH) was created in 1986 and addressed both drug addiction and Youth. Originally services developed bottom-up and were seeking financial support of the State. Preliminary work done in the framework of first drug action plan 1999-2004 allowed to better assess national needs and to initiate and develop interagency coordination mechanisms. To date, treatment agencies are specialised whether in polydrug use including illegal drugs, in alcohol abuse, or gambling, etc. As far as illegal drugs are concerned, drug care providers address the whole range of substances meaning that no specialised offers exist according to given type of substance or problems related to it. Currently there are signs that the national drug treatment strategies are evolving towards a more holistic concept of addiction treatment (including illegal substances related addictions and others).

As far as national expenditures for drug treatment provision are concerned please refer to chapter 1.

**TREATMENT SYSTEMS**

**ORGANISATION AND QUALITY INSURANCE**
All specialised drug treatment services are relying on governmental support and control. Specialised agencies need an accreditation to sign a *convention* with the ministry of Health that guarantees their annual funding. Outpatient drug treatment is provided free of charge by specialised agencies. Inpatient treatment and detoxification is covered by health insurance schemes. As far as substitution treatment is concerned, health insurance takes in charge medical interventions and counselling and State covers pharmaceutical costs and pharmacy fees.

---

NGOs involved in drug treatment fall under the obligation of the above referred to ‘ASFT’ law (8/09/98) and the subsequent grand ducal decree of 10 December 1998, both regulating the relation (duties and rights) between State and NGOs or organisation providing psycho-medico-social and therapeutic care. The overall management of the referred agencies is ensured by a ‘coordination platform’ that includes a maximum of 3 members of the concerned institution and at least one representative from the competent ministry. All major decisions have to be approved by the coordination platform. All referred institutions work in close collaboration and have to be viewed as an interdependent therapeutic chain. A series of formal collaboration agreements have been signed in 2008 and 2009 between various agencies in order to insure rational use of resources and through-care. The 2010-2014 national drugs action plans foresees to further develop this synergy by creating a national network of unique reference persons for each drug treatment demander entering the specialised care system.

The **governmental quality standard certification**, as foreseen by the law ‘ASFT’ of 8 October 1998, represents the main instrument of a standardised quality control of drug treatment offers. General guidelines on setting requirements and human resources/clients keys are set by a grand-ducal decree of 10 December 1998 regarding the accreditation of services from the medical, social and therapeutic field. Funding is, however, not a direct function of mandatory evaluation or outputs requirements. The quality standard certification commits respective NGOs to undertake necessary evaluation measures of their activities by means, however, they deem adequate. Drug treatment agencies have developed proper evaluation strategies mostly in collaboration with external evaluators. Recent examples are the evaluation of current offers in the field of socio-professional integration, which future development has been promoted by the national drugs action plan, the implementation of a computer based evaluation procedure by the national substitution programme and prevention interventions in schools by CePT. The external evaluation of the drugs action plan also significantly contributes to assess the functioning and the gaps of the national treatment network.

An external assessment of quality management mechanisms run by specialised NGOs has been foreseen by the national drug action plan and has become available in 2011. Outcomes have shown that current quality assurance routines implemented within involved drug agencies are highly diversified and differ in terms of coverage and complexity ranging from internal activity assessment procedures to EFQM certifications for instance. These outcomes are highly valuable for future improvement of quality assurance and documentation routines of drug related care services.

Also, the **RELIS database** on problem drug users provides relevant data for evaluation purposes since it includes detailed data on drug consume patterns, socio-economic situation, risk behaviour and treatment or law enforcement contacts, etc. In the long run, drug ‘careers’ can be analysed by means of the RELIS indexing system, which allows following up treatment demands and law enforcement contacts of indexed drug users. These data can be used to assess the impact and the performance of specific treatment approaches. A practical example of the application of evaluation results is to be seen in the conceptualisation and external evaluation of the national drug action plan 2005-2009, which did greatly rely on RELIS data and ad hoc evaluation initiatives from field institutions.

---

33 Règlement grand-ducal du 10 décembre 1998 concernant l’agrément à accorder aux gestionnaires de services dans les domaines médico-social et thérapeutique (entry in force 18/12/1998)
Table 5.1 records admission and contact statistics of national drug treatment agencies according to applied typology from 1994 to 2010. **Intra-institutional multiple counts** are excluded meaning that all treatment demanders indexed by a given agency are only indexed once by the referred agency during a reporting year. **Inter-institutional multiple counts** are not excluded since a given treatment demander may have contacted several national agencies during a given year. More detailed admission data, including low threshold agencies are provided in respective sub-chapters.

**AVAILABILITY AND DIVERSIFICATION OF TREATMENT**

As can be seen on map 5.1 drug treatment facilities are regionalised showing, however, a high concentration and diversity within the area of Luxembourg City. All listed services are specialised with the exception of regional general hospitals providing detoxification treatment via their respective psychiatric departments. In July 2005, the first ‘consumption room’ has been opened in Luxembourg City. It has been integrated in the ‘TOX-IN centre’ providing day care, night shelter and low threshold services to drug addicts.

It should be stressed that no national drug treatment services exclusively targets a given type of substance use and its correlates. Currently national services provide care for persons presenting problems related to heroin, cocaine, amphetamine, cannabis, etc. and polydrug use.
Map 5.1 Geographical coverage of specialised drug agencies in the Grand Duchy of Luxembourg (status 2010)

- **JDH**: Counselling, substitution, low threshold and after care
- **TOX-IN (CNDS)**: Low threshold
- **TOX-IN (CNDS)**: Night shelter, Injection room
- **SOLIDARITE JEUNES**: Youth counselling
- **Arcus asbl**: Counselling and referral
- **CHNP**: Treatment and referral
- **CTM**: Residential therapy, reintegration measures
- **CTM**: Aftercare, supervised housing
- **General hospitals providing detoxification**
The following treatment typology is applied:

**Outpatient: services and offers for adults**
The most relevant national outpatient treatment facility is the ‘JDH Foundation’. Regional antennas of JDH are respectively implemented in Luxembourg City, in the South and in the North of the Grand Duchy and are entirely financed by the Ministry of Health. Arcus asbl implemented in Luxembourg-City is primarily a counselling and referral agency.

A third specialized outpatient service is also implemented in Luxembourg-City (Alternative Counselling Centre). The main objectives of the referred centre are the following:

- Establish a first contact with the drug-addicted clients.
- Help the drug-addicted clients in the development of a therapeutic project with orientation either towards the intermediate-term structures, or towards residential therapy centres.
- Organization of detoxifications in local psychiatric services or further psychotherapeutic interventions.
- Informative and therapeutic discussions with the drug-addicted clients and their families before and after the detoxification.

Further agencies provide social care or therapeutic settings that are attended by drug addicts. These agencies, however, rarely provide drug specific treatment and separate data breakdowns are not available.

**Outpatient: services and offers for minors**
Specialised drug care agencies for minors exist in the centre and since 2007 in the north of the country. Although drug counselling agencies accept underage treatment demanders, part of the latter are referred to a specialised service established in the centre of the country (Solidarité Jeunes – Jongenheem asbl).

**Outpatient: substitution treatment**
Substitution treatment is currently defined as a medical assisted treatment with opioids’ agonists and with antagonists (and antagonistic agonists). The objectives of substitution and maintenance treatment are manifold. They range from no-digressive dose, outpatient low threshold maintenance to abstinence oriented (digressive doses) rehabilitation offers. The primary goal is the psychosocial and medical stabilisation of the patient by replacing ‘street’ drugs by quality controlled substitution drugs. The further development and outcome of the treatment is assessed individually. Both components, condition of the patient and reduction of public nuisance are considered.

Substitution treatment is provided at the national level since 1989 (JDH). Until the beginning of 2001, however, there has been no legal framework regulating drug substitution treatment. The law of 27 April 2001 modifying the basic drug law of 19 February 1973 introduced a legal framework for substitution and maintenance treatment. The grand ducal decree of 30 January 2002 regulates the practical modalities of substitution. The referred law regulates drug substitution treatment in general rather than it legalises a single national substitution programme. The law does this by means of substitution treatment licenses granted to MDs and specialised agencies, the application of training requirements for prescribing MDs and adequate control mechanisms of multiple prescriptions (i.e. centralised register of substituted patients).

34 The decree of 30 January 2002 regulating the modalities of substitution treatment can be downloaded at: http://www.eildd.emcdda.org
It should be stressed that following the application of the new legal framework, there still exists a **structured and multidisciplinary substitution treatment programme** (JDH - mainly liquid oral methadone provided by specialised agencies) and a **lower threshold substitution treatment** offer provided by freelance state licensed MDs (MEPHENON®, METHADICT® and SUBUTEX®).

Until 2001 methadone and buprenorphine have been prescribed as part of a long-term treatment with a medium or long-term abstinence goal. There are, however, a series of cases in which substitution treatment has to be considered rather as a harm reduction or maintenance measure than an abstinence oriented therapeutic action. The grand-ducal decree of 30 January 2002 lists medicaments as well as preparations containing methadone (liquid oral form in programme and pill form in lower threshold prescription) and **buprenorphine** if the notice mentions substitution treatment as a possible therapeutic indication. Furthermore, **morphine-based (salts)** medications can be prescribed if the listed substances are deemed inadequate by medical authority. Finally, the decree allows for heroin prescription in the framework of a pilot project managed by the Directorate of Health. The **list of substitution substances** may be rapidly modified by amending the referred decree. In addition to drug prescription and medical care, the grand-ducal decree on drug substitution treatment (30/01/2002) defines a series of psychosocial counselling services to be provided by licensed specialised centres. Licensed MDs may refer substitution patients to licensed treatment centres for more in-depth psychosocial counselling.

Diverted MEPHENON® (methadone in pill form prescribed by accredited MDs) is found on the national black market. Given that the centralised substitution treatment register did not yet reach full prescriber coverage, multiple prescriptions (a given patient visits more than one prescriber) may not be fully avoided. In that respect, a **central substitution register** is about to be implemented jointly by the ‘Surveillance Commission on Substitution Treatment’ 35, the national drug coordinator and involved specialised treatment centres. At the moment of writing, a test phase is running in order to find the best way to make the implementation of the substitution register and other surveillance mechanisms compatible with daily medical practice. The substitution treatment surveillance commission has been reformed by the Minister of Health and since August 2010 it is chaired by the National Drug Coordinator.

### Outpatient: low threshold services and offers

Currently two agencies offer harm reduction services in the Centre, the South and the North of the country including offers such as day and night shelter and supervised injection facilities (currently only in the centre). A new integrated low threshold centre for drug addicts is planned to be implemented in the main city of the South of the country. In the North of the country a needs assessment on low threshold offers is currently carried out. The further development of harm reduction services in the North is part of the national drug action plan.

### Inpatient: detoxification services and offers

Physical drug detoxification is provided by 5 different hospitals via their respective psychiatric units. The most important detoxification unit implemented within a specialised department of the CHNP (15 detoxification beds) has been restructured and does not provide detoxification treatment anymore. The ‘Centre Hospitalier du Kirchberg’ has

---

35 The decree of 30 January 2002 replaces the former ‘Methadone Commission’ by the ‘Surveillance commission on substitution treatment’ mandated to control all aspects of substitution treatment at the national level. Established in 2002, it is composed of delegates from the programme, the Directorate of Health, two pharmacists and two GPs affiliated to the programme, and is in charge of admissions, releases and exclusions of substitution treatment demanders or patients. The composition of the new commission is similar to the one of the former Methadone commission.
joined the list of national institutions providing detoxification treatment in 2005. Medical interventions and psychosocial support are provided to control and reduce withdrawal symptoms in the framework of a 1-2 week detoxification programme. Ideally, detoxified patients are referred to more psychotherapeutic oriented institutions.

Detoxification treatment is provided by psychiatric units within five general hospitals:
Centre Hospitalier du Nord – Ettelbrück (North)
Centre Hospitalier Emile Mayrisch – HVEA (South)
Centre Hospitalier de Luxembourg – CHL (Centre)
Hôpital Ste. Thérèse (Centre)
Centre Hospitalier du Kirchberg (Centre)

Inpatient: services and offers for adults

The national drug action plan foresees the set-up of an in-patient stabilisation unit. This unit is meant for detoxificated patients in transition to more psychotherapeutic care. A working group on drug treatment offers concluded that patients admitted for drug detoxification often stay longer than necessary in hospitals providing this type of treatment. The stabilisation unit should contribute to discharge hospitals and liberate capacities for detoxification demanders, who currently might have to enrol on waiting lists. By the end of 2009 a pilot phase has been started in the CHNP in order to gather first experience.

The national residential therapeutic centre called ‘Syrdallschlass’ (CTM-CHNP) is situated in the East of the G. D. of Luxembourg. The therapeutic programme of the CTM is divided into three progressive phases. The duration of a therapeutic stay varies from 3 months to 1 year.

In addition to individual and group therapies, the centre offers the opportunity to follow training activities in several professional domains and post therapeutic accommodation facilities. The final objective is the psychological, professional and social reintegration of treated clients. The latter is highly facilitated by the quality of provided professional training to patients. The collaboration with several employers willing to employ ex-drug addicts and the active involvement of social services offer a fair social and professional framing to released patients.

The national drug action plan 2000-2004 had foreseen the extension of CTM offers by creating a network of modular therapeutic annexes for specific target groups as for instance pregnant women, drug addicted couples, treatment demanders on methadone, etc. These annexes are operational since September 2002 and are situated in the vicinity of the main centre (see map 5.1) in order to take advantage of training and social reintegration facilities offered by the CTM. Based on past experience, the 2005-2009 drugs action plan has foreseen the further development of these annexes. In 2008 a new annexe providing therapeutic offers to specific target groups such as mothers with child/children or patients in the last therapy phase has become operational on the very site of the main centre.

The CHNP runs a residential facility with a capacity of 15 beds called “mid-term unit” in the North of the country. Its mission is defined as follows:
• Contribute to the physical and mental stabilization of the patient after clinical detoxification.
• Supervise the patient during the period going from the clinical detoxification to the admission in therapy or offer him a protected area to develop his project of social reintegration/rehabilitation.
• Free capacity of regional psychiatric services by admitting detoxificated patients for further care.

As the national inpatient therapeutic facilities are limited and not covering the whole spectrum of drug related symptoms (e.g. double diagnosis) a series of patients are referred to specialised institutions abroad. If approved, related costs are covered by the national social security schemes.

The 2010 – 2014 national drugs action plan foresees the creation of a Stabilisation Unit (SU) within the CHNP. The SU should have a capacity of 12 beds and a limited duration of stay (e.g. 3 weeks). The objective is to take in charge drug users, detoxificated in hospital settings to further stabilise their health and mental state as well as to prepare their release and re-integration process. Preparatory works were undertaken by the time of writing and it is foreseen to open this new facility in the course of 2012.

**Inpatient: services and offers for minors**

A specialised residential centre for problematic youngsters has been opened in the beginning of 2007 in the North of the country under the management of CHNP. A new project defined as a residential referral and rehabilitation centre for minors in a rural setting is supposed to become operational in 2011/12. The referred case management programme will contribute to fill current gaps in the care system for minors.

**CHARACTERISTICS OF TREATED CLIENTS AND TRENDS OF CLIENTS IN TREATMENT**

Table 5.1 summarises drug related institutional contacts of PDU. Inter-institutional multiple counts are not excluded meaning that a given PDU could be indexed twice and more. Hence, these data do not provide the national prevalence of PDU but they allow following up the increase or the decrease of the latter.

**Table 5.1 Drug related institutional contacts (Inter-institutional multiple counting included)**

<table>
<thead>
<tr>
<th>SETTING</th>
<th>NUMBER OF DRUG TREATMENT DEMANDERS (intra-institutional multiple counts excluded)</th>
<th>NUMBER OF ADMISSIONS (Specialised and hospital)</th>
<th>NUMBER OF CONTACTS (Low threshold)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OUTPATIENT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Drug Free</td>
<td>636 828 916 1,040 1,065 1,044 1,065 1,162 1,020 980</td>
<td>36 43 53 44 129 156 130 158 153 182 183 124 119 126</td>
<td>13,083 28,536 39,526 55,808 78,415 110,674 140,093</td>
</tr>
<tr>
<td>- Substitution</td>
<td>1,002 1,040 1,065 1,044 1,050 1,212 1,248</td>
<td>/ 617 637 656 615 527 429 476 484 397 324 297</td>
<td></td>
</tr>
<tr>
<td>INPATIENT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Specialised</td>
<td>43 57 53 44 129 156 130 158 153 182 183 124 119 126</td>
<td>13,083 28,536 39,526 55,808 78,415 110,674 140,093</td>
<td></td>
</tr>
<tr>
<td>- Hospital care 36</td>
<td>/ / 617 637 656 615 527 429 476 484 397 324 297</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOW THRESHOLD AGENCIES</td>
<td>13,083 28,536 39,526 55,808 78,415 110,674 140,093</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

36 Including F11 F14, F16, F18 and F19 episodes with or without over night stay. Source: CNS
The present section is divided in a general description of the drug treatment population and a more in-depth analysis of clients’ characteristics and observed trends. Both parts are based on RELIS data and on in-house statistics of specialised drug treatment agencies at the national level.

Overall the number of persons showing drug related contacts with national DR or SR agencies has reached 5,415 in 2010. Until 2004 a sensible increase in drug treatment demands has been observed followed by an overall stabilisation confirmed by 2010 data, whereas contacts with law enforcement agencies have been increasing, from 2008 onwards. The number of substitution treatment demands begun to plateau around 2002 and showed a sensible increase in 2009 to stabilise anew in 2010. The number of adult out- and inpatient clients tends to decrease, while out-patient minor treatment demanders have been continually increasing. The most remarkable increases between 2008 and 2010 have been observed in substitution treatment demanders and in the number of contacts in low threshold facilities (2010:140,093). 4.7% (5.4%) of respondents are first treatment demanders, all treatment centres included. As far as first treatment demanders are concerned, 16.7 % are female against 83.3% of males.

Of clients in drug treatment, 78.3 (79%) are male against 21.7 (21%) females. The mean age of treatment demanders has significantly increased during the last ten years (1997: 28 years/ 2010: 32.1 years) and this mainly because of an observed increase in average male age (1997: 28Y2M/ 2010: 32Y7M). The mean age of the female clients is consistently lower (2010: 30Y6M). Respectively 58.3% of clients in treatment are natives. The population of non-natives consists for the vast majority of Portuguese nationals, followed by French, Italian and German citizens.

Regarding the educational level of the clients in treatment, 73% have completed primary or complementary school, 26% have completed secondary school and 1% obtained a higher degree. 12.6% of respondents reported stable employment (important decrease - 1997: 65%) against 5.7% who are benefiting from unemployment allocations. Furthermore, 2.6% are students or engaged in a training contract. 27.8% of indexed treatment demanders had experienced one or more overdoses. As far as the exchange of syringes is concerned, 25.2% reported that they never shared syringes during their lifetime (39.1% during the last month). IDU combined to polydrug use (62.8%) is the most observed consume pattern in drug treatment demanders.
Below is presented a more detailed analysis of treatment demands and trends according to type of treatment:

**Outpatient: services and offers for adults**

**RELEVANT TREND:** Ongoing decrease of total number of clients (980) compared with 2008 and 2009 data. Increase of male treatment demanders (73% male, 27% female). Stabilisation of the proportion of clients aged 30 and more (2010: 63% / 2008: 61%). A current trend is also to be seen in the increasing number of young mothers or couples with their child/children seeking out- and inpatient treatment.

After several years of stability, national outpatient drug counselling centres have been showing decreasing admission rates from 2008 onwards and decreasing first treatment rates intra and inter-agency wide. Gender distribution showed an overall increase of male clients over the last 10 years. Age distributions are varying according to the geographical situation of treatment centres. All in all, however, the proportion of treatment demanders aged 30 years and more has sensibly increased during recent years (2010: 63% / 2006: 57%). Treatment demands from underage clients tend to decrease until 2007 and stabilised since then, mainly because specialised agencies for minors have been implemented meanwhile. Treatment demands for problem i.v. opiate use associated to multiple-use is the main demand pattern (2010:62% / 2009:61% / 2008: 53% / 2007: 57% / 2006: 51% / 1997: 72%). Cannabis-related demands have shown a clear upward trend in 2009 and stabilised in 2010. The prevalence of cocaine use-related treatment demands is stable, however, bearing in mind that the exact prevalence is difficult to assess as in most PDU concomitant use of heroine is observed.

**Outpatient: services and offers for minors**

**RELEVANT TREND:** Increasing number of episodes due to the development of new treatment capacities for underage users and/or offenders.

The rate of new treatment demanders has discontinuously increased since the implementation of the referred specialised agency. An increasing majority (71%) of clients are male. The proportion of clients aged below 14 years has been increasing slightly since 2008 (25% in 2008 and currently 30%). Cannabis use is the main reason of treatment demands (74%) witnessing a currently stable trend. However, the use/abuse of licit drugs and polydrug use is increasingly reported as reason of treatment. An increasing proportion of youngsters presenting psychiatric symptoms and/or socially deviant behaviour in addition to drug abuse are reported by specialised field agencies.

**Outpatient: substitution treatment**

**RELEVANT TRENDS:** Since 2005, decrease of number of patients in structured programme and increase in substitution treatment prescribed by licensed MDs - stabilisation of gender ratio (3 males/ 1 female) - Increase of substitution treatment demanders being aged between 30 and 34 years.

The number of patients admitted to the national multidisciplinary substitution programme (JDH) has been sensibly decreasing from 2005 to 2009, 90 patients in 2010, which is supposedly due to the increasing access and admissions to lower threshold substitution treatment provided by independent yet specially licensed MDs. 35% (43%) of clients started substitution treatment in 2010. The proportion of female substitution treatment demanders (+/- 30% stable) is higher than the proportion of female PDU in the overall drug treatment population. 18% (20%) of the clients in substitution treatment are aged under 30, 48% (42%) are between 30 and 39, while 34% (38%) are over 40 years old. The mean age of clients has significantly increased over the last 10 years (36.5 years),
which is due particularly to the steep increase of the number of treatment demanders over 35 (55% in 2008, 33% in 2000). The proportion of native substitution treatment demanders has dropped (43%). The socio-economical situation of substituted patients is consistently more beneficial than the one observed in other treatment demanders. Polydrug use is the most observed consume pattern (72.5%) in substitution treatment demanders.

The number of patients who did receive substitution treatment by prescription from independent and licensed practitioners has known a steep increase between 2008 and 2009 [(1,246 patients in 2010 and 1,212 patients in 2009 multiple counts excluded (2008: 961)].

The National Health Found (CNS) annually provides the number of patients receiving referred substitution drugs on prescription as well as the number of prescribing MDs. One observes a sound increase of substitution demands addressed to accredited liberal MDs and an ongoing decrease of the number of patients choosing the multidisciplinary JDH programme, more demanding in terms of therapeutic constraints. Over 95% of prescriptions delivered in the framework of substitution treatment refer to methadone followed by buprenorphine.

<p>| Table 5.2 Outpatient prescription of substitution drugs by the national network of licensed MDs (/1999-2010) |</p>
<table>
<thead>
<tr>
<th>YEAR</th>
<th>1999</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of indexed patients (double counting controlled)</td>
<td>745</td>
<td>844</td>
<td>849</td>
<td>820</td>
<td>913</td>
<td>/</td>
<td>970</td>
<td>939</td>
<td>979</td>
<td>961</td>
<td>1,212</td>
<td>1,246</td>
</tr>
<tr>
<td>Number of prescribing GPs (double counting controlled)</td>
<td>125</td>
<td>145</td>
<td>147</td>
<td>157</td>
<td>154</td>
<td>158</td>
<td>163</td>
<td>121</td>
<td>122</td>
<td>126</td>
<td>173</td>
<td>188</td>
</tr>
</tbody>
</table>

Source: CNS 2011

| Table 5.3 Age distribution (%) of patients substituted by the national network of licensed MDs (2008-2010) |
| AGE CATEGORIES | 2008 | 2009 | 2010 |
| 15-19 years | 2 | 1 | 0.5 |
| 20-24 years | 9 | 9 | 7 |
| 25-29 years | 17 | 16 | 15 |
| 30-34 years | 19 | 20 | 20 |
| 35-39 years | 19 | 18 | 20 |
| 40-44 years | 18 | 18 | 17 |
| 45-49 years | 9 | 11 | 12 |
| 50-54 years | 5 | 5 | 6 |
| 55-59 years | 1 | 1 | 1.5 |
| 60-64 years | 1 | 1 | 1 |

Source: CNS 2011 – data reformatted by NFP

The proportion of patients aged less than 25 years has been decreasing and the proportion of patients aged 45 and more increasing between 2008 and 2010.

Outpatient: low threshold services and offers

RELEVANT TRENDS: The number of contacts indexed by low threshold agencies has increased dramatically over the last 5 years (2010: 140,093 / 2005: 47,739), and so has the number of syringes distributed by the same agencies. The proportion of new clients within low threshold settings is on the decrease. Approximately 47% of clients are aged between 25 and 34 years, 31% of clients between 35 and 44, and 15% between 18 and 24.

The number of female clients has been showing a weak but constant decrease (currently 14% (20%)).
Inpatient: hospital care (detoxification treatment)

**RELEVANT TRENDS:** Drug detoxification units throughout the country have been showing a continuous increase regarding number of patients until 2006 (484) and a decrease to 297 in 2010. The number of treatment episodes, having remained fairly stable between 2004 (617) and 2009 (615), witnessed an obvious decrease to 527 episodes in 2010. Gender distribution has remained fairly unchanged between 2002 and 2010. Multiple drug use, including heroin, is the main reason for detoxification demands.

Inpatient: services and offers for adults

**RELEVANT TRENDS:** The number of inpatient treatment demanders (detoxification treatments excluded) appears to be slowly decreasing (183 in 2006, 2009: 119). The proportion of first treatment demands sets around 7%.

Heroin as preferential substance is reported by 76% (78%) (38% (49%) i.v./ 62% (29%) non-i.v.) of drug treatment demanders monitored by the national drug surveillance system RELIS whereas cocaine is only reported by 14% (9%) as first substance of use (18% (5%) i.v./ 82% (4%) non-i.v.) The average age at the first use of the preferred drug figures around 20.62 (18Y8M), whereas the mean age of the first i.v. consumption is 19.95 (21Y1M), 72% (73%) of the clients consume drugs more than once a day.

In 2009, a weak decrease in preference for intravenous heroin use (1997: 60%, 2009: 49%) was observed compared to 2008 (52%). This trend has been confirmed in 2010 (38%). The heroin inhalation mode (2010: 62%, 2009: 20%) has becoming more prevalent compared to 2008 (14%). Polydrug use is the most observed consume pattern (75%). The i.v. heroin sub-population shows the highest mean age (31.18) of all treatment groups. 5% (2%) of the latter are first treatment demanders compared to 8% (5%) of non-i.v heroin users.

Cocaine use as main reason of treatment demand showed a significant increase from 2004 to 2006 and decreased again in 2007 (2010: 14%). Mean age of preferential cocaine using treatment demanders in 2010 was 31.82. With 20% (21%) of first treatment demanders, primary cocaine users show the highest lifetime first treatment rate. Cocaine prevalence as secondary drug has decreased from 43% in 2004 to 34% in 2009. In 2010 however, a slight increase is observed: 40% of inpatient clients reported Cocaine as secondary drug. Crack has not been reported, neither as main problem drug nor as secondary or occasional drug.

The percentage of treatment demands related to cannabis use (5%) in 2010 has been decreasing following a peak in 2009 (11%). Treatment demands related to ecstasy use are rare (1-3%) and have shown a fair stability over the last years. The same comments apply to ATS use.

6. Health correlates and consequences

**Introduction**

At the national level two drug-related deaths indexing routines do currently exist:

1. The Special Drug Unit of the Judicial Police (SPJ) maintains a register on acute drug deaths (RSPJ). The RSPJ indexes all direct overdose cases due to illicit drug use documented by forensic evidence. As police forces are routinely informed by medical emergency services in case of a suspected overdose case, they are able to collect
evidence at the site of the incident and confirm or not, in combination with post mortem toxicological evidence, the suspected overdose. RSPJ applies the following definition of acute/direct drug-related death:

‘Lethal intoxication, voluntary, accidental or of undetermined intent, confirmed by forensic and contextual evidence, and caused directly by the use of illicit drugs or by any other drug(s) if the victim has been known to be a regular consumer of illicit drugs’. Death has occurred due to an adverse somatic reaction to substance intake’.

2. The statistical department of the Directorate of Health maintains the General Mortality Register (GMR) indexing all deaths that occurred on the national territory by means of death certificates provided by MDs. Since 1998 the GMR applies the 10th revision of the International Classification of Diseases (ICD-10). Special software jointly developed by the statistical department and the national focal point allows extracting drug-related death cases from the GMR by the application of a predefined standard (e.g. DRD).

Both sources are independent, meaning that for the SPJ register data collection occurs via police records and forensic evidence, while the GMR is updated according to information contained in death certificates. Discrepancies between the referred registers mainly originate from different encoding routines (e.g. death certificates often only mention primary cause of death) explaining the fact that the DRD v 0.3 systematically underestimates the SPJ based number of drug-related deaths as can be seen in figure 6.6.

Even though DRD based data is provided to the EMCDDA, national figures on drug induced deaths published in the national annual drugs report are, for reasons explained above, based on the RSPJ whose case definition is compatible with the EMCDDA definition: [...] deaths that are caused directly by the consumption of drugs of abuse. These deaths occur generally shortly after the consumption of the substance(s). (EMCDDA)

Infectious diseases, including HIV and viral hepatitis have to be reported (notification procedure) when diagnosed to the Directorate of Health (Ministry of Health) that compiles data and is in charge of nation wide epidemiological follow up. These data do however not allow to breakdown infection prevalence according to PDU status. The national drug monitoring system RELIS therefore allows to gather self-reported data on infectious diseases in PDU. Furthermore specific diagnosed based studies provide complementary information. The report includes data from the latest study on infectious diseases in PDU (Origer & Removille, 2007) based on serological test results to assess current prevalence rates and apply vaccination schemes when medically indicated.

- **DRUG RELATED INFECTIOUS DISEASES**

HIV/AIDS, viral hepatitis, STD, tuberculosis, other infectious morbidity

Data on drug-related infectious diseases are centralised at national level. No regional data sets exist. Official data from the national Retrovirology Laboratory of the CRP-Santé provide the number and proportion of IDUs in HIV infected patients. Between 1984 and 2010, 1,011 HIV infected persons have been registered at the national level; 121 of the former were reported IDUs, which leads to an average proportion of IDUs in the national HIV population of 11.96% since the registration of the first HIV case in Luxembourg in 1984.
Currently intravenous drug use appears to be the third most reported transmission mode of new HIV infection since 1989 (homo/bisexual and heterosexual transmission are currently in first and second position respectively). The proportion of intravenous drug use transmission has noticeably decreased between 1998 (23%) and 2010 (6.45%). The lowest proportion of IDU transmission mode ever recorded was observed in 2009.

The Origer and Removille study (2007) assessed the national HIV, HCV, HAV and HBV in the population of problematic users of illicitly acquired drugs prevalence via serological test results. Furthermore, the authors performed a cross sectional analysis of the relation between the studied infections and selected observable factors, to increase the national vaccination coverage and to refer infected persons towards appropriated medical treatment centres. (Reported in ST 9)

Main results are the following:

**Table 6.1** Prevalence of hepatitis B surface antigens (HBsAg), antibodies to hepatitis B core antigen (anti-HBc), hepatitis C virus (anti-HCV), and HIV (anti-HIV 1 and 2) in PDU and ever-injectors according to national recruitment settings

<table>
<thead>
<tr>
<th></th>
<th>Total number of respondents †</th>
<th>Anti-HBc and/or HBsAg*</th>
<th>Anti-HCV</th>
<th>Anti-HIV 1 and 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N, n (%; 95% CI)</td>
<td>N, n (%; 95% CI)</td>
<td>N, n (%; 95% CI)</td>
<td></td>
</tr>
<tr>
<td><strong>Total sample</strong></td>
<td>362</td>
<td>310 (21.6; 17.1 to 26.2)</td>
<td>343 (71.4; 66.6 to 76.2)</td>
<td>272 (2.9; 0.9 to 4.9)</td>
</tr>
<tr>
<td><strong>Ever injectors §</strong></td>
<td>310</td>
<td>239 (24.7; 19.6 to 29.8)</td>
<td>268 (71.3; 61.4 to 91.2)</td>
<td>202 (2.5; 0.2 to 4.8)</td>
</tr>
<tr>
<td><strong>Outpatient drug treatment centres</strong></td>
<td>159</td>
<td>147 (16.3; 10.3 to 22.3)</td>
<td>158 (58.2; 50.5 to 65.9)</td>
<td>158 (1.9; 0.0 to 4.0)</td>
</tr>
<tr>
<td><strong>Inpatient drug treatment centres</strong></td>
<td>61</td>
<td>53 (15.1; 5.5 to 24.7)</td>
<td>61 (75.4; 64.6 to 86.2)</td>
<td>49 (0.0; 0.0 to 0.0)</td>
</tr>
<tr>
<td><strong>Prisons</strong></td>
<td>135</td>
<td>110 (31.6; 23.1 to 40.5)</td>
<td>124 (66.3; 80.2 to 92.3)</td>
<td>65 (7.7; 1.2 to 14.2)</td>
</tr>
</tbody>
</table>

* Two respondents with valid blood test serology were HBsAg positive only
† Number of respondents for whom valid blood test serology for at least one infection (HBV, HCV or HIV) was available
‡ Number of respondents for whom valid blood test serology for HBV was available
§ Respondents that have injected at least once in their lifetime a drug for non therapeutic reasons

Concerning HAV prevalence, no case has been identified in the referred study. It should be stressed, however, that 43% of the participating PDU were not protected against hepatitis A.


Downloadable at: http://www.relis.lu
Since 1996, the national drug monitoring system RELIS allows for breakdowns of HIV and AIDS data by IDU and treatment status. In 2010, (N=156) 83% of RELIS indexed PDU reported a HIV test during the last 12 months. The testing rates of female PDU were slightly higher than those of male PDU.

**Table 6.2** Synopsis of national data on HIV infection rate in drug using populations (valid %)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV rate in problem drug users (RELIS self-report)</td>
<td>2.9</td>
<td>2.9</td>
<td>4.3</td>
<td>4.07</td>
<td>4.49</td>
<td>3.88</td>
<td>3.98</td>
<td>3.31</td>
<td>2.9</td>
<td>3.39</td>
<td>3.82</td>
<td>5.08</td>
<td>6.09</td>
</tr>
<tr>
<td>HIV rate in problem drug users (serology-based) (Origer &amp; Removille, 2007)</td>
<td>2.90</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>HIV rate in drug treatment demanders (RELIS self-report)</td>
<td>2.6</td>
<td>3.4</td>
<td>4.87</td>
<td>4.78</td>
<td>4.32</td>
<td>3.88</td>
<td>4.93</td>
<td>3.84</td>
<td>3.49</td>
<td>4.13</td>
<td>2.96</td>
<td>4.83</td>
<td>7.22</td>
</tr>
<tr>
<td>HIV rate in current IDUs (RELIS self-rep.)</td>
<td>3.5</td>
<td>3.3</td>
<td>3.6</td>
<td>3.41</td>
<td>4.08</td>
<td>4.17</td>
<td>5.10</td>
<td>3.96</td>
<td>2.76</td>
<td>3.48</td>
<td>1.75</td>
<td>4.32</td>
<td>8.14</td>
</tr>
<tr>
<td>HIV rate in current IDUs treatment demanders (RELIS self-report)</td>
<td>3.4</td>
<td>3.9</td>
<td>3.9</td>
<td>4.24</td>
<td>4.32</td>
<td>4.24</td>
<td>6.41</td>
<td>4.59</td>
<td>3.33</td>
<td>4.27</td>
<td>0.76</td>
<td>4.24</td>
<td>7.29</td>
</tr>
<tr>
<td>HIV rate in life-time IDUs (serology-based) (Origer &amp; Removille, 2007)</td>
<td>2.50</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>HIV rate in current IDUs prisoners (Schlink 1998)</td>
<td>4.4</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>

**Source**: RELIS 2010

**Table 6.3** Synopsis of national data on AIDS rate in drug using populations (valid %)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AIDS rate in problem drug users (RELIS)</td>
<td>2.5</td>
<td>1.25</td>
<td>1.35</td>
<td>2.03</td>
<td>1.72</td>
<td>1.71</td>
<td>2.13</td>
<td>1.81</td>
<td>1.19</td>
<td>1.86</td>
<td>0.87</td>
<td>1.33</td>
<td>3.05</td>
</tr>
<tr>
<td>AIDS rate in drug treatment demanders</td>
<td>/</td>
<td>1.66</td>
<td>1.76</td>
<td>2.43</td>
<td>1.60</td>
<td>2.04</td>
<td>2.69</td>
<td>2.37</td>
<td>1.65</td>
<td>2.64</td>
<td>0.92</td>
<td>1.96</td>
<td>3.96</td>
</tr>
</tbody>
</table>

**Source**: RELIS 2010

HIV rates in current PDU have been varying over the last ten years although in quite narrow margins figuring 3 to 5%. In 2010, however, based on self-reported data from RELIS, the HIV rate increased for all categories figuring 6 to 8%. During the last five years, the HCV infection rate decreased for all PDU and for drug treatment demanders,
but the same rate shows variations for IDUs and even increased in 2010 for this category.

**Table 6.4 Synopsis of national data on HCV infection rate in drug using populations (valid %)**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Self-reported HCV rate in drug users (RELIS)</td>
<td>25</td>
<td>32</td>
<td>46</td>
<td>50</td>
<td>49</td>
<td>59.92</td>
<td>64.55</td>
<td>64.95</td>
<td>64.95</td>
<td>64.06</td>
<td>63.39</td>
<td>50.55</td>
<td>49.61</td>
</tr>
<tr>
<td>HCV rate in PDU (Origer &amp; Removille)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>71.40</td>
<td></td>
</tr>
<tr>
<td>Self-reported HCV rate in drug treatment demanders</td>
<td>29</td>
<td>41</td>
<td>53</td>
<td>54</td>
<td>54</td>
<td>60.49</td>
<td>66.16</td>
<td>66.22</td>
<td>63.23</td>
<td>63.08</td>
<td>61.11</td>
<td>53.79</td>
<td>50.47</td>
</tr>
<tr>
<td>HCV rate in IDUs prisoners (saliva tests)</td>
<td>37</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td></td>
</tr>
<tr>
<td>Self-reported HCV rate in IDUs (RELIS)</td>
<td>45</td>
<td>50</td>
<td>53</td>
<td>56</td>
<td>53</td>
<td>67.97</td>
<td>74.14</td>
<td>74.38</td>
<td>69.58</td>
<td>72.02</td>
<td>65.48</td>
<td>58.94</td>
<td>62.63</td>
</tr>
<tr>
<td>HBV rate in ever-injectors (Origer &amp; Removille)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Source: RELIS 2010 (Origer &amp; Removille 2007)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Summarily, HCV prevalence in PDU appears to have reached a plateau at a high level in 2006-07, showing, however a sensible decrease in 2009 and 2010. HIV infection rates show an increase especially referred to IDUs.

The existing prevention efforts have to be completed putting particular emphasis on young and new drug users. Although the study confirms a low compliance of the target population, screening and vaccination facilities have to be further developed. In this context the authors put forward a series of approaches that may contribute to reduce incidence of infectious diseases and related risks in PDU (see Origer, Removille, 2007).

The DIMPS project (Mobile intervention facility for sexual health) described under chapter 7 aims to access difficult to reach sub-populations and provide prevention counselling and infectious disease testing on site to various populations. Based on experience gathered through the new DIMPS project, discussions are currently held whether to extend the DIMPS offer to free HBV/HAV vaccination (where appropriate) for clients of specialised drug agencies. This enlarged approach could also allow to collect serological based data on infectious diseases in PDU in a routine and cost effective way.

- **OTHER DRUG-RELATED HEALTH CORRELATES AND CONSEQUENCES**

**Psychiatric co-morbidity (Dual diagnosis)**

To date any genuine study on co-morbidity patterns in PDU has been performed at the national level. Data presented in the present chapter have been provided by specialised drug agencies and the RELIS drug monitoring system and thus reflect experiences and trends as observed during recent years.

Most common mental disorders observed in clients seeking help in specialised drug agencies or in contact with other institutions are: anxiety, depression, neurosis, psychosis and borderline behaviour. Residential drug care settings estimate that 10% of their clients show psychotic symptoms. Furthermore, Post Traumatic Stress Disorders (PTSD) are most common and show great similarities with borderline behavioural aspects as for instance rapidly changing mood and auto-destructive tendencies.
According to annual data provided by the national drug monitoring system RELIS the following picture can be drawn:

At the national level, most of detoxification treatments are provided by psychiatric departments of general hospitals.

Data from 1996 to 2010 reveal a fluctuating but a fairly stable long term proportion of PDU showing a psychiatric history.

There seems to be no significant differences of psychiatric profiles in clients according to the type of institutional settings. Multiple drug use is observed in almost all DD patients.

DD patients are considered as drug treatment demanders with specific and highly diversified needs that are difficult to encounter in traditional drug care agencies. The concept of ‘multiple vulnerabilities’, that is, concomitant vulnerabilities to drug abuse and mental disorders, tends to be recognised by professionals. DD patients very often present a lack of behavioural structure or stability. Usually those patients are unable to function in a regulated environment. Moreover, the requirement of most therapeutic settings include that the patients submit to detoxification treatment prior to admission.
This latter requirement is often impossible to meet with DD clients as drug intake often represent a kind of self-managed auto-medication, dangerous to change radically at the beginning of a therapeutic process. It is therefore most difficult to integrate DD patients in traditional drug care settings also in terms of consistency of rules to be respected by all drug treatment demanders. To date, no care facilities specialised in drug addiction co-morbidity exist at the national level. The Department of Medical Control of Social Security Administration, in collaboration with drug agencies, assesses whether a given patient should be referred to specialised institutions in foreign countries. Agreements between the latter administration and a series of specialised care agencies abroad have been made. If the referral demand is approved, related costs are reimbursed by Social Security.

As far as treatment of DD patients in prison is concerned, a collaboration convention between the national prison administration (CPL) and the national neuro-psychiatric hospital (CHNP) has been signed in 2002. The convention sets the framework for the creation of a psycho-medical department within prison and regulates prevention, care and referral of mentally disabled as well as alcohol and drug dependent inmates. Therapeutic care, substitution treatment and counselling is provided ad hoc. In case of severe mental disorders, imprisoned patients are referred to a high security department within the CHNP.

Compulsory treatment or confinement does only occur if there is a proved offence against the law by which the offender is declared irresponsible of his/her own behaviour. This only occurs following a legal psychiatric expertise.

In line with the recommendations of the previously referred to expert group 'Therapeutic chain' discussions held in the framework of the new drugs action plan 2010-2014 currently address the idea to create small supervised housing facilities where care is provided to DD patients on a case management basis.

Somatic co-morbidity

Health indicators retained by RELIS suggest a stabilisation of the general health state of indexed PDU except for HCV prevalence. In 2010, 81 (83) per cent of problem drug users reported a self-perceived satisfying general health condition against 53% in 1997. 56% (60%) report no non-fatal overdose(s) during lifetime which is a small decrease compared to the previous year.

Drugs and driving

Figure 6.4 provides data on cannabis exposure of persons suspected to drive under influence of psychoactive substances from 1995 to 2010. Around 50% of referred persons were tested positive on cannabinoids.
Fig. 6.5 Detection of cannabinoids - Suspicion on driving under influence of psychoactive substances (1995 - 2010)

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of samples</th>
<th>Number of positive cases</th>
<th>% positives</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>82</td>
<td>29</td>
<td>35.4</td>
</tr>
<tr>
<td>2000</td>
<td>125</td>
<td>60</td>
<td>48</td>
</tr>
<tr>
<td>2001</td>
<td>126</td>
<td>47</td>
<td>37.3</td>
</tr>
<tr>
<td>2002</td>
<td>150</td>
<td>70</td>
<td>46.7</td>
</tr>
<tr>
<td>2003</td>
<td>171</td>
<td>59</td>
<td>34.5</td>
</tr>
<tr>
<td>2004</td>
<td>165</td>
<td>62</td>
<td>37.5</td>
</tr>
<tr>
<td>2005</td>
<td>176</td>
<td>73</td>
<td>41.5</td>
</tr>
<tr>
<td>2006</td>
<td>152</td>
<td>60</td>
<td>39.5</td>
</tr>
<tr>
<td>2007</td>
<td>188</td>
<td>72</td>
<td>40</td>
</tr>
<tr>
<td>2008</td>
<td>181</td>
<td>72</td>
<td>43</td>
</tr>
<tr>
<td>2009</td>
<td>173</td>
<td>75</td>
<td>51</td>
</tr>
<tr>
<td>2010</td>
<td>162</td>
<td>83</td>
<td>51</td>
</tr>
</tbody>
</table>

Pregnancies and children born to drug users
See sub-chapter at-risk families in chapter 3.

- **Drug Related Deaths and Mortality of Drug Users**

**Direct Overdoses and indirect drug related deaths (see ST5 and 6)**

Methodological information and Drug-related Deaths (DRD) data collection and processing routines can be found in the introduction of the present chapter and in annex I under ‘Databases and information systems’.

As can be seen in figure 6.6 the DRD v.3.0 standard (selection B) appears to be fairly weak proxy of direct, indirect and total drug deaths as indexed nationally by the RSPJ. Overall drug related mortality, however, should not be assessed by the same standard as far as Luxembourg is concerned. Cases not filtered by selection B mainly include combined X49 codes, followed by Y34 and T65.9 codes. A very high to perfect agreement is observed between the RSPJ register and selection D (DRD v.3.0).

The number of **fatal acute overdoses** indexed at the national level has shown an overall discontinuous decrease since the beginning of the 21st century. In 2000, 26 acute drug deaths were registered whereas 12 cases were reported in 2010. Indirect drug-related deaths have known broad variations in number during the same period (2009 and 2010 data not available).
Confronted to most recent national prevalence figures on problem drug users referring to data of 2007 \((N = 2,470)\), (Origer, in press), overdose rate in PDU situates at 0.49 % cases / PDU (1.1 % in 2000). The overdose rate in the national general population figured 6.43 overdose deaths per 100,000 inhabitants 38 in 2000. In 2010 overdose rates of 2.39 and 3.5 per 100,000 inhabitants and 100,000 inhabitants aged 15 to 64 years respectively have been observed. International comparison should be considered with caution since methodologies used to determining prevalence of DRD deaths are not necessary comparable throughout EU as shows for instance the structural underestimation of the number of acute drug death based on the EMCDDA DRD v.3 standard.

38 All age groups
The overall discontinuous decrease of acute overdose cases from 1994 onwards has been associated to the regionalisation and extension of the methadone substitution programme as well as to the further development of low threshold facilities. The decreasing trend from 2000 to 2002 is thought to be a medium term consequence of the higher proportion of non-i.v. opiate users observed during that same period followed by a stabilisation around 4.5 percent. The positive evolution of direct drug deaths is to be associated to the implementation of a drug consumption room in 2005. Considering that since the opening in 2005 of the drugs injection room more than 550 overdose victims could be assisted and reanimated in this same facility, the life-saving effectiveness of such an offer is proven.

A retrospective study (1992-2006) on drug-related death cases performed in 2007 allowed a better understanding of risk and protective factors (Origer, 2008). Forensic data by the department of National Toxicology Laboratory on Health show that the most frequently involved substance in overdose cases is heroin, followed by methadone and cocaine. To stress that since 2000, methadone presence in blood samples of overdose victims has been increasing.

All the victims are male (100%) and their mean age at the moment of death shows an important increase over the past 15 years (in 1992: 28.4 years and in 2010: 31 years). Although the mean age of drug overdose victims has been increasing, the number of victims aged less than 20 years remains relatively unchanged during the referred observation period.

Also worth mentioning is that a majority of acute drug death victims are known by law enforcement agencies (+/- 80%) for their drug user ‘career’. As far as the place of death is concerned, since 2004 approximately 50-65% occurred at the victims’ home, followed by public place and detention centre.

![Figure 6.8: Gender distribution of direct drug-related death cases (1992 - 2010) (%)](image)

Source: RELIS 2010

39 Département de Toxicologie du Laboratoire National de Santé
Table 6.5. Age distribution of direct drug death cases indexed from 1992 to 2010

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 20</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19</td>
</tr>
<tr>
<td>20-24</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td>8</td>
<td>2</td>
<td>5</td>
<td>6</td>
<td>6</td>
<td>66</td>
</tr>
<tr>
<td>25-29</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>6</td>
<td>5</td>
<td>5</td>
<td>13</td>
<td>6</td>
<td></td>
<td>88</td>
</tr>
<tr>
<td>30-34</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>6</td>
<td>2</td>
<td>4</td>
<td>6</td>
<td>3</td>
<td>62</td>
</tr>
<tr>
<td>35-39</td>
<td>2</td>
<td>3</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>4</td>
<td>4</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>43</td>
</tr>
<tr>
<td>40-44</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>45-49</td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11</td>
</tr>
<tr>
<td>≥ 50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>4</td>
</tr>
</tbody>
</table>

Mean Age

- Male: 31Y, 32Y5M, 32YBM
- Female: 25Y, 33YBM

In 2010, the mean age of male overdose victims is sensibly lower than in 2009. In 2010, the youngest victim was aged 18 years and the oldest reached 48 years. No underage victims were reported in 2010. Considering the nationality of overdose victims, 92% were natives. During the entire observation period, Portuguese citizens have been the second most frequently observed victims. Recently, one could observe a rather stable number of victims from the frontier zone (BE, DE, F) and a decreasing number of victims of Portuguese origin.

For more detailed data on 2010 drug related deaths please refer to standard tables 5 and 6.

Mortality and causes of deaths among drug users

The above mentioned study (Origer & Dellucci, 2002)\textsuperscript{40}, has revealed that, as far as the Grand-Duchy of Luxembourg is concerned, the mere application of the DRD standard does not allow for a valid computation of drug related death cases. Therefore, the authors did compute the total number of drug-related deaths by adding cases of the SR that were not indexed by the application of the DRD standard to the GMR. The figures resulting from corrected DRD v.3.0. data are referred to as ‘national selection’ and provide the annual total number of controlled drug-related fatalities at the national level (12 direct/acute death cases in 2010).

\textsuperscript{40} A full text version of the study can be downloaded under: http://www.relis.lu

82
In 2000, a first cohort study on the mortality in the national drug population has been performed by the NFP in the framework of a multi-methods prevalence study (Origer & Pauly, 2000). The cohort included 242 opiate drug addicts followed from 1991 to 1999. Mortality data have been collected from treatment agencies, the RELIS database, the GMR and the Special Overdose Register of the SPJ. In accordance to applied methodologies, results show mortality rates varying between 2.36 and 2.51 per cent.

Since the implementation of ICD-10 coding by the GMR (1998), a vast majority of acute drug death cases have been recorded as ‘accidental poisoning’ (X40 – X49), which is consistent with the national definition of an acute overdose death. To date over 60 % overdose cases have been indexed as follows: X42.-, T40.-, T42.-, T43.-. At a more restricted level the code sequence: X42.-, T40.- includes around 70% of all reported overdoses.

### 7. Responses to health correlates and consequences

**Introduction**

Responses to health correlates and consequences of drug use aim at minimising the resulting damage for the drug users and their environment, and at increasing individual/collective resources. The concept of risk and harm reduction is directly linked to health consequences of drug use, whereas nuisance reduction is seen as a correlate of the latter.

Health care offers to drug users are provided by specialised drug care agencies as well as by the general health care system. Major efforts have been undertaken in recent years to improve data on drug treatment demands from general healthcare providers by including psychiatric departments of general hospitals in the RELIS data collection network and the pilot implementation of a national substitution treatment register. In addition to the national drug surveillance system RELIS, these new data sources and tools will allow to draw a more accurate picture of intervention outcomes.

In September 2011 a new national HIV/AIDS action plan (Ministry of Health, 2011) covering the period 2011 to 2015 has been launched by the Ministry of Health. The action plan is based on 8 pillars including prevention of infectious diseases and harm reduction in drug using populations. It builds upon the external evaluation results of the 2006-2010 national HIV/AIDS plan and complements or enhances infectious diseases’ reduction measures included in the national drugs action plan 2010-2014. The document can be downloaded under [http://www.ms.etat.lu](http://www.ms.etat.lu).

As far as availability of service is concerned, currently two agencies offer harm reduction services in the Centre, the South and the North of the country including offers such as day and night shelter and a supervised injection facility (currently only in Luxembourg City). The governmental programme 2010-2014 foresees the decentralisation of respective offers by implementing new integrated low threshold centres for drug addicts in the South of the country and by further developing harm reduction measures in the North. In this context the Ministry of Health has commissioned a specialised agency to perform a needs assessment of harm reduction measures in the northern region. Outcomes of the latter will be addressed below.
PREVENTION OF DRUG-RELATED EMERGENCIES AND REDUCTION OF DRUG RELATED DEATHS

Research and recommendations
In the framework of the first national drugs action plan 1999-2004 foundations have been laid for a comprehensive nation-wide strategy for the reduction of health consequences of drug use. A specific study (Origer & Dellucci, 2002) has been addressing the issue of the reduction of drug-related mortality. The following recommendations have been retained:
- 1. Opening of supervised injection rooms according to the national drugs action plan.
- 2. Heroin assisted treatment (foreseen by the national drugs action plan).
- 3. First aid training courses provided to users and their relatives and partners.
- 4. Gender and ethnic specific interventions.
- 5. Creation of ‘transition centres’ for ex or current PDU leaving institutional settings.

Drug injection room and low threshold shelters
A drug injection room is defined as a facility allowing IDUs who meet certain criteria to inject their own drugs in a medically supervised environment. Drug consumption (user) rooms meet the same definition; in terms of target population; they, however, give access to IDUs and non IDUs meeting the admission criteria.

The implementation of a first drug injection room in 2005 has to be seen as a part of a broader harm and nuisance reduction oriented strategy. The national drug action plan refers to the creation of low threshold emergency shelter facilities for drug addicts to be implemented regionally.

A low threshold emergency centre for drug addicts (TOXIN) was inaugurated in December 2003 and initially provided day care and night shelter. In July 2005, the first supervised injection room at national level has become operational and has been integrated in the TOXIN centre which from then on has been providing the whole range of harm reduction services, counselling facilities, accommodation, washing and laundering facilities. It should be added that the night accommodation is not to be seen as a permanent housing facility; there is a daily admission procedure. The target population for the consumption room are primarily IDUs. The main objective of the project is the reduction of drug-related harm and nuisances. More precisely it aims at reducing the risks of overdoses, infectious diseases, public nuisance in the neighbourhood, facilitating contact making with difficult to reach addicts, provision of special designed night shelter facilities and avoiding unnecessary prison journeys over night. The project was designed with the support of the Public Prosecutor’s Office and law enforcement agencies.

The national drugs coordinator’s office elaborated the operational concept of the injection room based on available international experience and evaluations. In terms of management, all involved parties meet regularly (called ‘the Monday round’) to assess the current situation and emerging problems related to the functioning of the consumption room. Incidents, nuisance reports, trends, quality assurance, workload, technical improvements and safety issues are addressed by the ‘Monday round’ in order to promote rapid solution finding and continuous adaptation to fast changing clients’ profile and consume patterns.
Table 7.1 provides an insight in clients’ and occupation statistics of the TOXIN services since their opening and for 2009 and 2010 respectively:

| Tab 7.1 Clients statistics of TOXIN centre services |
|-----------------------------------|-----------------|-----------------|
| **Injection Room**                | June 2005 - December 2010 | 2009 | 2010 |
| Number of user contracts signed   | 954              | 94   | 119  |
| Number of users episodes          | 64,479           | 36,558| 33,018|
| Number of injections              | 136,758          | 43,871| 39,960|
| Number of non-fatal overdoses     |                  |      |      |
| With loss of consciousness        | 790              | 149  | 641  |
| Without loss of consciousness     | 149              | 54   | 144  |
| Number of fatal overdoses         | 0                | 0    | 0    |
| Medical emergency interventions   | 121              | 46   | 33   |
| **Day care**                      | December 2003 – December 2010 | 2009 |      |
| Number of clients                 | 287,720          | 77,333| 65,307|
| **Night shelter**                 | December 2003 – December 2010 |      |      |
| Number of different residents     | 1,840            |      |      |

Opening hours have been modified in course of 2010 due to an increasing number of clients and resulting temporary staff shortages. Currently the night shelter is open 7 days a week with a capacity of 42 beds. The TOXIN day centre, and injection room (7 injection tables) is temporarily closed on Saturday. TOXIN facilities are mostly used by men (86%); the most commonly used drugs were heroin (79%), cocaine (15%) or both of them (6%). Cocaine use has obviously increased in 2010. Age category 25-34 is mostly represented (47%).

No fatal overdose has occurred thus far but almost 800 overdoses have occurred since the opening of the injection room and due to the immediate intervention of ad hoc staff all victims could be assisted, reanimated and their live saved. The drug scene of Luxemburg-City adheres to a great extend to the TOXIN concept with the positive effect that public nuisance has significantly decreased. The increasing number of users attracted by the TOXIN services poses however a problem of clients’ management given the fact that the container structure was meant to be of provisional use and is currently reaching the limits of its service capacity. Therefore, a new centre will replace the previous one and should become operational in the beginning of 2012. Its implementation site is the immediate vicinity of the current centre. Architectural planning of the replacement structure has built upon past experience and also foresees the inclusion of a supervised drug inhalation facility, currently not available in the present centre. The concept of the drug injection room has been revised accordingly.

As most relevant drug scenes concentrate in the City of Luxembourg and in the main city in the South of the country, the governmental programme has foreseen the creation of an integrated low threshold offer (including a supervised injection room) also in the city of Esch-sur-Alzette. The search of an appropriate site for the injection room is currently undertaken.

As far as the northern region of the country is concerned, it has been said that a needs assessment was commissioned by the Ministry of Health. The main objective of the latter was to determine the specificity of drug use patterns in this region and the gaps in existing harm reduction offers. During a 6 months prospection phase data have been collected via drug users, residents, shop owners, social actors and local municipal authorities. First results of the assessment (JDH, 2011) clearly emphasis the need of a tailor made low-threshold offer in the region. However, the type of offer needed appears to differ from those currently existing in bigger cities such as Luxembourg and Esch/Alzette. The drug user population living in the northern region is not locally concentrated and non-intravenous use is reported to be far more prevalent than IDU.
Large scale syringes exchange programmes are not a first priority and may even be counterproductive in a sense. This said, the phenomena of stigmatisation, isolation and marginalisation of drug users is far more concerning. Also, the development of region wide outreach work in addition to community offers appears to be a promising strategy for the northern region.

The law of 27 April 2001 introduced an important modification of the basic drug law with regard to overdose prevention. Art.10-1 of the referred law exempts drug users who call for assistance in case another user is in need of medical help, from prison sentences and from fines in certain circumstances. In general, witnesses meeting these conditions are not prosecuted. As an accompanying measure an information flyer has been elaborated jointly with field agencies and the Ministry of Health and broadly distributed. The flyer contains useful information on safer injection and advice in case of overdose events.

Heroin assisted treatment (HAT)

The future implementation of a heroin assisted treatment programme, as foreseen by the national drugs action plan 2010-2014, should further contribute to reduce drug-related health damage. In 2008 a feasibility study and an operational framework concept (Origer, 2008), partly inspired by the Swiss guidelines on Heroin Assisted Treatment (Bundesamt für Gesundheit, 2006) has been submitted to the Minister of Health. The main conclusions of these reports can be found in the 2009 edition of the present report. It should be underlined that the HAT is not conceptualized as a low threshold measure. It is intended to be implemented in the broader framework of the national drug substitution treatment strategy with clearly defined medical and psycho-social components.

A drug scene survey was performed in 2008 (JDH, 2009) in order to investigate perceptions and opinions regarding the implementation of HAT. 174 drug users in contact with drug care institutions were interviewed by using a standardised questionnaire. 85% of respondents consider HAT to be a useful complementary offer for the following reasons (in order of importance): reduction of criminality and petty crime, clean quality controlled heroin, reduction of drug-related mortality, social stabilisation and reduction of harm and health damage. 62% of interviewees declared themselves to be personally interested to enter HAT if available.

By the time of writing the general HAT concept was approved, a provisional budget has been set and agreement was reached with a specialised agency in terms of future management of the programmes. First resources have been allocated in 2010 and study visits to several countries running HAT facilities have been undertaken. National experts are currently fine-tuning the existing concept in order to operationalise this new treatment alternative. Also the necessary steps haven been taken to determine the import, management, stocking and preparation procedures of diacetylmorphine.

New specialised care structures foreseen in the framework of the 2010-14 action plan

The lack of national detoxification capacities has become a growing problem in the drug care network in recent years. According to international standards the number of detoxification slots in general hospitals revealed to be sufficient, however, waiting lists of new treatment demanders became consistently longer partly due to long duration stays. To further improve peri-hospitalisation procedures, two new projects have been retained in the new drug action plan.

The first refers to the set up of a so called diagnostic, referral and follow-up mechanism (DDOS). The main idea is to attribute a single (freely chosen by the treatment
A (social worker, etc) reference person (social worker, etc) to each treatment demander. This reference person organises jointly with the patient and care institutions treatment interventions, follows up progression and guarantees access after-care offers. The reference person also represents a single contact person for involved care institutions. A small scale pilot phase involving a series of specialised actors has been launched in order to gather experience until the necessary resources will be allocated to implement a referent system nation-wide.

Furthermore, in order to allow hospitals and psychiatric departments to concentrate their efforts to interventions for which they are competent, mainly medical care and withdrawal, to reduce relapses and after release overdoses, a stabilisation unit will be operational in 2012 with a capacity of 12 beds and a maximum stay of 3 weeks. The referred unit aims at stabilising recently detoxificated persons by providing them with necessary medical care and by offering them a safe environment to start or continue their re-integration process. Negotiations between the Ministry of Health and the CHNP have allowed finding adequate solutions to implement the referred unit in existing infrastructures of the CHNP and to plan its opening for 2012.

A mobile medical care unit, providing primary medical care to clients of all specialised low threshold agencies will be operational by the end of 2012. Its objective is to increase access to medical care and further referral of hard to reach drug using population.

- **PREVENTION AND TREATMENT OF DRUG-RELATED INFECTIOUS DISEASES**

**Prevention**

Interventions aiming at the prevention of drug-related infectious diseases as for instance needle exchange and substitution programmes have been initiated and developed prior to the set up of a specific legal framework. The drug law amendment of 2001 did not only allow maintaining and to further developing existing harm reduction offers but also set the foundation for the implementation of new services such as supervised drug injection rooms and medically assisted heroin distribution as foreseen by the national drugs action plan.

The objective of these interventions is straightforward, that is an optimised management of risk factors and mental/physical damage associated to drug use. Reduction of public nuisance is a secondary objective. Both IDUs and non IDUs are target groups of HR interventions. The planned inclusion of a drug inhalation facility in the new TOXIN centre is a sound example of the national approach. Furthermore infectious diseases prevention does not focus specifically on IDUs as shows a recent action-research project on HIV and hepatitis infection among PDU (Origer A and Schmit JC, 2010).

The most relevant measure in the field of prevention of infectious diseases in drug users is the national needle exchange programme established in 1993 and co-ordinated by JDH. In addition to free of charge needle provision by specialised drug and AIDS agencies, automatic syringes dispensers/collectors have been placed in the most appropriate locations in five different cities of the Grand Duchy.

Regarding the quantity of distributed syringes, table 7.2 shows that the number of distributed syringes stabilised in 2005 and has been significantly decreasing from 2006 onwards, although the return rate continued to increase. From 2008 onwards quantities of syringes distributed through NEP have been increasing anew.
According to RELIS data, one third of IDUs procure their syringes primarily in pharmacies. This proportion has remained fairly stable over recent years and does not directly impact on trend figures from specialised needle exchange points.

As can be seen in table 7.2, the number of re-collected used syringes exceeded in recent years the number of distributed syringes via the national NEP, (vending machines excluded), which suggests that users also bring along syringes bought in pharmacies or originating from vending machines, which is considered to be a highly positive evolution.

<table>
<thead>
<tr>
<th>Year</th>
<th>Distributed syringes</th>
<th>Collected used syringes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1996</td>
<td>76,259</td>
<td>26,646 (38%)</td>
</tr>
<tr>
<td>1998</td>
<td>109,743</td>
<td>56,886 (48%)</td>
</tr>
<tr>
<td>2000</td>
<td>189,413</td>
<td>112,535 (59%)</td>
</tr>
<tr>
<td>2002</td>
<td>254,596</td>
<td>211,521 (83%)</td>
</tr>
<tr>
<td>2004</td>
<td>435,078</td>
<td>376,491 (87%)</td>
</tr>
<tr>
<td>2006</td>
<td>332,347</td>
<td>282,909 (93%)</td>
</tr>
<tr>
<td>2008</td>
<td>259,607</td>
<td>249,400 (96%)</td>
</tr>
<tr>
<td>2009</td>
<td>289,355 of which 45,529 via injection room and 13,353 via vending machines</td>
<td>301,895 (104%)</td>
</tr>
<tr>
<td>2010</td>
<td>308,350 of which 44,830 via injection room and 8,109 via vending machines</td>
<td>297,400 (96.5%)</td>
</tr>
</tbody>
</table>

Source: RELIS 2011

A syringe and needle exchange programme has started in the national prison (CPL) in August 2005. Demanding inmates are seen by medical staff and if indicated, an initial injection kit containing sterile injection paraphernalia is handed out. Sterile replacement syringes are delivered on presentation of the used ones and the initial kit. The program is placed under medical secret.

<table>
<thead>
<tr>
<th>Year</th>
<th>Distributed injection kits</th>
<th>Distributed syringes</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/2005 – 12/2006</td>
<td>64</td>
<td>300</td>
</tr>
<tr>
<td>2007</td>
<td>24</td>
<td>77</td>
</tr>
<tr>
<td>2008</td>
<td>36</td>
<td>178</td>
</tr>
<tr>
<td>2009</td>
<td>33</td>
<td>261</td>
</tr>
<tr>
<td>2010</td>
<td>34</td>
<td>328</td>
</tr>
</tbody>
</table>

Source: CPL 2011

Quality assurance and follow-up of new injection paraphernalia on the market is ensured by a special expert group chaired by the national Drugs Coordinator. Although no mandatory guidelines have been submitted to specialised SEPs the latter do generally agree on common standards within the referred expert group.

Moreover, outreach interventions targeted at (drug using) sex workers aiming at establishing contact and to prevent dissemination of infectious diseases have taken place. According to EMCDDA’s key indicators and with a view to improve quality of national data on infectious diseases, the NFP has performed an action-research with the objective to estimate HCV and HIV prevalence in PDU and IDUs based on medical diagnosis data (blood testing) and to implement required health care measures. The development of new measures to reduce drug-related infectious diseases (e.g. rapid testing, DIMPS, inhalation rooms) largely built and still build upon the recommendations of the referred report published in September 2007 (Origer & Removille, 2007). The final
report may be downloaded at http://www.relis.lu. Several related publications in peer-reviewed journals have been accepted in 2010 and 2011.

Counselling and testing

AIDSBERODUNG (RED CROSS) is the main national counselling and prevention centre for HIV and AIDS. Prevention campaigns are conceptualised by the AIDSBERODUNG team in collaboration with the Ministry of Health and an important network of volunteers. AIDSBERODUNG is part of the RELIS network. Testing is provided by the CHL and the LNS and is free of charge. The 2011-2015 HIV/AIDS action plan foresees 2 new free testing sites in the North and the South of the country thus regionalising free testing opportunities.

Under the previous national HIV/AIDS action plan 2006-2010 a mobile intervention facility for sexual health (DIMPS) has been set up. DIMPS may be described as an outreach offer for specific target populations and vulnerable groups aiming to access difficult to reach sub-populations and provide prevention counselling and infectious disease testing on site to various populations. The project, started in May 2009, provides free rapid testing of HIV, hepatitis and outreach counselling targeting among others drug users’ scenes, sex workers and asylum seekers. From the recent start of DIMPS to the end of 2010, 58 interventions have been reported, 184 persons counselled and 113 HIV/HCV/ HBV rapid tests performed. Respectively 44% and 61% of persons tested declared that they have never been tested before for HIV and HCV respectively. More detailed information is retrievable at http://www.dimps.lu

Finally it should be stressed that HAV, HBV, HCV and HIV testing and vaccination for HAV and HBV is proposed to each person entering prison by intra muros medical staff.

Infectious diseases treatment

The National Service for Infectious diseases, implemented within the CHL provides specialised treatment in collaboration with the counselling staff of the AIDSBERODUNG/Red Cross. In case the patient has no or no valid health insurance, treatment costs may be covered by state.

Since 2009 a specialised medical department for transmittable diseases (COMATEP) is operational within the CPL. Given the fact that according to 2008 data 20.97% of inmates carry a transmittable disease and that yearly more than a third of new admissions in national prisons are drug law offenders, the project is considered to be pertinent and important also by the national drug coordination office.

Interventions related to psychiatric co-morbidity

The number of confirmed DD patients is estimated at 40-50 people (adults) nation-wide. These patients show explicit psychiatric disorders, are often socially disintegrated and need individual follow up although they tend not to be attracted by existing care offers. Furthermore, the staff of specialised associations must be specifically trained to take care of DD clients. Instead of creating a specialised and centralised care infrastructure, a better follow-up of patients within existing outpatient services is needed in the first place, knowing that the referred clients only integrate with difficulties in structures with compulsory residential character. The ‘Therapeutic Chain’ expert group has recommended in this context to fine-tune the concept of supervised / accompanied housing in order to move towards a case management approach in a private and individualised environment, knowing that DD patients often have difficulties to adapt to community oriented settings and offers.
RESPONSES TO OTHER HEALTH CORRELATES AMONG DRUG USERS

Somatic co-morbidity and general health related treatment

According to longitudinal RELIS data, the general state of health of drug users appears to have improved during the last decade, which could be partly due to the significant development of harm reduction and treatment referral offers.

The vast majority of specialised out- and inpatient and low threshold drug care facilities include medical or paramedical care in their service provision. If needed, patients are referred to specialised treatment. Related costs are covered by health insurance schemes or by the Ministry of Health in case the patient has no valid insurance.

In the framework of the new drugs action plan 2010–2014, a mobile medical service providing free and on site medical care to drug users independently of the institutional setting they are in (except hospitals) is about to be implemented.

Non-fatal drug-related emergencies

No specific data on drug-related emergencies are currently available at the national level. Figure 7.1 refers to RELIS data on previous non-fatal and medically assisted drug overdose self reported by PDU. The proportion of indexed drug users reporting at least one overdose (as defined) appears to be decreasing 2008 onwards. These figures have to be seen in the light of the significant number of overdose incidents that have occurred in the national supervised drug injection room without fatal consequences, due to immediate assistance (more than 800).

Prevention and reduction of driving accidents related to drug use

The law of 18 September 2007 modifies the national traffic code and introduces testing of illicit drug use in vehicle drivers. The homologation of respective road side tests should be regulated by a grand-ducal decree in the course of 2011. For more details on the new legislation please refer to chapter 1 (laws).

Interventions concerning pregnancies and children born to drug users

In the context of the development of social paediatrics at national level, child care professionals and paediatricians call for the implementation of specialised care structures for children at risk. The approach of social paediatrics considers a child in his global context including physical, psychological, social and cultural health, family and environmental context and promotes coordination and collaboration between different social and medical services.
Due to the improvement of, and the better access to drug-related treatment and especially the spread of substitution treatment, the birth rate in drug users has increased over recent years. According to data from the national drug surveillance system, the proportion of drug users having children has progressively increased over the last 10 years (RELIS 2010). This evolution has been leading to the first parental project launched by JDH in 2003 with the aim to provide psycho-social aid to drug-dependant parents and their children. The primary objective of the project is to ensure security and well-being to children and to strengthen parents’ educative abilities. This long term project is based upon contractual commitments, co-intervention, home visits and functions in close collaboration with involved services. An essential part of the project constitutes the outreach work. Meetings and interviews are held within the natural environment of the family (at home).

8. Social correlates and social reintegration

Introduction

Social correlates of drug use typically involve Justice, Health and Educational competences. The Ministry of Health and the Ministry of Family and of Integration both intervene by financing measures to reduce social consequences ranging from early detection of drug use to social-professional rehabilitation interventions. The reduction of drug related crime involves the Ministry of Justice, focuses on supply reduction activities and the Ministry of Health implements measures targeting socio-professional re-integration aiming at reducing daily expenses and depths of drug addicts and thus the prevalence of acquisition crimes.

- Social exclusion and drug use

Social exclusion among drug users

The question whether substance abuse leads to social degradation and exclusion or social factors (e.g. family situation, poverty, low education or job perspectives) lead individuals to substance use is an unsolvable one, although it tends to raise competence issues between ministries. Obviously a vast majority of homeless and socially excluded people also present to various extents licit and/or illicit substance abuse. Also, economic parameters tend to have a tangible impact on drug use prevalence and patterns as well as on the level of acceptance and perception of drug addicts by the general population.

A sound example of how social rejection and drug abuse are dynamically linked might be seen in the national results of the 4th wave of the European Values Study. 55% of national respondents (N: 1,610) described drug addicts as most unwanted neighbours. In 1999 drug addicts still occupied the second position (43%).

Also, providing medical and psychological care to drug dependent persons is not enough as the social situation of these people needs to be improved before sustained outputs in drug treatment is expectable. This said, the national strategy of care for socially excluded people is based on the principle of progressive reintegration through capacity building and the improvement of the social abilities and environment. Associations as ‘Stëmm vun der Strooss’ (Street voice) and ARCUS asbl, financed by the Ministry of

41 EVS Foundation/Tilburg University: European Values Study 2008, 4th wave, Integrated Dataset. GESIS Cologne, Germany, ZA4800 Data File Version 1.0.0 (2010-06-30) DOI:10.4232/1.10059.
Health, try to involve the target population again in active life by providing a safe and common environment and respecting individual capacities and resources by applying case management methodologies further described below.

Drug use among socially excluded groups

**Homelessness**

According to latest estimations around 700 persons are currently homeless in the Grand Duchy of Luxembourg. The study reported a proportion of 54% males and 46% females and a relatively young age of homeless population. Half of the population of homeless people is aged 18 to 34 years and only 9% are aged more than 55 years.

More specifically, housing status of registered drug users has markedly improved during recent years and tends to stabilise over the last years, even though 2009 and 2010 data witnesses a first decrease. Since 1995, the proportion of persons disposing of a stable accommodation has more than doubled. Currently 62 percent (64%) of PDU report a stable housing situation (RELIS 2010). This positive evolution may be linked to an increased awareness of the housing problem and the set up of new housing networks for socially deprived people by the Ministry of Health and specialised agencies. Recent figures also tend to confirm that although specialised accommodation offers have been further developed, the current economic situation has created an even higher demand for this type of housing.

![Fig. 8.1 Last known housing situation of problem drug users. 1995 - 2010](source: RELIS 2010)

Youngsters aged less than 25 and living in the street are referred to as a quite new phenomenon. Societal changes as the increase of mono parental families, an increased number of divorces, increasing youth jobless rates and the necessity to work for economic reasons for the two partners of a parental couple are likely to have a negative impact on youngster’s psychological development, education and perspectives.

**Unemployment**

The unemployment rate (69%) shows an increase for 2010. However, an in-depth analysis shows that the proportion of active respondents reporting a stable job situation (e.g. long term contract) (12%) has sensibly decreased over the 3 last years, which might be partly due to the ongoing economic crisis.

---

42 Centre d’Etudes de Populations, de Pauvreté et de Politiques Socio-Economiques (2007). L’exclusion liée au logement des personnes prises en charge par les centres de jour, les foyers de nuit, les centres d’accueil et les logements encadrés. Luxembourg

92
Remark: STATEC: Statistical Department of State – Unemployment rate in active general population.

Data on revenues confirm observed trends in occupational status:

- increase of social dependence associated to a stable **financial autonomy**. The Guaranteed Minimum Income constitutes the primary source of revenue of PDU.

- illegal activities as main **revenue** have witnessed an ongoing downward trend since 1995, although they have gained in importance in 2009 to decrease again in 2010.

**School drop out**

The study of 'School leave in Luxembourg' (2006) surveyed a population of 37,347 secondary school students during 1st November 2004 and 30 April 2006. A total of 2,422 students left school without a professional certification (temporary stay offs from school have also been taken into consideration). The study refers to a proportion of 6.5% of 'school leavers'. This proportion figures 3.6% if one is considering the total number of students having been reached but did not reintegrated a school in Luxembourg. Concerning this category of school leavers, composed of students attending courses abroad, being employed, following professional insertion measures and those without occupation (N=1,357), the situation was as follows: 41.2% of students who dropped school have integrated the job market (work or professional insertion measure), 39.8% didn’t work nor went to school and 19% attended school courses abroad. In general, boys, youngsters from abroad and aged more than 15 years (age of school obligation in 2006) are more vulnerable to the risk of early school leave.

Regarding PDU, the educational level of the latter, low and mostly incomplete, has been showing a creeping deterioration since 1999 according to baseline data from RELIS. However, an increasing proportion of respondents start secondary school without bringing their studies to term. The average age at the end of studies shows a global decreasing tendency and currently situates at 17 years. Lower levels are particularly observed as regards acquired secondary and high school diploma.

Financial problems
The RMG (Guaranteed Minimum Income) (31%) and the proper salary (16%) represent the main income sources of PDU. Between 1997 and 2010, strong variations were observed in relation with these two revenues. RMG as a primary source of revenue has known a remarkable increase from 1997 onwards in contrast to the proper salary, which decreased during the last years (annual fluctuation in 2010 to be further observed). Money provided by parents as first source of income has also decreased (18% in 1997 to 4% in 2010).

Concerning secondary income sources, 38% referred to ‘illegal activities’ and 18% were provided money by parents.

In contrast with previous years, the degree of social dependence shows an increasing tendency (71.5% in 2010 – 66% in 2009 – 42% in 1995) which correlates with an inverse trend as far as financial autonomy is concerned.

- SOCIAL REINTEGRATION

Housing
Social reintegration measures, and in particular improvement and diversification of housing offers for drug addicts, have been one of the priorities of the 2000-2004 national drugs action plan. The 2005-2009 drugs action plan has foreseen the expansion of existing projects and the implementation of new decentralised reintegration measures based on the previously described principle of progressive reintegration through capacity building and the improvement of the social abilities and environment.

In the framework of the 2000-2004 action plan, the Ministry of Health, jointly with the City of Luxembourg opened a night shelter (called ‘Nuetseil’) for drug addicts in December 1999.

Fig. 8.4 Educational level of RELIS respondents (2010)

<table>
<thead>
<tr>
<th></th>
<th>Concluded levels (N:209)</th>
<th>Non-concluded levels (N:142)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary school</td>
<td>73</td>
<td>3</td>
</tr>
<tr>
<td>Secondary school</td>
<td>26</td>
<td>94</td>
</tr>
<tr>
<td>High school</td>
<td>1</td>
<td>3</td>
</tr>
</tbody>
</table>

Source: RELIS 2010

44 Mainly selling of drugs
2003 which has evolved in an integrated low threshold care centre for drug addicts (TOX-IN) including day and night shelter offers, accommodation and a supervised drug injection facility.

A project called ‘Les Niches’ functions as a social real estate agency for drug addicts. Approximately 35 flats and apartments are rented by a drug-counselling centre and provided to drug addicts in need by means of tailor made renting contracts. One of the medium term aims of the project is to allow demanding drug addicts to take over the renting contract on basis of their own financial means and thus dispose autonomously of a stable accommodation. The project is jointly financed by the Ministry of Health, National Fund against drug trafficking, and the City of Luxembourg (VDL). The vast majority of real estates are rented by the JDH from private proprietors; the remaining ones belong to the national housing Fund (Fonds de logement) or to municipalities.

A network of supervised housing facilities for specific target groups as for instance pregnant women, drug addicted couples, treatment demanders on methadone are operational since September 2002 and are situated in the vicinity of the main centre in order to take advantage of training and social reintegration facilities offered by the CTM. The CTM also offers educational aid in several domains as well as professional training opportunities. 25 persons benefit from the referred offer that builds upon apartments and houses situated in 6 different municipalities.

In both programmes, apartments are subcontracted by the JDH foundation or CTM to clients and the former are liable to the actual proprietors. This avoids immediate conflict situations in case a client has transitional problems to pay the monthly rent. Rents are also typically lower than general real estate market prices. In the framework of these programmes, beneficiaries are also offered the possibility of financial management and follow-up in case of debts for instance. In the medium and long term, residents may be able to sign a proper rental contract or move to an autonomous housing. The supervised housing projects have allowed thus far to stabilise most of beneficiaries, to avoid relapse and to create the necessary conditions for a socio-professional (re)-integration.

Education, training
Aiming professional reintegration, a series of residential drug care centres offer oral and written language courses in order to provide clients with basic language skills (if necessary) or to improve their writing skills.

‘D’Stémm vun der Strooss’ association (‘Street voice’ association) primarily takes care of homeless people providing them with low threshold facilities and offering social and professional reintegration activities such as literacy courses (provided by volunteers) and workshops (in journalism and radio broadcasting) held by professionals. ‘The voice’ (‘d’Stémm’) monthly broadcasts a one and a half-hour programme on a local radio. Providing clients with the opportunity to widen their knowledge and introducing them to different or less common professions has lead to a fair success in terms of interest of participants and retention rates.

Employment
Another reintegration project run by the referred association is the therapeutic redaction board, where homeless people are given the opportunity to editing, printing, publishing and distributing an in house magazine. This activity is supervised by professionals (one educator and one pedagogue). Addressing social matters is supposed to help clients to regain a sense of responsibility and to increase the level of acceptability in the general public (therapeutic aim). Another aim is sensitizing a wider
public and helping homeless people familiarize with new technologies. PDU constitute a significant fraction of their clients.

Additionally clients are offered task and job opportunities in the laundry service called ‘Schweessdrëps’ (Drop of sweat) which covers the south of the country and is specialised in washing sports teams’ uniforms. In 2010, 1 social worker, 2 educators and 30 clients have been working for 220 sports teams, washing, drying etc. 3,300 to 3,500 uniforms weekly. Besides these two main work-opportunities, the service also offers a therapeutic workshop called ‘Dressed for success’. In 2010, the service has been managed by 2 clients (offering them a job opportunity and responsibility). Their main task was to organise (collect, wash, store, etc) clothes offered by donors.

A new occupational project foreseen for 2013 and run by the ‘Street voice’ (‘Stëmm vun der Strooss’) association should further close the gap in occupational offers for drug addicts at the national level. The final concept of the residential centre offering temporary accommodation and day jobs will be described in the 2012 report.

Co-financed by the Ministry of Labour and Employment and the European Social Fund, the Centre Emmanuel association launched the project ‘START’ in 2007, targeting progressive re-integration of drug users into the first job market (G. Lambrette, 2009). The applied methodology combined case oriented follow-up and job coaching and aimed at helping beneficiaries to find a work or professional training place (e.g. establishing contact with companies, preparing job interviews, editing of resumes, etc.) and to assist them in their daily work routine (definition of tasks, conflict management, mediation between employee and employer, motivational follow-up, etc.). Intermediate feedback and final evaluation contributed to improve autonomy of clients and are ideally leading to a permanent work contract. As one of the main impediments regarding access to jobs by vulnerable groups, is the initially or even permanently reduced work performances. The main objective of a job coaching project is the mobilisation of individual resources and capacities of the beneficiary in tune with the need of the company he or she is given the opportunity to work for.

In 2002 Arcus asbl candidated for the EU programme “Job Alliance” an initiative of the European Social Fund. Priorities of the referred project are:

1. Improve access to employment and sustained inclusion in the job market
2. Activate the category of persons most distant from the job market.

Decision on acceptance of the national project was still pending at the time of writing.

The referent system

The 2010-2014 national drug action plan foresees the creation of a national ‘referent system’ for drug addicted persons in need of care. The rationale of this project is straightforward and stems from the observation that drug related care and rehabilitation offers are diverse and a given person enters in contact with several national and transborder care providers and law enforcement authorities in the course of their treatment and (re)-integration history. Often the link between these different stages and institutions could be improved if a designated referent could follow-up patients individually and centralise information on the patient and his/her treatment history. Sound examples of the utility of this system are the preparation of release from prison

45 LAMBRETTE, G. (2009), Projet “START!” – Constats et réflexions autour d’un projet de réinsertion professionnelle pour personnes toxicomanes au Grand-Duché de Luxembourg, Luxembourg.
(e.g. continuation of substitution treatment or housing finding), referral to a national care provider for patients in residential treatment abroad or preparation of admission to therapy following a detoxification treatment in hospital. Provided the necessary financial means are made available, the referent system will be operational by 2013.

### 9. Drug related crime, prevention of drug related crime and prison

#### Introduction

The main source of Information of this part of the report is the Judicial Police Service (SPJ) in Luxembourg.

Due to obvious disparities at the European level in terms of concept definitions in the field of law enforcement data, the respective national terminology should be clarified:

- **‘Interpellation’ (Eng. Interpellation/peremptory questioning, to call on):**
  Intervention of law enforcement agents based on reasonable suspicion. The ‘interpellated’ person is heard and a police record occurs. At this level, however, there is no notification to the Public Prosecutor and no mention in the judicial record.

- The term **‘prévenus’** (interpellated/indicted person):
  Refers to persons who have been apprehended by legal enforcement agents for alleged offences against the national drug law (or against law in general).

- **‘Arrestation’ (Eng. Arrest):**
  Interpellation followed by a deprivation of liberty and notification to the attorney at law. The preliminary examination (instruction) refers to the subsequent judicial procedure that leads to public audience, which claims the sentence.

- **‘Condamnation’ (Eng. Conviction):**
  Judgement by which the accused person is found guilty.

- **‘Détention’ (Eng. Imprisonment):**
  deprivation of liberty. Distinction is made between protective custody (prior to the judgement) and regular detention (following conviction).

#### DRUG-RELATED CRIME

The NFP collects and re-formats nation-wide data on drug-related offences provided by the SPJ. A staff member of the NFP actively collaborates with the SPJ team in order to adapt law enforcement data to standards required for the editing of the national report on drugs and the EMCDDA annual report.

**Drug law offences**
As can be seen in tables 9.1, the total number of arrests (229) has increased discontinuously during the last 10 years. Traditionally heroin was the most frequent substance involved in drug-related arrests. In 2004, cocaine has turned to be the main substance involved in those arrests (confirmed by 2005 data), followed by heroin and cannabis.

Table 9.1 Arrests broken down by type of reporting institution (1995-2010)

<table>
<thead>
<tr>
<th>Year</th>
<th>1995</th>
<th>1997</th>
<th>1999</th>
<th>2001</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>S.P.J.</td>
<td>27</td>
<td>25</td>
<td>27</td>
<td>7</td>
<td>25</td>
<td>38</td>
<td>26</td>
<td>39</td>
<td>49</td>
<td>32</td>
<td>20</td>
<td>15</td>
</tr>
<tr>
<td>Gendarmerie</td>
<td>8</td>
<td>15</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Police</td>
<td>32</td>
<td>32</td>
<td>32</td>
<td>45</td>
<td>82</td>
<td>103</td>
<td>94</td>
<td>124</td>
<td>79</td>
<td>102</td>
<td>92</td>
<td>166</td>
</tr>
<tr>
<td>Customs</td>
<td>61</td>
<td>82</td>
<td>34</td>
<td>40</td>
<td>28</td>
<td>37</td>
<td>35</td>
<td>62</td>
<td>41</td>
<td>54</td>
<td>33</td>
<td>48</td>
</tr>
<tr>
<td>Total</td>
<td>128</td>
<td>154</td>
<td>108</td>
<td>92</td>
<td>135</td>
<td>178</td>
<td>155</td>
<td>225</td>
<td>226</td>
<td>188</td>
<td>145</td>
<td>229</td>
</tr>
</tbody>
</table>

The number of police records for presumed offences against the modified 1973 drug law (code: DELIT-STUP), stable between 1996 and 1998, showed an important increase from 1998 to 2003 (825 to 1,660) and has been stabilising since then. In 2009 and 2010, however, the number of referred police records increased anew (2010: 2,546 records).

The number of drug law offenders (‘prévenus’) has declined from 1,368 in 1996 to 1,170 in 1998 followed by a subsequent increase. From 2003 to 2008 (1,487), one observes a significant decrease in drug law offenders, but obviously a new increase in 2009 (1,963) and 2010 (2,530). The number of arrests on the same charge has decreased from 154 in 1997 to 135 in 2003 to increase and reach its peak in 2010 with 229 arrests.

Table 9.2 records the total number of law enforcement interventions and number of ‘prévenus’ at the national level ensured by respective law enforcement actors that are the Specialised Drug Department of the Judicial Police (SPJ), Police and Board of Customs from 1995 to 2010.

Table 9.2 Number of national law enforcement interventions (1995-2010)

<table>
<thead>
<tr>
<th>Year</th>
<th>95</th>
<th>97</th>
<th>99</th>
<th>2001</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>S.P.J.</td>
<td>123</td>
<td>137</td>
<td>342</td>
<td>216</td>
<td>239</td>
<td>190</td>
<td>177</td>
<td>110</td>
<td>121</td>
<td>134</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gendarmerie</td>
<td>198</td>
<td>255</td>
<td>782</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Police</td>
<td>199</td>
<td>177</td>
<td>189</td>
<td>1,126</td>
<td>1,326</td>
<td>824</td>
<td>998</td>
<td>881</td>
<td>1,146</td>
<td>1,969</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Customs</td>
<td>244</td>
<td>236</td>
<td>173</td>
<td>113</td>
<td>95</td>
<td>186</td>
<td>197</td>
<td>228</td>
<td>328</td>
<td>443</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>764</td>
<td>805</td>
<td>1,187</td>
<td>1,455</td>
<td>1,660</td>
<td>1,200</td>
<td>1,372</td>
<td>1,219</td>
<td>1,976</td>
<td>2,546</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>95</th>
<th>97</th>
<th>99</th>
<th>2001</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>S.P.J.</td>
<td>152</td>
<td>182</td>
<td>434</td>
<td>321</td>
<td>369</td>
<td>248</td>
<td>203</td>
<td>203</td>
<td>212</td>
<td>121</td>
<td>131</td>
<td></td>
</tr>
<tr>
<td>Gendarmerie</td>
<td>319</td>
<td>335</td>
<td>916</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Police</td>
<td>371</td>
<td>280</td>
<td>283</td>
<td>1,272</td>
<td>1,753</td>
<td>1,007</td>
<td>1,160</td>
<td>1,009</td>
<td>1,459</td>
<td>1,960</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Customs</td>
<td>421</td>
<td>408</td>
<td>306</td>
<td>182</td>
<td>148</td>
<td>320</td>
<td>324</td>
<td>350</td>
<td>325</td>
<td>439</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>1,263</td>
<td>1,205</td>
<td>1,939</td>
<td>1,776</td>
<td>2,270</td>
<td>1,575</td>
<td>1,687</td>
<td>1,487</td>
<td>1,963</td>
<td>2,530</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Specialised Drug Department of the Judicial Police


47 A summary of the general activity report of the “Anti-Drugs and Sensible Products” division of Customs can be found in annex H. The original report can be downloaded from: [http://www.gouvernement.lu/publications/informations_gouvernementales/rapports_activite/index.html](http://www.gouvernement.lu/publications/informations_gouvernementales/rapports_activite/index.html)


49 A summary of the general activity report of the “Anti-Drugs and Sensible Products” division of Customs can be found in annex H. The original report can be downloaded from: [http://www.gouvernement.lu/publications/informations_gouvernementales/rapports_activite/index.html](http://www.gouvernement.lu/publications/informations_gouvernementales/rapports_activite/index.html)
The population of drug law offenders is composed of 85% males; a proportion that has been varying between 79% and 89% during the past decade. Since 1997, non-natives (53% in 2010) have been representing the majority of drug law offenders (52-68%). The spectacular increase in 2002-2003 of the proportion of first drug law offenders is confirmed and even exceeded by 2010 data reporting an increase from 808 in 2003 to 949 in 2010. Also the percentage of minors (< 18 years) among drug law offenders having increased between 1994 (4.9%) and 2000 (8.7%) shows a clear decrease in 2004 (5.7%) and tended to stabilize from there on. However in 2010, the percentage of minors among drug law offenders increases again (9.2%). Heroin and cocaine are the main drugs involved in first drug offences.

### Table 9.3 Socio demographic data on ‘prévenus’ (1986-2010)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE</td>
<td>TOTAL</td>
<td>623</td>
<td>1,137</td>
<td>1,531</td>
<td>1,358</td>
<td>1,170</td>
<td>1,039</td>
<td>1,756</td>
<td>1,776</td>
<td>2,218</td>
<td>2,271</td>
<td>1,808</td>
<td>2,034</td>
<td>1,575</td>
<td>1,687</td>
<td>1,487</td>
<td>1,963</td>
</tr>
<tr>
<td>0-14</td>
<td>Male</td>
<td>503</td>
<td>970</td>
<td>851</td>
<td>1,248</td>
<td>938</td>
<td>1,138</td>
<td>958</td>
<td>1,658</td>
<td>1,415</td>
<td>1,546</td>
<td>1,905</td>
<td>1,935</td>
<td>1,581</td>
<td>1,751</td>
<td>1,319</td>
<td>1,484</td>
</tr>
<tr>
<td>15-19</td>
<td>Female</td>
<td>120</td>
<td>166</td>
<td>220</td>
<td>256</td>
<td>209</td>
<td>173</td>
<td>193</td>
<td>248</td>
<td>241</td>
<td>215</td>
<td>292</td>
<td>288</td>
<td>181</td>
<td>237</td>
<td>218</td>
<td>190</td>
</tr>
<tr>
<td>20-24</td>
<td>gender unknown</td>
<td>27</td>
<td>21</td>
<td>30</td>
<td>50</td>
<td>20</td>
<td>31</td>
<td>32</td>
<td>46</td>
<td>44</td>
<td>55</td>
<td>46</td>
<td>106</td>
<td>95</td>
<td>70</td>
<td>43</td>
<td>14</td>
</tr>
<tr>
<td>25-29</td>
<td>TOTAL ('Prévenus')</td>
<td>1,531</td>
<td>1,174</td>
<td>1,358</td>
<td>1,170</td>
<td>1,039</td>
<td>1,756</td>
<td>1,776</td>
<td>2,218</td>
<td>2,271</td>
<td>1,808</td>
<td>2,034</td>
<td>1,575</td>
<td>1,687</td>
<td>1,487</td>
<td>1,963</td>
<td>2,530</td>
</tr>
<tr>
<td>30-34</td>
<td>Male</td>
<td>162</td>
<td>154</td>
<td>121</td>
<td>109</td>
<td>133</td>
<td>114</td>
<td>103</td>
<td>110</td>
<td>84</td>
<td>83</td>
<td>88</td>
<td>70</td>
<td>109</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35-39</td>
<td>Female</td>
<td>64</td>
<td>39</td>
<td>34</td>
<td>30</td>
<td>37</td>
<td>64</td>
<td>125</td>
<td>86</td>
<td>52</td>
<td>37</td>
<td>48</td>
<td>35</td>
<td>62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40-49</td>
<td>gender unknown</td>
<td>5</td>
<td>15</td>
<td>11</td>
<td>18</td>
<td>9</td>
<td>12</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>8</td>
<td>5</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50-59</td>
<td>TOTAL (substances HRC)</td>
<td>233</td>
<td>221</td>
<td>186</td>
<td>184</td>
<td>197</td>
<td>225</td>
<td>239</td>
<td>218</td>
<td>148</td>
<td>126</td>
<td>154</td>
<td>114</td>
<td>218</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Source:** Specialised Drug Department of the Judicial Police (Data formatted by NFP) 2010.
Other drug-related crime

The routine data protocol of the national drug monitoring system (RELIS) includes a series of drug-related offences’ items: The following results summarise the situation observed in 2010:

- 85% of drug users indexed by specialised health care institutions have already been in conflict with law enforcement agencies during lifetime.
- 59% of the total PDU population show multiple law enforcement contacts (increase).
- The proportion of ‘interpellations’ for other reasons than presumed offences against the drug law (e.g. petty crime such as criminality linked to drug supply or fights) has been decreasing since 1997 (38%) and has been fairly stable in recent years. In 2010 however, data on ‘interpellations’ for other reasons report an important increase (2006: 34%, 2009: 35% and 2010: 65%).
- 76% (58%) of indexed PDU have already served at least one prison sentence during lifetime. The proportion of PDU having served more than one prison sentence at the time of reporting (36% slight increase) has stabilised during the last years.

• PREVENTION OF DRUG-RELATED CRIME

In recent years, involvement of major cities in the management of drug-related problems and nuisances has developed. So-called municipal ‘prevention committees’ that include local authorities, police forces and specialised NGOs are in place. The setup of the first national drug injection room in Luxembourg City obviously enhanced the involvement of municipal authorities. The Ministry of Health created a management group that is mandated to follow up developments with regard to the injection room and to react precociously to emerging problems. The national action plan clearly emphasises the importance of a visible involvement of major cities in the management of public safety and order, urban nuisance and hygiene problems related to drugs to guarantee the necessary decentralisation of DR offers and SR interventions.

As far as preventive measures targeting youngsters are concerned, a mechanism has been put in place in 1996 aiming at underaged and juvenile drug use offenders and in order to prevent recidivism. The Youth Solidarity (Jongenheem asbl) project is financed by the Ministry of Health and intervenes in case a minor of age has been running in conflict with law enforcement forces with respect to a drug-related offence. In this respect the Youth Solidarity team may be considered as a crisis situation manager, offering their services to drug offenders referred by judicial and penal institutions. The available services are free of charge.

The intervention team, in direct collaboration with Youth magistrates and competent law enforcement actors, offers a large variety of services with the primary aim to prevent minor aged drug offenders to enter in the criminal justice system. Interventions are based on a holistic approach of the problem, including the involved person him/herself and his/her family. Youth Solidarity directly reports on intervention progress to the demanding authority. Client statistics show an increasing demand for this kind of intervention from both the criminal justice system and the social oriented institutions.

---

50 Persons who have been indexed by the RELIS network during a reporting year.
### Number of episodes

<table>
<thead>
<tr>
<th>Year</th>
<th>1998</th>
<th>1999</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count</td>
<td>46</td>
<td>99</td>
<td>132</td>
<td>195</td>
<td>208</td>
<td>231</td>
<td>267</td>
<td>249</td>
<td>322</td>
<td>352</td>
<td>357</td>
<td>432</td>
<td>461</td>
</tr>
</tbody>
</table>

### Referral from the criminal justice system

<table>
<thead>
<tr>
<th>Year</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count</td>
<td>26.1%</td>
<td>26.3%</td>
<td>41.4%</td>
<td>44.1%</td>
<td>44.2%</td>
<td>37.2%</td>
<td>46.2%</td>
<td>44.4%</td>
<td>43.4%</td>
<td>44.1%</td>
<td>50.8%</td>
</tr>
</tbody>
</table>

### Gender distribution

<table>
<thead>
<tr>
<th>Gender</th>
<th>Female</th>
<th>Male</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>28%</td>
<td>72%</td>
</tr>
<tr>
<td>2001</td>
<td>34.1%</td>
<td>65.9%</td>
</tr>
<tr>
<td>2002</td>
<td>32.3%</td>
<td>67.7%</td>
</tr>
<tr>
<td>2003</td>
<td>34.1%</td>
<td>65.9%</td>
</tr>
</tbody>
</table>

### Age distribution

<table>
<thead>
<tr>
<th>Age</th>
<th>&lt; 14</th>
<th>14-15</th>
<th>16-17</th>
<th>&gt; 17</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>9.5%</td>
<td>38.1%</td>
<td>39.8%</td>
<td>12.6%</td>
<td>4.9%</td>
</tr>
<tr>
<td>2001</td>
<td>2.9%</td>
<td>22.9%</td>
<td>43.4%</td>
<td>18.7%</td>
<td>20.5%</td>
</tr>
<tr>
<td>2002</td>
<td>4.7%</td>
<td>27.9%</td>
<td>46.9%</td>
<td>11.2%</td>
<td>16.5%</td>
</tr>
<tr>
<td>2003</td>
<td>5.9%</td>
<td>25.6%</td>
<td>46.6%</td>
<td>12.6%</td>
<td>18.7%</td>
</tr>
</tbody>
</table>

### Main substance involved

<table>
<thead>
<tr>
<th>Substance</th>
<th>Cannabis</th>
<th>Heroin</th>
<th>XTC/Cocaine</th>
<th>Legal drugs</th>
<th>Polydrug</th>
<th>Other</th>
<th>None</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>83.1%</td>
<td>3.5%</td>
<td>1.3%</td>
<td>1.3%</td>
<td>2.6%</td>
<td>8.2%</td>
<td>0.0%</td>
<td>10.5%</td>
</tr>
<tr>
<td>2001</td>
<td>72.3%</td>
<td>5.6%</td>
<td>2.2%</td>
<td>3.0%</td>
<td>3.0%</td>
<td>10.6%</td>
<td>2.2%</td>
<td>7.1%</td>
</tr>
<tr>
<td>2002</td>
<td>71.5%</td>
<td>3.7%</td>
<td>1.6%</td>
<td>3.0%</td>
<td>2.4%</td>
<td>10.4%</td>
<td>3.7%</td>
<td>7.3%</td>
</tr>
<tr>
<td>2003</td>
<td>73.3%</td>
<td>3.7%</td>
<td>1.6%</td>
<td>3.0%</td>
<td>2.4%</td>
<td>10.2%</td>
<td>3.7%</td>
<td>73.7%</td>
</tr>
</tbody>
</table>

Source: Solidarité Jeunes (Jongenheem). 2010

- **INTERVENTIONS IN THE CRIMINAL JUSTICE SYSTEM**

### Alternatives to prison

The Grand-Duchy of Luxembourg counts two state prisons at the national level; the CPL situated in the vicinity of Luxembourg City and the CPG implemented in the East of the country.

The CPG, may be considered as an alternative to a strict penitentiary regime as it is defined as a semi-open prison established in a fairly rural setting. During daytime, inmates follow a professional activity or participate in one of the centre’s workshops (agriculture, animal breeding, kitchen, horticulture, woodwork, locksmith’s and duties). After work they return to their individual cells for the night. Every block has its own living room, kitchen, bathroom and laundry allowing inmates to live in more or less autonomy.

Part of inmates participates in the ‘DEFI’ programme (see below under ‘Reintegration of drug users after release from prison’) working outside for a minimum loan (RMG - Guaranteed Minimum Income). Others live under a semi-liberty regime (they live at CPG but have an individual and external work contract).

The ‘injonction thérapeutique’ is another alternative to prison (only possible in case of offences for personal possession or use of illicit substances): the offender is proposed to undergo treatment instead of a prison sentence. In other cases, community services (‘TIG: travaux d’intérêts généraux’) may also be an alternative (depending on the gravity of the offence and the sentence). The sentence may be suspended if the ‘prévenu’ agrees to undergo treatment (‘sursis probatoire’). This said, these two alternatives are applicable in case of drug possession or use only (not for cases of production, dealing or trafficking of illicit substances), as in the Grand-Duchy of Luxembourg a drug addict is not considered a criminal but a person in need of psycho-social and medical help.

A further, still experimental, alternative to prison available in Luxembourg is the electronic tag. In November 2006, the Minister of Justice presented the introduction of the electronic tag as an alternative to incarceration.

In an experimental phase, this system was exclusively meant for prisoners:
- whose sentence was less than one year
- who did not represent a danger
- socially integrated and residing in Luxembourg
- who were working or undergoing training

- **DRUG USE AND PROBLEM DRUG USE IN PRISONS**

In 1998, the Ministry of Justice commissioned the medical department of the state prison (CPL) to perform an epidemiological study on HIV and HCV prevalence in prison population (Schlink, 1999). The research protocol relied on a self-administrated anonymous questionnaire on health behaviour and injecting drug use prior and during prison sentence.

<table>
<thead>
<tr>
<th>MAIN RESULTS:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drug use in prison</strong></td>
</tr>
<tr>
<td>- 32% of prisoners qualified themselves as injecting drug users;</td>
</tr>
<tr>
<td>- 28% reported current drug injection in prison;</td>
</tr>
<tr>
<td>- 9% have been initiated to injecting drug use in prison;</td>
</tr>
<tr>
<td><strong>Risk behaviour</strong></td>
</tr>
<tr>
<td>- 58% of current IDU prisoners report life-time needle sharing in prison;</td>
</tr>
<tr>
<td>- 8% of current IDU prisoners report last month needle sharing in prison;</td>
</tr>
<tr>
<td>- 70% of IDU prisoners only use water to clean up syringes, 22% do not clean syringes at all;</td>
</tr>
<tr>
<td>- 90% of prisoners reporting sexual intercourse in prison did not use condoms.</td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
</tr>
<tr>
<td>- IDUs have served more prison sentences than non drug users (control group);</td>
</tr>
<tr>
<td>- IDUs showed lower average age than non drug users;</td>
</tr>
<tr>
<td>- a majority of imprisoned IDUs were natives</td>
</tr>
</tbody>
</table>

Source: Schlink, 1999

The recent study ‘Prevalence of viral hepatitis A, B and C and HIV in problematic drug users of illicitly acquired drugs’ (Origer & Removille, 2007), also addressed drug use and drug-related harm in prison settings. Referred to the total study sample (N:246), 56.1% of respondents who have had prison experience during the past ten years reported illicit drug use in prison; 30.5% reported intravenous drug use. 26.7% of lifetime IDUs inmates reported needle sharing in prison which is sensibly lower than the rate observed in 1998 by Schlink (1999). Among all settings (inpatient, outpatient treatment, low threshold, etc.) prevalence rates of HIV, HBV and HCV were highest in persons recruited in prison settings.

- **RESPONSES TO DRUG-RELATED HEALTH ISSUES IN PRISONS**

Table 9.7 provides the number of general admissions and the number of admissions according to drug-related convictions (DELIT ‘STUP’) in both national prisons from 1989 to 2010.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>New entries (Total)</td>
<td>665</td>
<td>796</td>
<td>767</td>
<td>795</td>
<td>1.078</td>
<td>1.341</td>
<td>1.043</td>
<td>1.030</td>
<td>990</td>
<td>892</td>
<td>927</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New &quot;STUP&quot; entries</td>
<td>163</td>
<td>244</td>
<td>157</td>
<td>288</td>
<td>292</td>
<td>167</td>
<td>161</td>
<td>101</td>
<td>92</td>
<td>247</td>
<td>243</td>
<td>212</td>
<td>332</td>
<td>224</td>
<td>232</td>
</tr>
</tbody>
</table>

Source: Greffe CPL, CPG. 2010

Drug treatment in prison
Following the law of 27 July 1997 concerning the modification of the penitentiary organisation\(^{51}\), a pilot project named ‘Global Drug Care Programme in Prison’ (2000-2005 - TOX project) was set up by a group of experts assigned by the Ministry of Justice in 1999. The concept was designed to implement, among other objectives primary, prevention measures in regard to drug consumption and infectious diseases. The overall aim of the project was to integrate drug dependant inmates into a medico-psycho-social drug care network in order to reduce recidivism, risks and criminality after release from prison. The implementation of the project had to be adapted to the two different prison settings. Joint financing by the Ministry of Justice, the National Fund against drug trafficking and the EU (regarding evaluation) was ensured.

The TOX programme (previously TOX project) takes care of the drug dependant inmates in the two state prisons of Schrassig (CPL) and Givenich (CPG). This service is run by a multidisciplinary staff. The basic principles of the TOX programme in the CPG are the voluntary participation, the cooperation, the transparency, the quality of service, the determination of realisable objectives and the empowerment of participants. Additionally, the programme TOX also prepares inmates to enter a second treatment option available in prison: a “drug-free” programme called “Charly”. The programme provides a “drug-free” zone, where inmates can serve their sentence, or part of it, under certain conditions. Staying drug free and accepting to participate in psycho-social interventions are part of the admissions criteria.

A special programme targeting exclusively women exists and becomes operational when a minimum number of women enrol. Otherwise, individual offers are available for the female population.

**Detoxification treatment** is either provided in-house under the responsibility of the prison medical unit, or by external detoxification units of general hospitals according to strict rules and procedures. CPL has signed a convention with a major general hospital situated in Luxembourg City ensuring out-of-prison medical care if required.

**Psychosocial and therapeutic care** is provided by both, in-house staff members and specialised external agents from accredited drug agencies. An example of good practice in this respect is the inclusion of clearly time on content defined service providing of external specialised drug agencies contractually foreseen by state conventions (in the framework of the global drug care programme). This mechanism also applies to external agents in the field of HIV and other infectious diseases. One should also stress the role of the Central Probation Service (SCAS), which motivates inmates to undergo treatment and enables contacts with external therapeutic agencies. Although the psychosocial care strategy is similar in both national prisons, the CPG currently disposes of a more structured intervention programme.

**Substitution treatment** is also provided in prison but not by the services mentioned above. The nursery and MDs are in charge of methadone prescription within prison. More detailed figures on this type of treatment can be found in respective sections and STs. Three scenarios may occur:

- most frequently encountered situation applies to new prisoners who underwent substitution treatment prior to their current incarceration. Medical prison staff inquires the accuracy of the information provided by involved inmates by contacting the prescribing GP or the national substitution programme. In case of confirmation,\(^{51}\) The law of 27 July 1997 concerning the modification of the penitentiary organisation regulates the creation of specialised medical units for drug addicts and psychiatric patients within prison.
substitution treatment is continued and may be followed by maintenance, dose reduction or detoxification treatment,
- increasingly substitution treatment is initiated within prison. It also includes inmates who have started opiates use in prison,
- opiate using or already substituted prisoners may introduce an admission demand to the national substitution programme 6 weeks before release. Continuity of care and re-socialisation measures are ensured by the intervention of social workers from external field agencies (substitution, HIV, hepatitis, etc.).

The main substitution opiates prescribed in prison are methadone (MEPHENON®), and to a lesser extend buprenorphine (SUBUTEX®) and codeine. Prescription of benzodiazepines is widespread.

Official figures show that 24.5% of the inmates (of full age) who entered CPL in 2010 received drug substitution treatment, representing a total of 219 persons.

<table>
<thead>
<tr>
<th>Year</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone</td>
<td>192</td>
</tr>
<tr>
<td>Subutex®</td>
<td>9 (SUBUTEX + METHADONE) / 18 (SUBUTEX only)</td>
</tr>
<tr>
<td>Total (persons)</td>
<td>219</td>
</tr>
</tbody>
</table>

Source: Comité de Surveillance SIDA: Activity report 2010

The average dose of distributed methadone was 24 mg per day (minimal dose 1mg and maximal dose 80mg). The average period of treatment was 127 days.

Of clients in treatment units in prison, 93% (98%) are male against 7% (2%) of females. The mean age of treatment demanders is 27.93 (32 years and 8 months), whereas the average male age is 28.44 (32Y9M) and the mean age of the female clients is consistently lower (2010: 21Y, 2009: 29Y). Respectively 55% (46%) of clients in treatment are natives against 45% (54%) of non-natives. The population of non-natives consists for the vast majority of Portuguese nationals, followed by French citizens.

Regarding educational level of the clients in treatment, 52% (83%) have completed primary school, 41% (15%) have completed secondary school. 21% (37%) of clients in treatment units in prison experienced one or more overdoses. As far as the sharing of used syringes is concerned, 39% (64%) reported that they never shared syringes during their lifetime (83% during the last month, 2009: 82%). IDU combined to polydrug use (27%, 2009: 34%) is the most observed consume pattern in drug treatment demanders.

Prevention and reduction of drug-related harm

In 2010, the activities of the previously referred to TOX-programme in prison were centred on three pillars:

- **psychosocial prevention**: psychosocial care of drug-addicted inmates, in order to prepare their future after release from prison and to reduce risks of relapse and recidivism – intensive programme without drugs to prepare post-release ambulatory therapy and/or individual preparation for release.
- **prevention of the STDs**: this health service is proposed in individual and collective settings.
- **coordination of interventions**: the drug-addicted platform was created in order to coordinate interventions of involved professionals.
The TOX programme in the CPG has established psycho-educational activities. The group has focused on two axes:

- **Health development** and
- **Specific psycho-educational practice** for the drug-addicted inmates within a collective pavilion without drugs (specific entourage of at least 4 months with an optional prolongation).

- follow-up of the drug free section together with the “Program Charly” started in May 2007, as preparation for multidisciplinary and intensive therapy: 25 (11) inmates.

As far as the CPL is concerned, in 2010, 157 demanders were provided with an individual psychosocial follow-up. 144 clients have benefited from 45 health prevention groups. A total of 18 clients participated in the “Programme Charly”.

For 2010, the CPG reports a total of 37 groups (withdrawal prevention, tobacco prevention, HIV/AIDS prevention etc.) with a total of 410 participants. 61 clients were provided with an individual psychosocial follow-up and 635 individual counselling sessions were held.

In 2007, the external evaluation report\[52\] of the TOX project has been published and recommended the continuation of the action.

The programme is currently part of the RELIS routine data reporting network and first data on treatment demand became available in 2010. Thus, 93% (98%) of RELIS indexed clients are male against 7% (2%) of females. The mean age of treatment demanders is 27.93 (32 years and 8 months), whereas the average male age is 28.44 (32Y9M) and the mean age of the female clients is consistently lower (2010: 21, 2009: 29Y). Respectively 55% (46%) of clients in treatment are natives against 45% (54%) of non-natives. The population of non-natives consists for the vast majority of Portuguese nationals, followed by French citizens.

Regarding educational level of the clients in treatment, 52% (83%) have completed primary school, 41% (15%) have completed secondary school. 21% (37%) of clients in treatment units in prison experienced one or more overdoses. As far as the sharing of used syringes is concerned, 39% (64%) reported that they never shared syringes during their lifetime (83% during the last month, 2009: 82%). IDU combined to polydrug use (27%, 2009: 34%) is the most observed consume pattern in drug treatment demanders.

- **Prevention, treatment and care of infectious diseases**

New inmates are seen by medical staff in the framework of the admission procedure of both national prisons. A HIV screening test is suggested during the medical counselling. If the inmate accepts, a simultaneous screening of other infectious diseases like syphilis and hepatitis A, B and C is undertaken.

In 2010, approximately 800 HIV tests have been carried out. 11 tests were positive (9 men and 2 women), 3 co-infections (HIV/HCV) were diagnosed (all of those were known drug users). To prevent further contamination, vaccination against hepatitis B and A is recommended to those who present a negative serology.

A structured syringes distribution programme has officially been launched in 2005 in the framework of the global drug care programme in prison. In order to enrol, inmates have to send a written request to the prison’s doctor. After counselling, the inmate is handed a kit containing 2 syringes which may be exchanged at the nursery. As the consumption

and possession of drugs is illegal, those inmates in possession with a syringe in its kit, are exempted from sanctions for detention of injection paraphernalia. In 2010, 34 kits have been distributed and 328 syringes exchanged. The programme is under medical secrecy and is operational although a series of changes are currently being discussed to increase the coverage and impact of the programme. Ascorbic acid, filters, sterile physiological water, antiseptic wipes and small plasters are available at the two nurseries. Condoms are also available at different discrete spots of the prison (at the two nurseries, TOX-programme and at the psychiatric ward).

In order to meet specific needs in terms of infectious diseases in prison settings, the creation of a specialised transmittable disease counselling offer (COMATEP) involving prison administration and CHL has become operational in 2011.

Prevention of overdose-risk upon prison release

Overdose incidents following prison release is a documented reality that has also been addressed by national research. For instance, the Origer & Dellucci study in 2002 recommended the following measures to prevent overdose risk following an in-depth longitudinal analysis of drug-related death nationwide:

- opening of supervised injection rooms according to the national drugs action plan (1)
- medical controlled heroin distribution programme (foreseen by the national drugs action plan) (2)
- first aid training courses provided to users and their relatives and partners (3)
- gender and ethnic specific interventions (4)
- provision of morphine receptor antagonists to users and selected persons (5)
- creation of ‘transition centres’ for ex or current PDU leaving institutional settings (6)
- development of reintegration programmes for prisoners in the framework of the recent ‘Global care programme for drug addicts in prison’ (7)

Besides, the law of 27 April 2001 introduced an important modification of the basic drug law with regard to overdose prevention. Art.10-1 of the referred law exempts drug users who call for assistance in case another user is in need of medical help, from prison sentences. This change is supposed to reduce drug-related deaths occurring in consumer groups. A new flyer addressing measures to be undertaken by witnesses of a drug-related overdose and the genuine legal situation was elaborated and was broadly distributed among PDU in various settings in 2009.

For persons (with drug careers) leaving prison, a series of measures such as; information and peer education, banning multiple prescriptions of substitution drugs, considering interaction of substitution treatment and concomitant/persistent street drug use and ensuring through-care after prison release need to be further developed.

- REINTEGRATION OF DRUG USERS AFTER RELEASE FROM PRISON

The CPL runs a proper psychosocial and educational department (SPSE). Jointly with the SCAS and the prison guards’ association, it has set up a project called ‘DEFI’ (Challenge) that aims at the development of therapeutic means, training facilities, socio-professional reinsertion measures and indebtedness management, during prison journey and after the prison release phase.

The future development of synergies with external drug care agencies aiming at a comprehensive concept of through care in terms of psychosocial measures, substitution treatment or economical start-up help are some of the cornerstones of national after-prison reintegration strategies.
The Arcus asbl (see above chapter on social reintegration) also contributes in various ways to (re)insert drug users as far as (re)integration is possible. The future referent system will also contribute to improve the re-integration process of drug-addicted inmates upon release.

10. Drug Markets

Introduction

Drug markets are of changing nature. They rely on factors such as supply mechanisms, on the economic situation of the country they develop in and on the efficiency of law enforcement strategies. Availability and supply indicators should be interpreted with caution as they rely on the interplay of all these factors. Law enforcement authorities, the National Laboratory of Health and special surveys have provided data for the present chapter.

Overall, the national drug market has become of a more aggressive nature in terms of selling techniques (e.g. dealers approach potential clients and not vice-versa, the dealers insist on selling). New distribution networks have developed in recent years and operate in an obviously professional way and by doing so, have significantly increased drug availability and in particular the supply of cocaine and cannabis. Dealers increasingly tend to actively approach confirmed or potential clients. More recently ethnic groups join to improve their drug distribution strategies whereas previously none of these criminal groups actively searched contact with other groups. Moreover it has been noted that traffickers tend to delocalize their selling points to locations or settings less visible to police as for instance private flats or bars.

Asylum demanders implicated in illicit cocaine trafficking mainly originate from West African countries, particularly from the Ivory Cost. Their number tends to stabilise. In regard to heroin trafficking, no predominant profile of nationality has been reported. A large number of drug traffickers come from North Africa by transiting through Belgium. Numerous traffickers have changed from heroin to cocaine and currently are also involved in cannabis traffic.

Compared to the situation in 2004, purity of heroin remains fairly stable while the purity of cocaine has decreased (2004: 61.78% / 2010: 47.9%). Attention has to be paid to the striking differences in maximum and minimum purities as well as to a historically high maximum concentration of THC (over 40%) in herbal cannabis samples seized in Luxembourg in 2009. However in 2010, the maximum concentration of THC (34.2%) as in 2009 has not been observed. Prices show broad ranges for heroin and cocaine. Cannabis and derivates however have known certain stability during the last 6 years as far as street prices are concerned.

In terms of seized quantities, important variations are observed for heroin since 2000. As far as cocaine and mainly cannabis are concerned, increasing quantities have been reported in 2010. The number of seizures also has been showing great variations during the same period, especially for cannabis.

The perceived illicit drug availability in general population is high and follows a weak increasing trend.
• **AVAILABILITY AND SUPPLY**

Perceived availability of drugs

In addition to availability indicators from law enforcement sources, perceived availability of the general public provides a complementary insight in the current situation. Both, the 2004 Flash Eurobarometer 158 survey “Young people and Drugs” and the 2002 Eurobarometer 57.2 survey inform about the level and the evolution of illicit drugs availability in the G. D. of Luxembourg.

**Tab. 10.1** Ease of acquisition of drugs in Luxembourg (2002/2004)

<table>
<thead>
<tr>
<th></th>
<th>Near where I live</th>
<th>In or near my school/college</th>
<th>At parties</th>
<th>In pubs/clubs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luxembourg</td>
<td>62.2 (66%)</td>
<td>60.5 (63%)</td>
<td>74.7 (74%)</td>
<td>73.2 (70%)</td>
</tr>
<tr>
<td>EU</td>
<td>61.9 (63%)</td>
<td>54.9 (57%)</td>
<td>76.0 (79%)</td>
<td>72.3 (76%)</td>
</tr>
</tbody>
</table>

In May 2008, the Directorate-General Justice, Liberty and Security of the European Commission published a public opinion poll named “Young people and drugs among 15-24 years olds” (N°233) within the scope of Eurobarometer surveys. Questions were included on the ease of access to illicit drugs, alcohol and tobacco:

The following figure presents the results of the question: “How difficult would it be for you to get hold of any of the following substances if you wanted to?”:

**Tab. 10.1 bis** Ease of acquisition of drugs in Luxembourg (2008)

Concerning heroin, youngsters from Luxembourg considered it slightly more difficult (77%) to obtain or to have access to heroin than the European average (72%). Similar to the EU average, only 23% of interviewees thought that getting hold of heroin was easy.

Even if heroin was the substance considered to be most difficult to get hold of, also cocaine was quoted by 67% of young people from Luxembourg as more difficult to obtain than did the EU average (61%). Ecstasy was considered being more difficult to obtain in Luxembourg (65%) compared to the EU average (56%). Only 34% of youngsters from Luxembourg considered the access to ecstasy as easy (EU average: 38%).
Concerning cannabis, less youngsters from Luxembourg (28%) declared the access to cannabis difficult than the EU average (34%). Access to cannabis was perceived easier (71%) than the EU average (63%). Four out of ten youngsters (41%) found it very easy to obtain cannabis (EU average: 32%, three out of ten).

Luxembourg’s youngsters considered the access to licit substances as tobacco and alcohol as easier than the EU average. Concerning tobacco, 88% of youngsters from Luxembourg found the access very easy compared to the EU average (81%). Also the access to alcohol was referred to as very easy (LU: 86%, EU: 80%).

In summary one may note that a majority of Luxembourg’s youngsters are of the opinion that licit drugs are very easily available in contrast to illicit drugs seen as very difficult to obtain with however the exception of cannabis.

In May 2011, the Eurobarometer study “Youth attitudes on drugs” (N°330) provided results summarised in table 10.1 ter. Although answer categories are slightly different, results clearly show that acquisition of illicit drugs is perceived to be more difficult in 2011 if compared to 2008.

<table>
<thead>
<tr>
<th>2011</th>
<th>Ease of access to heroin (if desired)</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>impossible</td>
<td>24</td>
<td>36</td>
<td>22</td>
<td>8</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Luxembourg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EU27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2011</th>
<th>Ease of access to cocaine (if desired)</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LU</td>
<td>22</td>
<td>33</td>
<td>32</td>
<td>9</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>EU27</td>
<td>19</td>
<td>28</td>
<td>26</td>
<td>14</td>
<td>5</td>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2011</th>
<th>Ease of access to ecstasy (if desired)</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LU</td>
<td>21</td>
<td>33</td>
<td>31</td>
<td>9</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>EU27</td>
<td>20</td>
<td>28</td>
<td>25</td>
<td>14</td>
<td>8</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2011</th>
<th>Ease of access to cannabis (if desired)</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LU</td>
<td>12</td>
<td>10</td>
<td>23</td>
<td>27</td>
<td>25</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>EU27</td>
<td>11</td>
<td>13</td>
<td>15</td>
<td>28</td>
<td>29</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2011</th>
<th>Ease of access to tobacco (if desired)</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LU</td>
<td>2</td>
<td>2</td>
<td>14</td>
<td>82</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EU27</td>
<td>2</td>
<td>2</td>
<td>14</td>
<td>82</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2011</th>
<th>Ease of access to alcohol (if desired)</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LU</td>
<td>3</td>
<td>3</td>
<td>15</td>
<td>79</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EU27</td>
<td>1</td>
<td>2</td>
<td>14</td>
<td>82</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Origins of drugs
The national production of illicit drugs appears to be irrelevant in terms of quantities and quality. In 2010 no clandestine drug-manufacturing laboratory has been dismantled at the national level. Law enforcement sources\(^{53}\) indicate that currently the majority of illicit drugs consumed in the G. D. of Luxembourg originate from the Netherlands (cannabis production and transit of other drugs), followed by Belgium (ecstasy and ATS production) and Morocco (cannabis production). Till the beginning of the nineties, most of the persons involved in illicit drug distribution were consumers who supplied themselves in the Netherlands or acquired limited extra quantities of drugs in order to sell them within restricted local networks. Since the opening of EU borders, more organised distribution networks tend to develop within the national drug market.

Drug Trafficking patterns
The expansion of more structured distribution networks by organised criminal associations has been reported earlier. More recently different ethnic groups started to

\(^{53}\) Non published information from the Specialised Drug Unit of the judicial Police
create synergies in drug distribution and traffic, whereas previously these groups have been operating separately. The proportion of non-natives involved in drug trafficking has been increasing until 2005 and has been decreasing quite sensibly since then, although non-native drug traffickers represent 63% (67% in 2009). Typically, involved dealers carry small quantities of drugs hidden in their mouth ready to be swallowed promptly in case of police controls. Initially drugs of high quality have been sold at low prices. Progressively however, the quality and diversity of sold drugs have been decreasing. The national drug market has been flooded by a high proportion of low quality injection drugs, which has induced major changes in consume patterns of national drug users.

Little, however, is known on the provision sources of the referred distribution networks. They are highly organised and have managed to significantly increase the supply and availability of drugs at the national level. In 2005, it was estimated that 0.5 kg of cocaine are sold daily to drug users within the Luxembourg City drugs scene.

- **SEIZURES**

In terms of seized quantities, important variations are observed for heroin since 2000. As far as cocaine and mainly cannabis are concerned, increasing quantities have been reported in 2010. The number of seizures also has been showing great variations during the same period, especially for cannabis.

**Quantities and numbers of drug seizures**

Striking variations have been observed as to the quantity of illicit substances seized since the beginning of the nineties. A longitudinal data analysis indicates a general decreasing tendency of heroin, cocaine and cannabis seizures until 2002\(^{54}\). Since 2002 however, one observes a significant increase in the quantity of drug seizures mainly concerning heroin and herbal cannabis. However, this trend is not observed in 2009 and 2010 for heroin. Cocaine seizures (quantity) are highly variable since the beginning of the nineties. Compared to 2009 data, the quantity of seizures of nearly all listed substances went up in 2010 (except for MDMA and heroin, which is almost stable compared to 2009 data). This observation particularly applies to cocaine and cannabis.

Notwithstanding the quantities seized, increasing between 2009 and 2010, the **number of seizures** has grown discontinuously since 1990. This means that more seizures of bigger quantities have been reported. Since 2000 the number of cannabis seizures has clearly increased but likewise the number of heroin and cocaine seizures tends to stabilise. Markedly, the number of cannabis seizures has risen from 167 to 947 between 1994 and 2010. The total **number of persons** involved in traffic has followed a constant upward trend until 2000 and stabilised afterwards (2010: 2530, 2009: 1963 persons). In 2010, the data show an increasing trend concerning the total number of persons involved in traffic. A confirmed majority of offenders are non-natives. For detailed information, see standard table 13.

**Crack** (cocaine-base) seizures have not been reported to date by national authorities. It has, however, appeared on the national market according to field agencies. The first national seizures of **ecstasy type substances** (MDMA, MDA, etc.) were recorded in 1994. After years of rather modest XTC type pill seizures, 2009 data reveals consistently higher amounts of seizures. In 2010 however, the MDMA seizures show again an important decrease.

\(^{54}\) Non–transit drugs destined to the national market
Fig. 10.1 Total quantities of national yearly seizures: heroin, cocaine, ecstasy type (1988 - 2010)

Source: Specialised Drug Department of the Judicial Police 2010

Fig. 10.2 Total number of national yearly seizures: Cannabis, Heroin, Cocaine, MDMA (1988 - 2010)

Source: Specialised Drug Department of the Judicial Police 2010

Fig. 10.3 Number of offenders involved in seizures according to type of offence (1988-2010)

Source: Specialised Drug Department of the Judicial Police 2010

Quantities and numbers of precursor chemicals
No information available.
Number of illicit laboratories and other production sites dismantled
The last time the dismantling of a synthetic drug manufacturing laboratory was reported by law enforcement dates back to 2003. Since then, no further laboratory seizure on the national territory was reported.

According to police records, single cannabis growing fields are found on a fairly irregular basis. Local cultures of cannabis remain rather insignificant in terms of quantity and national production is limited to small indoor cannabis cultivations (mostly for personal use and not primarily meant to procure economic profit).

- **PRICE/PURITY**

Price of drugs at retail level
Average street prices of heroin (brown), cocaine and ecstasy type substances have fallen from 1998 to 2002/2003 but broader price ranges as well as higher maximum prices for cocaine and heroin have been observed since 2004, which is due to a high variability of purity. Cannabis and derivates however have known a fair stability during the last 8 years. Heroin is frequently sold as ‘boule’ containing 0.2-0.4 grams for 11-33. – EUR. Typical street retail cannabis is sold in pieces of 2.5 to 3 grams for 26 -30. – EUR.

**Table 10.2 Price per unit evolution at the street level (1994-2010)**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannabis &amp; Hashish</td>
<td>5-6</td>
<td>5 – 6</td>
<td>7.4</td>
<td>7</td>
<td>7.3</td>
<td>7.3</td>
<td>8</td>
<td>8</td>
<td>8-10</td>
<td>5-16</td>
<td>4-10</td>
</tr>
<tr>
<td>Marijuana</td>
<td>2.5 - 3</td>
<td>6.2</td>
<td>7</td>
<td>7.3</td>
<td>7.3</td>
<td>7</td>
<td>7.5</td>
<td>5-10</td>
<td>5-16</td>
<td>7-25</td>
<td></td>
</tr>
<tr>
<td>Cocaine</td>
<td>100-150</td>
<td>120 -170</td>
<td>90</td>
<td>50</td>
<td>20-120</td>
<td>20 – 110</td>
<td>30-100</td>
<td>30-100</td>
<td>70-100</td>
<td>50-200</td>
<td>50-250</td>
</tr>
<tr>
<td>Heroin (brown)</td>
<td>65-150</td>
<td>90 -150</td>
<td>74.4</td>
<td>50</td>
<td>82</td>
<td>80</td>
<td>50-90</td>
<td>50-90</td>
<td>60-80</td>
<td>33-100</td>
<td>20-250</td>
</tr>
<tr>
<td>STA</td>
<td>25-30</td>
<td>n.a.</td>
<td>25</td>
<td>n.a.</td>
<td>n.a.</td>
<td>5</td>
<td>5</td>
<td>20</td>
<td>n.a.</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Ecstasy</td>
<td>9 - 13</td>
<td>10.7</td>
<td>7</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>5</td>
<td>5</td>
<td>5-15</td>
<td>n.a.</td>
<td>5-12</td>
</tr>
<tr>
<td>LSD</td>
<td>11-13</td>
<td>11-13</td>
<td>n.a.</td>
<td>n.a.</td>
<td>10</td>
<td>10</td>
<td>n.a.</td>
<td>n.a.</td>
<td>5-15</td>
<td>n.a.</td>
<td>12</td>
</tr>
</tbody>
</table>

*Source: Specialised Drug Department of the Judicial Police (1994-2007), Tox-In (2008-2010)*

Price: expressed in EURO at street level.
For cannabis, cocaine & heroin (since 2009) and amphetamines, price per gram is indicated.
For heroin and cocaine, minimum prices refer to traffic units (until 2008) Maximum and average prices refer to street retail quantities.
For ecstasy and LSD, price per pill or unit are indicated.

Purity/potency of illicit drugs
Compared to the situation in 2004, purity of heroin tends to stabilise while the purity of cocaine decreased (2004: 61.78% / 2010: 47.9%). However, a slight increase can be observed in 2010, compared to the data of 2009. Attention has to be paid to the striking differences in maximum and minimum purities as well as to a historically high maximum concentration of THC (over 40%) in herbal cannabis samples seized in Luxembourg in 2009. However in 2010, the maximum concentration of THC has decreased again (34.2%). Prices show broad ranges for heroin and cocaine. Cannabis and derivates however have known certain stability during the last 8 years as far as street prices are concerned.

Attention has to be paid to the striking differences in maximum and minimum purities of all substances. For instance heroin and cocaine show very high maximum purity rates. These values should however be considered carefully, the sampling may contain intermediary seizures, not ready for street consumption and to which cutting agents were supposed to be added.
Historically high maximum concentration of THC in cannabis samples seized in Luxembourg has been observed in 2009. Herbal cannabis showed highest maximum levels of THC concentrations (34.2% in 2010, 40.78% in 2009, 25% in 2008). In 2010 average THC concentration in herbal cannabis was higher than in resin cannabis. For more detailed information please refer to standard table 14.

Table 10.3 Purity of drugs at street level (1994-2010)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pur. (%)</td>
<td>AVRG.</td>
<td>AVRG.</td>
<td>AVRG.</td>
<td>AVRG.</td>
<td>AVRG.</td>
<td>AVRG.</td>
<td>AVRG.</td>
<td>AVRG.</td>
<td>MIN.</td>
<td>MAX.</td>
</tr>
<tr>
<td>Cannabis (THC)</td>
<td>8.03</td>
<td>7.96</td>
<td>6.94</td>
<td>7.36</td>
<td>9.61</td>
<td>9.82</td>
<td>11.25</td>
<td>0.28</td>
<td>34.23</td>
<td>11.32</td>
</tr>
<tr>
<td>Marihuana</td>
<td>10.21</td>
<td>9.75</td>
<td>11.18</td>
<td>8.52</td>
<td>10.3</td>
<td>12.39</td>
<td>0.70</td>
<td>34.23</td>
<td>11.84</td>
<td></td>
</tr>
<tr>
<td>Hashish</td>
<td>60-90</td>
<td>60-90</td>
<td>60.25</td>
<td>62.99</td>
<td>62.37</td>
<td>58.80</td>
<td>51.00</td>
<td>52.00</td>
<td>43.20</td>
<td>11.58</td>
</tr>
<tr>
<td>Cocaine</td>
<td>15-23</td>
<td>20-25</td>
<td>17.59</td>
<td>9.97</td>
<td>17.07</td>
<td>15.80</td>
<td>16.60</td>
<td>16.10</td>
<td>18.50</td>
<td>0.71</td>
</tr>
<tr>
<td>Heroin (brown)</td>
<td>15.09</td>
<td>9.44</td>
<td>7.1</td>
<td>13.81</td>
<td>18.2</td>
<td>15.38</td>
<td>3.47</td>
<td>19.36</td>
<td>10.43</td>
<td></td>
</tr>
<tr>
<td>Ecstasy (MDMA) (MDEA) (MDA)</td>
<td>35.5</td>
<td>6.8</td>
<td>71.11</td>
<td>29.77</td>
<td>6.25</td>
<td>26.44</td>
<td>20.52</td>
<td>1.25</td>
<td>23.52</td>
<td>13.94</td>
</tr>
<tr>
<td>Psylocine</td>
<td>0.15</td>
<td>0.41</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>0.016</td>
<td>0.065</td>
<td>0.05</td>
<td></td>
</tr>
</tbody>
</table>

Sources: Specialised Drug Department of the Judicial Police / Laboratoire National de Santé. Division Toxicologie. 2010

Purity:
For cocaine, heroin and amphetamines, purity is expressed in percentages of pure active substance at the street level.
For cannabis, purity refers to percentage of THC.

In 2011 S. Schneider and F. Meys published a paper on analysis results of illicit cocaine and heroin samples seized in Luxembourg from 2005 to 2010. Abstract: This article discusses drug purity, frequency of appearance and concentration ranges of adulterants of 471 illicit cocaine and 962 illicit heroin samples seized in Luxembourg from January 2005 to December 2010. For cocaine samples the mean concentration was lowest in 2009 (43.2%) and highest in 2005 (54.7%) but no clear trend could be observed during the last 6 years. 14 different adulterants have been detected in cocaine samples, from which phenacetin has been the most abundant in terms of frequency of appearance and concentration until 2009. In 2010 the veterinary antihelminthic drug levamisole has become the most abundant adulterant detected in cocaine samples, its concentrations however remained low (1.5-4.1%). The mean heroin concentration was 26.6% in 2005, a decline has been observed in 2006 and the concentrations have been relatively stable since then (15.8-17.4%). Paracetamol and caffeine were by far the most abundant adulterants detected in heroin samples.

Composition of illicit drug tablets
Information for this section was provided by the National Laboratory of Health (LNS) and formatted by the NFP. 49 pills were analysed during year 2010. 11.7% of analysed pills contained MDMA as main active substance and 58.8% contained other substances, as caffeine, paracetamol or ibuprofene.

55 Ecstasy : dose in mg/pill
Most common cutting agents found in MDMA, amphetamine or mCPP containing products were sugar and caffeine.

For detailed information please refer to standard table 15.
Part B: Selected Issues

11. Drug-related health policies and services in prison

Prior to the implementation of the ‘Global Drug Care Programme in Prison’ (TOX project 2000-2005) in the two national state prisons, only limited offers specifically designed for drug addicts in prison were available. It was further observed that the referred population, once released from prison, showed high rates of recidivism. As far as health condition of inmates is concerned, an epidemiological study on HIV and hepatitis C infections (Schlink, 1999) showed that 28% of inmates declared an intravenous drug use in prison. 9 out of 10 inmates who declared injecting drug use before imprisonment continued intravenous drug use in prison. Results also showed that a proportion of 4.3% of IDU had been infected with HIV and 37% infected with hepatitis C. This evidence obviously contributed to reconsider drug-related health policies in prison.

1. Prison systems and prison population: contextual information

1.1. Contextual information on national prison system and prison population

The Grand-Duchy of Luxembourg counts two state prisons; the CPL situated in the vicinity of Luxembourg City and the CPG implemented in the East of the country. The CPL is a closed penitentiary institution whereas the CPG may be considered as an alternative to a strict penitentiary regime as it is defined as a semi-open prison established in a more rural setting. During daytime, inmates follow a professional activity or participate in intra-muros workshops (agriculture, animal breeding, kitchen, horticulture, woodwork, etc.). After work they return to their individual cells for the night. Available facilities (e.g. kitchen, bathrooms, laundries) allow inmates to live more or less autonomously.

In 2009 an average of 607 detainees in the CPL and 79 in the CPG have been registered. On date of 25 February 2010, a total number of 719 detainees has been reported. On average, nearly 70% of detainees are foreign nationals and more than half of them are non-residents. Half of the detainees of the CPL are indicted persons (on remand). Detainees convicted for offences against the national drug law represent the largest group of inmates (149 from a total of 385 convicted persons on 1 September 2009).

1.2. Characteristics of population, health and social status

On 1st September 2009 the total number of prison inmates reached 679 persons (thereof a total of 32 women). 256 persons were imprisoned because of drug-related crimes (107 indicted and 149 convicted persons). The majority of the latter were aged between 31 and 40 years.

At the date of the 16 March 2010, 645 inmates were staying at the CPL, composed of 615 male and 30 female prisoners. 179 of the 645 inmates were natives. 121 convicted and 107 indicted persons were detained at the CPL because of drug offences, followed by thievery.
Table 11.1 General admissions and the number of admissions to drug-related convictions in the two State prisons of Luxembourg (CPL and CPG) from 2006 to 2010

<table>
<thead>
<tr>
<th>Year</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>New entries</td>
<td>1,043</td>
<td>1,030</td>
<td>990</td>
<td>892</td>
<td>927</td>
</tr>
<tr>
<td>New entries for offences against the national drug law</td>
<td>243 (23.3%)</td>
<td>212 (20.6%)</td>
<td>332 (33.5%)</td>
<td>224 (25.1%)</td>
<td>232 (25.02%)</td>
</tr>
</tbody>
</table>

In 1998, the Ministry of Justice commissioned the medical department of the state prison (CPL) to perform an epidemiological study on HIV and HCV prevalence in prison population (Schlink, 1999). The research protocol relied on a self-administrated anonymous questionnaire on health behaviour and injecting drug use prior and during prison sentence. According to the referred study, 32% of prisoners qualified themselves as injecting drug users; 28% reported current drug injection in prison; 9% have started injecting drug use in prison. Concerning the risk behaviour of inmates, 58% of current IDU reported life-time needle sharing in prison; 8% of current IDU prisoners reported last month needle sharing in prison; 70% of IDU prisoners only used water to clean up syringes and 22% did not clean syringes at all. Results also showed that a proportion of 4.3% of IDUs had been infected with HIV and 37% infected with hepatitis C.

A recent research paper “Prevalence of hepatitis B and C and HIV infections among problem drug users in Luxembourg. Self-report versus serological evidence” (Origer & Schmit, 2010) reported a HCV prevalence rate of 86.3%, a HBV prevalence rate of 31.8% and a HIV prevalence of 7.7% in in-prison respondents. The highest prevalence rates for all reported infections have been observed among prison population if compared to other settings (e.g. out-patient, in-patient treatment, substitution treatment, low threshold facilities). According to the same main study (Origer & Removille 2007) 56.1% of drug law offenders who have had prison experience during the past ten years (N:246) reported illicit drug use in prison; 30.5% reported intravenous drug use. A total of 26.7% of lifetime IDUs inmates reported needle sharing in prison.

In 2009, the medical service of the CPL registered 5,216 general medical consultations, on average 20 per day, and 346 specialised medical consultations. A total of 640 consultations outside prison have been registered.

In 2010 (2009), 76% (58% in 2009, 62% in 2008) of indexed PDU by the national drug monitoring system (RELIS) have already served at least one prison sentence during lifetime. The proportion of PDU having served more than one prison sentence has stabilized during the last years (36% in 2010 and 30% in 2009).

2. Organisation of prison health policies and service delivery

2.1. Prison Health

2.1.1. Regulatory/legal framework/funding of general health care in prison

The law of 27 July 1997 concerning the reorganisation of the penitentiary administration foresees the implementation at the CPL of a special medical section destined to receive drug law offenders and inmates suffering from a mental illness as well as persons being subject of a law placement. The directorate of this special medical unit is represented by a chief agent designated by a joint decree (“arrêté conjoint”) of the Ministry of Health and the Ministry of Justice. The law of 1997 was the determining factor for the

57 Law of 27 April 2001 modifying the basic drug law of 19 February 1973
implementation of the so called TOX project (2000-2005), which developed into a well established routine programme (TOX programme), operational since 2007.

Psycho-medical health care within CPL is provided by a medical unit depending on the Hospital Centre of Luxembourg (CHL), the medico-psychological unit SMPP depending on the Neuro-psychiatric Hospital Centre of Ettelbruck (CHNP), the pharmacy (CHL) and the medical doctor of the prison.

The main budget lines 2011 related to prison health care are the following:

- hospital costs, medical and psychiatric treatment, pharmaceutical costs which cannot be paid by the inmate, preventive vaccinations: 2,000,000 EUR (art.07.2.12.150);
- CHNP room rental fees: 35,115 EUR (art. 07.2.12.330)
- reimbursement to the CHL and the CHNP for the organization of health care services inside prison: 3,909,350 (art. 07.2.12.331)
- programme for drug-addicted persons inside prison: 823,420 EUR (art.07.2.12.370)

2.1.2. Implementation of the principle of “equivalence of care” in prison

A person in detention has the same rights in terms of global health care as a person in liberty. To assure equivalence of medical, dental and psychiatric care, the Ministry of Justice has signed several conventions with two main national hospitals; namely the CHL and the CHNP.

2.1.3. General level of health resources

Space I – annual penal statistics – on 1st September 2009 - Council of Europe reveals that 8.5 full-time equivalents have been dedicated to the medical and paramedical staff of the national penal institutions. A total of 5 full-time equivalents are dedicated to the staff responsible for assessment and psychologists. The total staff number reaches 402.5, thereof 2.1% of medical and paramedical staff.

The multidisciplinary team of the TOX-programme in the CPL is composed of 3 psychologists, a psychiatric nurse, a social assistant, a psycho-corporal therapist and an art-therapist (3 full-time equivalents).

The medical unit is composed of 14.45 full-time equivalents nurses, 2.5 medical doctors and 1.5 secretaries (31.08.2011).

The psycho-socio-educative service SPSE (includes 3 services: psycho-social and socio-educative unit, education unit and leisure and sport unit) is composed of 4 psychologists, 1 social assistant, 7 graduate educators, 11 foreman instructors, 8 fulltime teachers, 5 sport tutors (30.10.2009).

The medical psychiatric unit SMPP (of the CPL) is composed of 1.5 full-time equivalent ergonomic specialist, 13 psychiatric nurses, 2.5 psychiatrists, 0.20 child psychiatrist, 1 psychologist and 1.5 secretaries.

The medical, psychiatric and sanitary team is composed of more than 50 professionals. Roughly estimated, one may also consider a number of 50 health care professionals per
1000 prisoners as the total number of prison admissions fluctuated the last years between 900 and 1000 inmates.

2.2. Drug-related health policies targeting prisoners

2.2.1. Prison-related targets in national drug policies

Following the law of 27 July 1997 concerning the reorganisation of the penitentiary administration a pilot project named ‘Global Drug Care Programme in Prison’ (2000-2005 – TOX project) was set up by a group of experts assigned by the Ministry of Justice in 1999. The concept was designed to implement, among other actions, primary prevention measures in regard to drug consumption and infectious diseases. The overall aim of the project was to integrate drug dependant inmates into a medico-psycho-social drug care network in order to reduce recidivism, risks and criminality after release from prison.

In 2007, the TOX project became the TOX-programme. This programme is currently to be seen as a routine offer in the two national prisons (CPL and CPG). The TOX-programme comprises individual support, programmes for groups of drug dependent persons and institutional interventions. It is based on two pillars: psychosocial prevention (preparation for a residential or outpatient therapy) and sanitary prevention (STD –HIV, hepatitis and “harm reduction”).

Regarding the TOX-programme, a convention between the Ministry of Justice and the Neuro-Psychiatric Hospital Centre of Ettelbruck (CHNP) has been signed. In the CPG, the TOX-programme helps and supports drug-dependant inmates by a multidisciplinary team. In the CPL, the TOX team collaborates closely (case management) with the internal services of the institution (SPSE, SMPP – medical-psychological unit depending on the CHNP, medical ward, directorate and administration, guardsmen service, medical doctors) as well as with external services such as residential and outpatient treatment centres, detoxification centres, prevention centres, service of probation (SCAS) as also other penitentiary centres and universities.

In order to get in contact with the TOX-team, the inmate or a given referral service has to formulate a demand. The demand of the client is analysed and the type of intervention is determined as well as the duration of the required interventions. The interventions comprise: information on the TOX-programme, the services and the prison in general, referral to other services, prevention of STD and psycho-social follow-up. The client may then be guided to the “programme Charly” (drug-free zone), a programme designed for drug dependent women, the preparation of an external, outpatient or residential therapy and the preparation for release (family relations, employment, housing, further training etc.).

The “Programme Charly” allows inmates to stay during their prison sentence in a drug-free zone while benefiting from an intensive therapy preparation programme and prevention of recidivism. In addition to body and art therapy sessions, individual and group sessions, a special training for prevention of recidivism (RPT: 12 group sessions) is also offered.

The TOX-platform assembles each actor and service involved in the TOX-programme (director, SPSE, guards, doctor and medical ward, SMPP, central probation services SCAS). The platform coordinates and improves professional practice inside prison establishment in regard to drug dependence.
The TOX project has been evaluated in 2006 by the University of Landau (DE) (Fisher, 2006). Evaluation results showed that inmates expected more qualified individual interventions whereas staff members formulated a higher demand for collective coordinated actions. All in all, the programme was qualified as well-functioning but it was recommended to consolidate it with regard to its internal and external visibility. It has also been evaluated in 2007 by the University Paul-Verlaine (Trepos, 2007). The referred evaluation recommended the continuation of the programme.

Accordingly to the governmental declaration of 29 July 2009, the government declares to continue efforts to ensure best possible human conditions in national prisons and to support the resocialisation of detainees.

In this context, a new concept/reform dedicated to the governmental policy concerning the penitentiary institutions was presented in March 2010 in the judicial commission of the parliament (Ordinary session 2009-2010, Judicial Commission, report of the 17 March 2010 meeting). The new concept is based on prisoners care, accommodation, administrative reorganisation, recruitment of guardsmen and their further training. Also a third State prison will be implemented in the south of the country. The structure of the future CPU (Centre Pénitentiaire Urschterhaff) is inspired by the Swiss system and will have a capacity of 400 persons. Only indicted persons (on remand) will be admitted by the CPU. The CPU should be operational by 2017.

The CPL (Centre Pénitentiaire de Luxembourg) will remain in charge for inmates (indicted and convicted persons) who need greater care in terms of surveillance and special healthcare. An excellence centre will be created inside the CPL to better respond to the needs of certain categories of inmates such as pregnant women, drug users and offenders with psychiatric disorders. The CPG (Centre pénitentiaire de Givenich) will remain responsible to prepare the resocialisation after imprisonment. Furthermore, a special section for women is planned.

Concerning the inherent philosophy of penitentiary policies, the development of a more proactive one can be noticed. The aim is to limit to the strict minimum imprisonments and to prepare inmates to (re)-integrate society. In that respect it is foreseen to complete the range of alternative sentences (e.g. social work, the electronic bracelet) and to enhance resocialisation processes of inmates through individual resocialisation contract, with the aim to avoid recidivism.

The prisoners themselves should be actively implicated in their resocialisation process. The detention has therefore to be organized following an interactive balance between rights and responsibilities of prisoners (social behaviour, work, education, health, family and social relations etc.).

2.2.2. Policies regarding drug prevention, harm reduction and care of imprisoned drug users

Policies regarding drug prevention, harm reduction and care of imprisoned drug users are derived from the TOX project (2000-2005). The subsequent TOX programme proposes direct interventions for drug dependent inmates (therapeutic and psycho-educational interventions, creation of prevention groups) as well as the implementation of coordination structures among professionals.
The intervention strategy of the CPL rests on 3 main pillars:

1) demand reduction: sensibilisation and prevention actions, support and follow-up of drug-addicted inmates, substitution treatment and preparation of a therapy after release,
2) supply reduction: searches, seizures and urine tests (if required), dog units from grand-ducal police and customs, cooperation with the judicial police, every drug is reported to judicial authorities,
3) harm reduction: sensibilisation of detainees by information on risks and responsibilities, medical and psychological support for HIV patients, provision of sanitary products and syringe exchange programme.

2.2.3. Models of service delivery for drug users in prison

The TOX programme is run by a multidisciplinary staff. The basic principles of the TOX programme of the CPG are the voluntary participation, the cooperation, the transparency, the quality of service, the determination of realisable objectives and the empowerment of participants.

Detoxification treatment is either provided in-house under the responsibility of the prison medical unit, or by external detoxification units of general hospitals according to strict rules and procedures. The CPL has signed a convention with a major general hospital situated in Luxembourg City (CHL) ensuring out-of-prison medical care if required.

Psychosocial and therapeutic care is provided by both, in-house staff members and specialised external agents from accredited drug agencies. An example of good practice in this respect is the inclusion of clearly time on content defined service providing of external specialized drug agencies contractually foreseen by state conventions (in the framework of the global drug care programme). This mechanism also applies to external agents in the field of HIV and other infectious diseases. One should also stress the role of the Central Probation Service (SCAS), which motivates inmates to undergo treatment and enables contacts with external therapeutic agencies.

3. Provision of drug-related health services in prison

3.1. Prevention, Treatment, Rehabilitation, Harm reduction

3.1.1. Drug use assessment as part of routine examination upon entry into custody

Drug use assessments are not part of the routine examination upon entry into custody. A drug test can be proposed for medical reasons. Following the law of 27 April 2001 modifying the basic drug law of 19 February 1973, article 4, the inmate can only be obliged to undergo a drug use assessment in the case of serious indications of illicit drug use. This test can be completed by a blood sample and/or radiological exams. If the detainee refuses he cannot be forced to undergo medical exams. In case of refusal, the inmate is found guilty and the offence(s) will be prosecuted.

3.1.2. Drug prevention, information and education activities for prisoners

The aim of the TOX programme, as mentioned above, is to help the imprisoned persons regaining responsibility and to promote health in general. Three pillars guided the work in 2010: psychosocial prevention, health prevention and work promotion activities. The psychosocial prevention includes therapeutic accompaniment/supervision of the inmate
by a reference person as well as group therapy. The health prevention aims at risk reduction, prevention of recidivism and prevention of STD. Individual or group supervision is available. The “Charly Programme” (CPL) allowing beneficiaries to stay during their arrest in a drug free zone of the prison, benefitting of an intensive programme of preparation for therapy and recidivism prevention. This programme takes between 4 and 8 months.

A coordination platform was created in order to coordinate interventions of involved professionals. In order to meet specific needs in terms of infectious diseases in prison settings, the creation of a specialized transmittable disease counselling offer (COMATEP) involving prison administration and the CHL has been put in place in 2009.

Trained staff members of the “Jugend-an Drogenhellef” foundation (JDH) are regularly proposing drug counselling in prisons.

Their services include:
- information, orientation, advisory service and individual therapy
- preparation for the therapy in specialised residential centres
- preparation for the methadone substitution programme
- preparation for release
- information and social help in general

At the CPL, sensibilisation and information modules are proposed for both, men and women in collaboration with services as the medical department of the CPL, the Aidsberodung, the JDH etc. Prevention modules against tobacco as well as discussion groups by external experts, health forum, arrival groups for new detainees are organised at the CPG.

Concerning the TOX programme at the CPL (2010), 101 activity groups related to psycho-social prevention, 1,238 therapeutic counselling sessions with 157 clients, 45 health prevention groups with 144 participants, 17 programme TOX information groups with 95 participants, 274 individual prevention interviews have been reported.

In the CPG (2010), 214 activity groups have been organised, 635 therapeutic interviews with 61 clients held, 7 anti-tobacco sessions with 64 participants, 16 sessions of training against recidivism (RPT) with 176 participations (+/- 10 clients/module), 2 health forums divided into 8 workshops with 79 participants have been organised.

The CHNP manages a medical – psychological service inside prison (SMPP: service medico-psychologique pénitentiaire). The mission of the SMPP is to offer systematic early detection examinations of psychological troubles, to guarantee medico-psychological care by means of individual interviews, to organize therapeutical workshops, to deliver psychiatric treatment and prepare follow-up of psychological care at release. Moreover the SMPP has the mission to fight against alcoholism and drug consumption and to coordinate mental health care with professionals to prepare post-penal treatment programmes.

The CPL runs a proper psycho-social and educational department (SPSE). Jointly with the SCAS and the prison guard’s association, it has set up a project called “DEFI” (challenge) that aims at the development of therapeutic means, training facilities, socio-professional reinsertion measures and indebtedness management, during prison journey and after the prison release.
3.1.3. Characteristics of clients entering drug treatment while in prison

Substitution treatment is proposed to all inmates who present opiate drug dependence when entering prison. Nearly every opiate drug user accepts treatment. The imprisoned person may choose between maintenance, dose reduction or detoxification treatment.

In 2009, 202 inmates have been substituted with methadone, 6 with methadone and buprenorphine and 2 only with buprenorphine. According to official figures 23% of inmates (of full age) who entered the CPL in 2009 received substitution treatment.

In 2010, 24.5% (219 persons) of prisoners in the CPL and 10.5% (16 persons) of prisoners in the CPG underwent intra-muros substitution treatment. In the CPL, a total of 69 persons have been substituted on average each day. In the CPG a total of 6 persons have been substituted on average each day. A total of 201 persons of the CPL have been substituted with methadone whereof 9 have used concomitant Suboxone. A total of 18 persons only used Suboxone. In the CPG only methadone was prescribed. The mean duration of treatment in 2010 was 127 days. A total of 126 patients stopped substitution treatment during their prison stay. A total of 30 persons restarted substitution treatment in prison.

3.1.4. Type of drug treatment, high-intensity and numbers of clients receiving such treatments

Idem 3.3

Regarding substitution treatment in prison, three scenarios may occur:
- most frequently encountered situation applies to new prisoners who underwent substitution treatment prior to their incarceration. Medical prison staff inquires the accuracy of the information and contacts the prescribing GP or the national substitution programme. In case of confirmation, substitution treatment is continued and may be followed by maintenance, dose reduction or detoxification treatment,
- substitution treatment may be initiated within prison. It also includes inmates who have started opiates use in prison,
- opiate using or already substituted prisoners may introduce an admission demand to the national extra-muros substitution programme 6 weeks before release.

Detoxification treatment is either provided in-house under the responsibility of the prison medical unit, or by external detoxification units of general hospitals according to strict procedures. Psycho-social and therapeutic care is provided by both, in-house staff members and specialized external agents from accredited drug agencies.

3.1.5. Overdose risk assessment

Overdose incidents after prison release is a documented reality that has also been addressed by national research. For instance, the Origer & Dellucci study (2002) recommended the following measures to prevent overdose risk following an in-depth longitudinal analysis of drug-related death nationwide:
- opening of supervised injection rooms
- heroin assisted treatment programme (foreseen by the national drugs action plan)
- first aid training courses provided to users and their relatives and partners
- gender and ethnic specific interventions
- provision of morphine receptor antagonists to selected users or persons
- creation of ‘transition centres’ for former or current PDU Leaving institutional settings
- development of reintegration programmes for prisoners in the framework of the 'global care programme for drug addicts in prison'

Also, the law of 27 April 2001 introduced an important modification of the basic drug law with regard to overdose prevention. Art 10-1 of the referred law exempts drug users who call for assistance in case another user is in need of medical help, from prison sentences. This change is supposed to reduce drug-related deaths occurring in consumer groups.

3.1.6. Other harm reduction interventions in prison: infectious diseases counselling and testing; needle and syringe programmes

New inmates are seen by medical staff in the framework of the admission procedure of both national prisons. A HIV screening test is suggested during the medical counselling. If the inmate accepts, a simultaneous screening of other infectious diseases like syphilis and hepatitis A, B and C is proposed.

In order to meet specific needs in terms of infectious diseases in prison settings, the creation of a specialized transmittable disease counselling offer (COMATEP) involving prison administration and CHL is operational.

A structured syringes distribution programme has officially been launched in 2005 in the framework of the global drug care programme in prison. In order to enrol, inmates have to send a written request to the prison’s doctor. After counselling, a decision is made and in case of enrolment, the inmate is handed a kit containing 2 syringes which may be exchanged at the nursery. As the consumption and possession of drugs are illegal, those inmates in possession with a syringe in its original kit are exempted from sanctions. The programme is under medical secrecy and is operational, although a series of changes are currently being discussed to increase the coverage and impact of the programme.

In 2010, 34 kits have been distributed and 328 syringes have been exchanged. At the date of 31 December 2010, 25 kits circulated in the CPL. Drug paraphernalia such as sterile spoons, water, filters, ascorbic acid and alcohol pads are available in the two nurseries of the CPL. Condoms are also available at different discrete spots of the prison (at the two nurseries, TOX-programme and the psychiatric ward.)

At the CPG, the same offer is available but there has been no demand to participate in the syringes exchange programme thus far.

3.1.7. Provision of health services tackling health and social determinants of drug users in prison

Principles of HIV and hepatitis prevention and confidentiality applied outside prison settings are also applied inside prison (CPL and CPG). Each detainee has the possibility to undergo a HIV and hepatitis screening test. The announcement of a positive result is either made by a doctor of the national service of infectious diseases from the “Centre Hospitalier de Luxembourg” (CHL) or a doctor from the penitentiary centre. HIV seropositive detainees have access to free medical care. Periodic follow-up is assured by the national service of infectious diseases. Counselling service for HIV related questions are provided by a psychologist from a specialised agency (Aidsberödung).
As mentioned above the TOX-programme offers global care to imprisoned drug users in the CPL and the CPG. Each detainee is offered psycho-social prevention (preparation for a residential or outpatient therapy) as also a sanitary prevention (hepatitis, HIV and harm-reduction). Individual support, group therapy and institutional interventions are offered by the TOX-programme.

The TOX programme also published a leaflet called “health”. This leaflet is distributed to all new prison inmates. It contains chapters on activities in prison, physical health, mental health, drug consumption, prevention of diseases, preparation for release and important addresses.

3.1.8. Preparation of release and continuity of care upon release in community

The CPL runs a proper psychosocial and educational department (SPSE). Jointly with the SCAS and the prison guards’ association, it has set up a project called ‘DEFI’ (challenge) that aims at the development of therapeutic means, training facilities, socioprofessionnel reinsertion measures and indebtedness management, during prison journey and after the prison release phase.

External drug care agencies, for example Centre Emmanuel and the Youth-and Drug Help foundation JDH contribute to prepare release and assure continuity of care.

3.2. Drug testing

3.2.1. Drug testing in prison (mandatory/not mandatory): programme description, sampling, coverage, evaluation

Urine tests are not mandatory in prison unless there is reasonable suspicion of illegal drug use. Furthermore, drug testing might be necessary to ensure safety of substitution treatments. Between 1st January 2009 and 1st December 2010 1,822 urine tests have been collected in the CPL whereof 374 tests have detected metabolites of drugs as cocaine, opiates, THC etc. These tests have been collected because of medical reasons to treat, where appropriate, the addiction with legal substitution products.

4. Service quality

4.1. Practical guidelines and standards of drug-related health services for prisoners

4.1.1. Quality assurance of drug-related services in prison

Substitution treatment in prison is underlying internal guidelines (good clinical practice), based on international guidelines (i.e. AWMF: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften). All psychiatrists, medical committee of the CHNP and the pharmacy of the CPL recognize this standard. Internal guidelines have also been developed. Since September 2009, a psychiatrist assures drug substitution in prison.

4.1.2. Description of existing guidelines on drug treatment (prevention, treatment, rehabilitation, harm reduction) including standards for prison OST: medications, delivery models, control of diversion

Internal guidelines based on international standards have been developed.
4.2. Training

4.2.1. Training of prison staff in drug-related prevention, risk awareness and reduction

An e-learning project is available for the penitentiary staff. Training lessons on PC with individual login on themes of drug dependence prevention, risk reduction, prevention of HIV and hepatitis etc. are part of the project. Guardsmen receive once a month further training on HIV and hepatitis prevention and other infectious diseases by nurses from the TOX programme. Furthermore, the reform of prison establishments (in progress) foresees a reorganisation of prison staff training.

5. Discussion, methodological and information gaps

5.1. Equivalence of care

5.1.1. Available information on drug-related health policies and services with a view of the principle of 'equivalence of care'

The law of 11 April 2010 foresees an “external controller of all facilities of deprivation of liberty”. The mission of this “Ombudsman” is, among others, to control detention settings and to safeguard the rights of imprisoned persons. A first visit of the ombudsman of national prisons in 2011 included interviews with 150 persons, thereof 65 detainees. An inventory of detected problems also included the presence of a significant illicit drug use problem in prison. A survey performed by the intra-muros medical department and the TOX programme showed that 40% of new detainees of the CPL had drug-related problems. These are 230 to 240 persons whereof 100 are in substitution treatment. The report from the ombudsman recommended the implementation of a clear organisational chart and the function of a medical coordinator. Concerning “equivalence of care”, each detainee has the right to gain fast and easy access to medical and psychiatric care. The referred report published in April 2011 and containing 99 recommendations was presented to the Ministry of Interior, Ministry of Justice and Ministry of Health. The ombudsman further welcomed the new reform of the prison establishments.

Methodological limitations and information gaps

5.1.2. Main methodological limitations gaps regarding epidemiological situation of and interventions targeting drug users in prison

Since the implementation of the TOX programme, a whole range of interventions are offered to the inmates. However, the paper “Prevalence of hepatitis B and C and HIV infections among problem drug users in Luxembourg: self-report versus serological evidence” performed by Origer & Schmit (2007) showed that the highest prevalence rates of HIV, HBV and HCV have been observed among prison population.

58 Loi du 11 avril 2010
(1) portant approbation du protocole facultative se rapportant à la Convention contre la torture et autres peines ou traitements cruels, inhumains ou dégradants, adopté par l’Assemblée Générale de l’Organisation des Nations Unies à New York, le 18 décembre 2002 et
(2) portant désignation du médiateur en tant que mécanisme national de prévention et fixant ses attributions
Furthermore, the study revealed that a respondent is 5.4 times more at risk to get infected with hepatitis C, if he had more than 3 stays in prison compared to a person not having had a prison stay. A respondent is also 3.3 times more likely to get hepatitis C if he or she has consumed drugs in prison compared to a person with prison experience but who declared not having consumed drugs.

Concerning needs assessment, a total of 67.6% (90/133) of prison respondents declared that psychological counselling was the most essential service to be offered, 47.3% declared the need of a medical service with easy access, 22.5% declared the need to get screened by external specialized agencies, 18.8% expressed the need for a drug injecting room, 15.7% for syringe exchange programme, 15% for providing drug paraphernalia, 3.7% for therapy or reintegration, 2.2% for the Tox Programme or methadone programme, 0.7% more sport activities and more prevention of infectious diseases.

The study recommends that existing prevention efforts have to be completed by putting particular emphasis on young and new drug users. Although the study confirms a low compliance of the problem drug users, screening and vaccination facilities have to be further developed.

6. Bibliography


7. Alphabetic list of relevant internet addresses

http://www.celpl.lu
http://chd.lu
http://www.chnp.lu
http://legilux.public.lu
http://mj.public.lu
http://ms.public.lu
http://www.spse.etat.lu
12. Drugs users with children

A specialised service called “service parentalité” (parenthood service) was implemented by the Youth and Drug-help foundation “Jugend an Drogenhellef” (JDH) in 2003. The service provides assistance to pregnant women and parents with drug problems and to their children. Its first mission is to guarantee the child’s security and well-being. Another primordial objective is to strengthen the educative and parental abilities.

The referred service has been implemented in response to a growing number of pregnancies, related to a stabilisation and improvement of life conditions of drug dependant persons, partly due to treatment options such as substitution treatment, and in response to an increasing number of help demands from parents with drug dependency problems. The service is run by a multidisciplinary team (5 collaborators: psychologist, social assistants and graduate educators).

1. Size of problem

1.1. Studies or data collection on the prevalence and characteristics of drug using in pregnant women and parents

The JDH foundation has created a service designated for pregnant drug-dependant mothers or parents. Special studies on drug-dependant pregnant women or parents have not been carried out in Luxembourg thus far. According to the activity report 2010 of the “Service parentalité” the following situation emerges:

- 16 births during 2010 (13 in 2009, 12 in 2008),
- total number of adult interventions: 96 adults with 50 children living with their parent(s) and 47 children living without their parents (17 situations),
- 33 situations (57%) are situated in a judicial context as a result of a decision of juvenile court (minor protection).

The total number of counselling sessions held by the service was: 1,035 in 2010 (985 in 2009). A total of 287 meetings have been held in 2010 with participants of the internal services of the JDH and external specialised services of the judicial, psychosocial, educative and medical domain. A total of 41 meetings with other members of the family have been registered. 1,035 conversations with representatives of the “service parentalité” have been held. All in all, 422 (41%) consultations occured in the facilities of the JDH, 613 (59%) outside of them, of which 347 at the child's home and 266 in hospital, the maternity unit or another institution.

1.2. Studies or data collection on the physical, mental and other risks/harms among drug using pregnant women / parents and their children

No specific national studies or data exist on the physical, mental and other risks/harms among drug using pregnant women / parents and their children.

2. Policy and legal frameworks

2.1. Policies addressing drug using parents/pregnant women and their children
The national drug action plan (2010 – 2014) refers explicitly in its section “demand reduction” to the “service parentalité” as a priority 1 project, which should be further developed. The rationale of the action plan stresses that an increasing demand is observed because of a higher life expectancy and better life quality of drug users. The offer of the “service parentalité” should therefore be diversified and specialised and further facilities should be created. It is also foreseen to reduce waiting lists by increasing dedicated human resources. The action plan further foresees to increase the budget line of the service and the employment of a paediatric nurse. Impact and result indicators retained in the national action plan are: a growing capacity (R), adjustment between needs and capacity and reduction of the number of persons on waiting lists (I).

According to its work principles, the “service parentalité” focuses on the needs of the children by means of contractual engagement, co-intervention, networking with other services, house visits and long term interventions.

2.2. Legal frameworks addressing drug using parents/pregnant women and their children

So called “judicial situations” are situations met by the “service parentalité” when judicial measures are taken for families in the framework of the child protection act. Procedures vary from an enquiry prescription/order following a notification to measures announced by a judicial judgment (educative assistance, conditions to maintain the child inside its family…) to a formal placement. In case of a placement and following the demand of the concerned parents, the “service parentalité” aims to maintain the contact with the placed child or aims at creating the conditions for the return of the child.

Table 12.1 Number and description of judicial situations managed by the JDH (2009)

<table>
<thead>
<tr>
<th>Judicial situations 2009</th>
<th>Number of situations</th>
<th>Educational assistance</th>
<th>Measures of past placement</th>
<th>Placement 2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>monoparental</td>
<td>27</td>
<td>3</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>couple</td>
<td>30</td>
<td>8</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>total</td>
<td>57</td>
<td>11</td>
<td>11</td>
<td>5</td>
</tr>
</tbody>
</table>

Source: JDH activity report 2009

Likewise previous years, slightly more than half of the situations were judicial measures in the framework of childhood protection.

The law of 10 August 1992\textsuperscript{60} is the main reference law concerning youth protection.

Following a formal notification, the magistrate of the juvenile court asks the general prosecutor to mandate a probation officer to proceed to a social inquiry and to inform him or her on the physical and psychological state of the minor as well as on his living environment. The probation officer gets into contact with the person who did the notification, the minor, the person(s) who has(ve) the parental authority and possibly involved psycho-social professionals (social assistant, teacher, psychologist etc.). The probation officer has the right to make announced (or not announced) home visits. He can be accompanied by police forces in case the family refuses the entry. The probation officer analyses risk and protection factors, composes a report to the magistrate of the juvenile court and proposes, if needed, measures of change.

Article 1 of the law of 10 August 1992 defines all measures the magistrate of the juvenile court can take in regard to the minor. These measures are: reprimand, placement in a socio-educative centre of the State, placement in a specialized establishment or a host family, maintenance of the minor in his family with educative assistance and a follow-up under certain conditions. In case a judgment is pronounced, a probation officer of the

\textsuperscript{60} Loi du 10 août 1992 relative à la protection de la jeunesse
central service of social assistance (SCAS) has to execute the measure. The probation officer advises and supervises the parents in their educational mission and the well-being of the minor. He/she regularly informs the magistrate of the Juvenile Court of the actual situation.

In Luxembourg the Parliament founded in 2002 the “Ombudscomité fir d’Rechter vum Kand” (Ombudスcommittee for children rights). It is a neutral organisation safeguarding the Convention of Children Rights. This committee analyses the situation of children at national level and reports and recommends improvement in children’s rights to the government and Parliament.

By the law of 16 December 2008 “loi du 16 décembre 2008 relative à l’aide à l’enfance et à la famille”, the Ministry of Family has set up an “national office of childhood” (ONE: Office National de l’Enfance) in order to prevent and to help at an early stage children, young adults and families who are in need. The ONE has the mission to guarantee support and quality of help to parents and children in need. ONE evaluates resources and difficulties, organises family or institutional communication sessions, elaborates socio-educative and psycho-social projects and assures the follow-up of specific situations by case-management. The administration of ONE has, among other tasks, to provide statistical data on children placed in national institutions and abroad.

The service “Treffpunkt”, a service managed by the “State Children homes”, offers a meeting opportunity for children and their parents in case one or both parents have the right to visit their child or children under surveillance only. This service is also offered to children who want to see their parent(s) in prison, as the child has the right to see his mother and father. Regular contact of an inmate with his child/children is of utmost importance in the context of a successful reintegration.

3. Responses

3.1. Availability of responses addressing drug using parents/pregnant women and their children

The “service parentalité” (JDH) jointly with the National Drug Addiction Prevention Centre (CePT) has started in 2007 a pilot-project of expression groups and training for mothers having had drug problems. This pilot-project was called “O Mamm O Kanner”. Key topics were parent-child relation and educative abilities in general. Professionals from both services have participated in training regarding interventions for drug dependant mothers in Cologne (Germany). Inspired from the “Eltereschoul”61 (school for parents) of the “Kannerschlass” foundation, a module of further training had been elaborated. The objective was to strengthen and improve parental competencies and to empower parents in their educational missions.

In 2009, the project “O Mamm O Kanner” was revised and was called “1-2-3 Lass!” (1-2-3 Go). A more structured concept targets henceforth pregnant women and mothers with children under 2 years of age. Further training (8 sessions / 2 hours) on child development, attachment, emotions, educative models and values is provided by specialised staff members from the JDH and the CePT.

The paediatric clinic of the CHL as well as the “Service parentalité” of JDH have organised in December 2010 a public conference on “Care of babies from drug dependant mothers”, the “kangaroo” method. The kangaroo method is a method which

---

61 The Janusz Korczak school offers parents, fathers and mothers a whole range of further training sessions and activities.
allows a non medical treatment, which shortens the detoxification period of new born babies.

3.2. Availability of guidelines addressing drug using parents/pregnant women and their children

To date no national or local guidelines addressing drug using parents/pregnant women and their children are available.

4. Bibliography

Centre de Prévention des Toxicomanies (2010), Bilan d’activités 2009. CePT, Luxembourg.


Ministère de la Santé (2010), Stratégie et plan d’action 2010-2014 en matière de lutte contre les drogues et les addictions.

5. Alphabetic list of relevant internet addresses

http://www.cept.lu
http://www.droitsetdevoirs.lu
http://www.jdh.lu
http://kannerschlass.lu
http://www.legilux.public.lu
http://www.mfi.public.lu
http://www.ork.lu


Centre d’Etudes de Populations, de Pauvreté et de Politiques Socio-Economiques (2007), L’exclusion liée au logement des personnes prises en charge par les centres de jour, les foyers de nuit, les centres d’accueil et les logements encadrés, Luxembourg.


Centre de Prévention des Toxicomanies (2010), Bilan d’activités 2009. CePT, Luxembourg.


European Commission (2001), Public opinion regarding security and victimisation in the E.U. Contact with drug related problems, Eurobarometer surveys n° 44.3 and 54.1, Brussels.


EDDRA. Système d’information sur les échanges en matière d’activités de réduction de la demande, http://eddra.emcdda.eu.int/


Goerens, R. (1998), Alcohol and Drugs at the workplace – Attitudes, policies and programmes in Luxembourg, Ministry of Health, Luxembourg.

Groupe de Mondorf (2001), Classeur d’information, NFP – CRP Santé, Luxembourg.


Lambrette, G. (2009), Projet « START », constats et réflexions autour du projet de réinsertion professionnelle pour personnes toxicomanes au Grand-duché de Luxembourg, Centre Emmanuel asbl, Luxembourg.


Matheis, J. et al. (1995), Schüler an Drogen. IEES, Luxembourg.


Origer, A. & Cloos, J.-M. Dr. (2003), Study on socio-economic costs of drug addiction and the fight against drugs. Séries de recherche n°4. EMCDDA Focal point - CRP-Santé, Luxembourg.


Schlink, J. Dr (1999), Etude épidémiologique des infections à l’HIV et à l’hépatite virale C dans les prisons luxembourgeoises, CPL, Luxembourg.


Annex I

- List of Graphs

Fig. 1.1 Annual budget of the Ministry of Health allocated to drug-demand reduction (2000-2011)
Fig. 1.2 Annual progression of the budget of the Ministry of Health and human resources allocated to drug-related activities 2004-2011
Fig. 1.3 National coverage of written media regarding drug related topics from August 2009 to July 2010
Fig. 2.1 Lifetime prevalence according to age (Fischer 1999)
Fig. 2.2 Current and lifetime prevalence of cannabis use according to age (Cinema sample)
Fig. 2.3 Current and lifetime prevalence of cannabis use according to age (Council districts)
Fig. 2.4 Lifetime prevalence of drug use according to age (Matheis, Prussen 1995)
Fig. 2.5 Lifetime prevalence according to age (HBSC 2000)
Fig. 2.6 Lifetime prevalence of drug use according to age groups (Meisch 1998)
Fig. 2.7 Current and lifetime prevalence of cannabis use according to school levels (Fischer 2000)
Fig. 2.8 Lifetime prevalence: school population - 12-20 years
Fig. 2.9 Lifetime prevalence: school population - 16-20 years
Fig. 2.10 Lifetime prevalence: school population - 13-14 years
Fig. 2.11 Lifetime prevalence: school population - 15-16 years
Fig. 2.12 Last 12 months prevalence: school population - 12-20 years (HBSC 2000)
Fig. 2.13 Last 30 days prevalence: school population - 13-20 years (Fischer 2000)
Fig. 3.1 Nationality of DIMPS clients (2009-2010)
Fig. 3.2 Potential sources of information about illicit drugs and drug use
Fig. 3.3 Information channels used in the past year to be informed about the effects and risks of illicit drugs
Fig. 3.4 How should society’s drug problems be tackled?
Fig. 3.5 Absolute prevalence estimation of problem HRC drug use (2007) and confidence intervals
Fig. 3.6 Absolute prevalence estimation of problem HRC drug use (1997-2007)
Fig. 3.7 Prevalence rates of PDU, heroin use and iv use (1997-2007) per 1,000 inhabitants
Fig. 3.8 Prevalence estimates (problem use of HRD) and evolution of selected indirect indicators
Fig. 3.9 Synopsis of national data in HIV infection rates in drug using populations
Fig. 3.10 Previous contacts with psychiatric services of RELIS indexed drug users (1998-2010)
Fig. 3.11 Reasons for psychiatric care demands (1996-2010)
Fig. 3.12 Detection of cannabinoids – Suspicion of driving under influence of psychoactive substances (1995-2010)
Fig. 3.13 Evolution of drug-related death cases (direct-indirect-total mortality) (1990-2010)
Fig. 3.14 Evolution of drug-related mortality rates (direct-indirect-total mortality) per 100,000 inhabitants aged 15 to 64 from 1990-2010 (Orger 2011)
Fig. 3.15 Gender distribution of direct drug-related death cases (1992-2010)
Fig. 3.16 Mean age of acute drug overdose victims (1992-2010)
Fig. 3.17 Non fatal, medically assisted drug overdoses in RELIS respondents (1994-2010)
Fig. 3.18 Last known housing situation of problem drug users (1995-2010)
Fig. 3.19 Unemployment rate in problem drug users (1995-2010)
Fig. 3.20 Primary source of income of problem drug users (1995-2010)
Fig. 3.21 Educational level of RELIS respondents (2010)
Fig. 3.22 Total quantities of national yearly seizures: heroin, cocaine, ecstasy type (1988-2010)
Fig. 3.23 Total number of national yearly seizures: Cannabis, Heroin, Cocaine, MDMA (1988-2010)
Fig. 3.24 Number of offenders involved in seizures according to type of offence (1988-2010)

- List of Tables

Tab. 1.1 National estimates of labelled and non-labelled public drug demand reduction expenditures
Tab. 1.2 National estimates of non labelled drug related expenditures (attributable proportions)
Tab. 1.3 Comparative analysis of drug demand reduction costs in Luxembourg 1999 vs. 2009/2010
Tab. 1.4 Comparative analysis of overall drug related public expenditures in Luxembourg 1999-2009 according to various indicators
Tab. 2.1 Comparative results from the serial HBSC 2002 and HBSC 2005/2006 surveys
Tab. 2.2 HBSC 2002 and 2005/2006: Analysis according to age (last 12 months prevalence)
Tab. 4.1 Prevalence and prevalence rates according to selected sub-groups (1997-2007)
Tab. 4.2 Main characteristics of PDU indexed by the national drug monitoring system, RELIS 58
Tab. 5.1 Drug related institutional contacts (Inter-institutional multiple counting included) 68
Tab. 5.2 Outpatient, prescription of substitution drugs by the national network of licensed MDs (1999-2010) 71
Tab. 5.3 Age distribution (%) of patients substituted by the national network of licensed MDs (2008-2010) 71
Tab. 6.1 Prevalence of hepatitis B surface antigens, antibodies to hepatitis B core antigen, hepatitis C virus, and HIV in PDU and ever-injectors according to national recruitment settings 74
Tab. 6.2 Synopsis of national data on HIV infection rate in drug using populations (2010) 75
Tab. 6.3 Synopsis of national data on AIDS rate in drug using populations 75
Tab. 6.4 Synopsis of national data on HCV infection rate in drug using populations 76
Tab. 6.5 Age distribution of direct drug death cases indexed from 1992 to 2010 82
Tab. 7.1 Clients statistics of TOXIN centre services 85
Tab. 7.2 National needle exchange programme 1996-2010 including specialised agencies, vending machines and supervised injection room 88
Tab. 7.3 Needle exchange programme in prison (2005-2010) 88
Tab. 9.1 Arrests broken down by type reporting institution (1995-2010) 98
Tab. 9.2 Number of national law enforcement interventions (1995-2010) 98
Tab. 9.3 Socio demographic data on ‘prévenus’ (1986-2010) 99
Tab. 9.4 Distribution of ‘prévenus’ according to first offence and underage status (1992-2010) 99
Tab. 9.5 Distribution of first offenders (use and use/traffic) according to substance involved ad minima (1992-2010) 99
Tab. 9.6 Clients core statistics Solidarité-Jeunes (1998-2010) 100
Tab. 9.7 General and DELIT ‘STUP’ admissions in both prisons (1989-2010) 102
Tab. 9.8 Number of prisoners receiving opioid substitution treatment (2010) 104
Tab. 10.1 Ease of acquisition of drugs in Luxembourg (2002/2004) 108
Tab. 10.1 bis Ease of acquisition of drugs in Luxembourg (2008) 108
Tab. 10.1 ter Ease of acquisition of drugs in Luxembourg (2011) 109
Tab. 10.2 Price per unit evolution at the street level (1994-2010) 112
Tab. 10.3 Purity of drugs at street level (1994-2010) 113
Tab. 11.1 General admissions and the number of admissions to drug-related convictions in the two State prisons of Luxembourg from 2006 to 2010 116
Tab.12.1 Number and description of judicial situations managed by the JDH (2009) 129

- List of Maps

Map 5.1 Geographical coverage of specialised drug agencies in the Grand Duchy of Luxembourg 64

- List of Standard Tables and Structures questionnaires used in text

5 – ST05: DIRECT DRUG-RELATED DEATHS/DRUG-INDUCED DEATHS
6 – ST06: EVOLUTION OF DIRECT DRUG-RELATED DEATHS FIGURES
9 – ST09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING DRUG USERS
11 – ST11: REPORTS OF DRUG LAW OFFENCES
13 – ST13: NUMBER AND QUANTITY OF SEIZURES OF ILLICIT DRUGS
14 – ST14: PURITY/POTENCY AT STREET LEVEL OF SOME ILLICIT SUBSTANCES
15 – ST15: COMPOSITION OF ILLICIT DRUG TABLETS
16 – ST16: PRICE AT STREET LEVEL OF SOME ILLICIT SUBSTANCES
32 – SQ32: DRUG POLICY, EVALUATION AND COORDINATION
34 – TDI DATA

135
• Relevant data bases and information systems

Relying on a multi-sectorial data network including specialised in- and outpatient treatment centres and low threshold facilities, general hospitals as well as law enforcement agencies and national prisons, the RELIS drug monitoring system, established in 1995 by the NFP in collaboration with the Ministry of Health enables the assessment of new trends in the problem drug users population in general as well as in drug treatment demanders in particular. The NFP has opted for a holistic monitoring of the drug population, which by definition, is heterogeneous and not limited to drug treatment demanders. RELIS data refer to HRC drug users indexed by the national specialised treatment and law enforcement network and, as such, defined as problem drug users.

The main objectives of RELIS are the following:

- present comprehensive information on the drug phenomenon in the Grand Duchy of Luxembourg
- estimate the drug prevalence at the national level (problem drug users)
- unfold emerging trends
- track any drug-related activities, be they in policy, demand reduction or research areas
- assess the impact of offer, demand and risk reduction activities on current drug consume behaviours
- serve as a data base for research activities.

The RELIS data collection procedure is based on a **standardised extensive data protocol** including 23 core items and over 60 sub-items. The standard protocol, including 95 per cent of the Pompidou protocol’s items, has been last modified in 2000 in order to reach compatibility with the TDI (Treatment Demand Indicator) standard. The RELIS standard protocol includes a series of internal consistency items that allow to assess quality and consistency of provided data and to operate unreliable data extraction.

A second protocol, namely the **Actualisation Protocol** is completed each time a previously known problem drug user is re-indexed after a period of one year following the previous indexing. Finally, a third protocol (**Identification Protocol**) including only the identification code, the name of the contacted institution and the date and context of admission is applied if a previously known user is re-indexed in the course of the year following his previous indexing. The registration system allows for highly updated, detailed and comparable data and for a follow-up of institutional careers of problem drug users by means of a routine and cost-effective data collection procedure.

To avoid multiple counting and to allow for a follow-up of drug users’ careers, RELIS is based on a 9-digit numerical code obtained by indating 3 core variables (attributers) namely: gender (i.e. 01/02), date of birth (i.e., 10051967), and country of birth into a code - calculator developed by the NFP in collaboration with the CRP-Henri Tudor. The solution found is time and cost effective because it relies on a simple HP calculator that runs an attributor-to-code transcription programme based on a multiple-step algorithm.

Each contact person from the participant field institutions disposes of such a calculator and produces the code by him/herself. The reliability in terms of data protection was approved by national data protection authorities, by German partner regions of the Mondorf Group and by the National Commission for Informatics and Liberties (CNIL) of France.

One of the main benefits of the described procedure is that no personal data can be inferred directly from the identification code. The indating and encoding procedures are carried out at the very level of the field institutions. Thus, NFP is provided with individualised data (reporting protocols) without any reference to identifying information or attributors on the indexed persons, which is undoubtedly one of the major preoccupations of field institutions.

RELIS data processing is based on ORACLE ® database software and allows for multiple variable breakdowns as well as separated data analysis for different treatment or law enforcement settings. Separate data can be provided for participation regions and institutions.

In terms of data provision, RELIS further relies on following national registers:
- Register of drug law offenders - Special Drug Department of the Judicial Police,
- National Mortality Register - Ministry of Health,
- Special Overdose Register - Special Drug Department of the Judicial Police,
- AIDS and HIV Register - Laboratory of retrovirology - CRP-SANTE.
- Early warning system on new synthetic drugs
Agreements have been made between the monitoring system highly facilitates the implementation of Joint Action-related activities. The implementation of EWS relies on a network of institutional key-informants. Currently all specialised drug agencies (low/high threshold) at the national level are involved in the data providing process in terms of routine data transmission on new trends. Recently two new agencies have joined the EWS network, namely a counselling centre for drug users and a register on drug law offenders.

**b. Register on drug law offenders (SPJ)**

The register on drug law offenders is paper-based and maintained by SPJ. Research and queries on drug law offenders are performed manually. Special authorisation has been reached by the NFP to access the referred register and to manually include non-nominative data on offenders into the RELIS database. The NFP thus has developed a standard data collection protocol relying on SPSS ® based data analysis. This procedures has enabled the NFP to dispose of detailed anonymous data on all drug law offenders indexed by SPJ and to operate breakdowns referring to use and traffic offences and to substances involved according to types of drug law offences.

**c. General Mortality Register (GMR)**

The GMR is run by the Health Statistics Department of the Directorate of Health. The main impediment towards refined data provision on drug-related deaths and the application of the EMCDDA promoted DRD standard has been the 3-digit ICD coding applied by GMR until 1997. In 1998, ICD-10 standard was first applied by GMR. Currently, drug-related death data are extracted from GMR by means of a separate extraction routine. An integrated software based on the DRD ICD-10 standard allows to extract DRD cases from the GMR according to EMCDDA standards.

**d. Special Overdose Register (SR) of SPJ**

The SR is a paper-based register on acute drug-related deaths run by the SPJ. Over the past years, NFP relies on computer-based indexing procedure (SPSS ®) of drug-related deaths by means of a comprehensive data form. NFP is maintaining a standardised database on acute drug-related deaths from 1985 to 2010. Anonymous drug-related death data is encoded at the SPJ and transmitted to the NFP according approved standards.

**e. AIDS and HIV register (CRP-SANTE)**

Official statistics from the national Retrovirology Laboratory of the CRP-Santé provide the number and proportion of IDUs in HIV infected patients. Breakdowns by limited core socio-demographic variables are available. Provided data has public status.

**f. Early Warning System on Synthetic Drugs (NFP / SPJ)**

In the framework of the Joint Action on Information Exchange, Risk Assessment and Control of New Synthetic Drugs, the NFP has developed a nation wide cross-sectional data exchange network.

Decision has been made to adopt a centralised structure relying on a nation wide EWS partners’ network (local contact persons) as well as centralised coordination of key data providers’ activities. The national coordination unit of EWS is implemented within the NFP. The head of NFP has been appointed national EWS coordinator.

The new mandate of the Inter-ministerial Group on Drugs (November 2000), which represents the top decision level in the field of drug policies, expressively includes the follow-up of the national EWS system. Governmental delegates represented within the Inter-ministerial Group have disseminated information on EWS within their respective administration and have undertaken the required steps towards an effective inter-ministerial collaboration.

The implementation of EWS relies on a network of institutional key-informants. Currently all specialised drug agencies (low/high threshold) at the national level are involved in the data providing process in terms of routine data transmission on new trends. Recently two new agencies have joined the EWS network, namely a counselling centre for drug users under age and a low threshold project. The first does provide relevant data on new consume patterns and trends within youngster population and the second focuses on opiate users. One has to stress that the key-informants network does mainly provide data on trends in drug use but not on toxicological characteristics of substances since the referred agencies do not propose substance related services.

Currently, drug seizures are still one of the most important and the most reliable data source as to substance profiling and detection of new drugs. Samples seized by Customs or Police are either analysed (rapid tests) by the SPJ, or sent, via the Prosecutors office, to the National Laboratory of the Department of Health (LNS) for toxicological profiling. Respective results are not systematically transmitted to the department of Health or the NFP. However, effective bilateral co-operation between the NFP and the national Europol unit (SPJ) allow for rapid data transmission in case a new trend or substances should be detected by the latter. The active involvement of law enforcement agencies in the national monitoring system highly facilitates the implementation of Joint Action-related activities.

Agreements have been made between the National Fund Against Drug Trafficking, the NFP and the National Health Laboratory (LNS) on the funding of new technical equipment allocated the toxicology unit of the latter. This achievement has largely contributed to the improvement of the quality of toxicological analysis provided by LNS.

General practitioners have recently been involved in the EWS in terms of data provision on new substances and new consume patterns. All GPs and psychiatrists registered in the Grand-Duchy of Luxembourg have received a standardised data form allowing them to provide relevant information to the NFP in case they were confronted with an unknown psychotrophic substance or unusual consume patterns. The NFP, as a counter part, committed to provide GPs and psychiatrists with information on the detected trends or substances, as far as there is any information available.

Drug-related deaths have to be reported by emergency services to the Police and the SPJ. Non-fatal drug-related emergencies requiring medical intervention have not to been reported systematically. Moreover, emergency services do not index drug-related interventions separately, which means that no monitoring of those cases can be performed. The
referred situation is not likely to change and thus, the inclusion of emergency services in the EWS appears to be unfeasible at the present stage.

National drug legislation does not foresee a legal framework for testing or profiling illicit drugs in nightclubs, public events or rave parties. No such activities have been planned or carried out under the authority of public administrations. Taking into account that the first official seizure of ‘ecstasy’ has only been recorded in 1994, harm reduction and close monitoring activities in this particular field were previously not viewed as a priority.

In October 1995, a new drug help line was created, under the responsibility of the CePT. Given its easy access and the anonymity it guarantees, phone help lines often represent the first step with regard to further orientation or treatment demand proceedings and as such are able to provide high quality data on recent trends in drug use. The National Drug Help Line has been included in the EWS system in the course of 1999. In 2008 the drug phone help line has been replaced by an drug help on-line service run by CePT (Fro NO).

The drug issue is largely covered by various media supports. Press, music, fashion and leisure industries are often the mirror of life styles and current trends in substance use. Information could be collected by screening the media targeted at young people and sub cultural groups. Radio, television, newspaper, magazines, fanzines, books, comics, announcement of events, opening of new clubs, etc., are to be viewed as complementary indicators towards the global monitoring of new drug trends. Since the resources of the NFP do not allow for an overall monitoring of media supports, decision has been made to compile, in collaboration with the information and press department of the State’s Ministry, a monthly national and international press review on drugs.

g. Documentation Centres (NFP / CePT)

The Centre Logistique de Documentation sur les Drogues et les Toxicomanies (CLDDT) is a logistic documentation service run by the NFP since 1995. CLDDT runs the only computer-based national documentation management base specifically focusing on licit and illicit drugs. The CLDDT indexes about 2,900 documents mainly in French, German and English language. Users of information services provided by the CLDDT are mainly researchers, journalists, policy makers, drug treatment and prevention specialists, and general public. The majority of indexed documents are paper-based and abstracts are provided.

In addition to its function of documentation base, CLDDT also ensures the conceptualisation and execution of drug documentation dissemination strategies as required by the NFP. Topic-specific mailing lists have been developed and maintained by active contact making and demand response.

CLDDT is linked to the Centre de Documentation du Centre de Prévention des Toxicomanies run by CePT since 1996. The CePT documentation centre mainly focuses on primary prevention, training and evaluation in the fields of licit and illicit drugs. The current stock approaches 1,000 documents or media supports. Queries are handled manually and no computer-based consultation facilities are provided.

• Alphabetic list of relevant Internet addresses

  http://www.ceps.lu/
  http://www.cept.lu/
  http://www.crp-sante.lu/
  http://www.ecbap.net/
  http://eddra.eu.int/
  http://eldd.emcdda.eu.int/
  http://www.emcdda.eu.int/
  http://www.etal.lu/
  http://www.etal.lu/MS/
  http://www.gouvernement.lu/
  http://www.lires.com/
  http://www.jdh.lu/
  http://www.legilux.public.lu/
  http://www.msr.lu
  http://www.police.public.lu/PoliceGrandDucale
  http://www.relis.lu/
  http://www.statec.lu/
  http://www.unodc.org/
  http://www.who.int/